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The nuclear factor-B (NF-B) signaling cascade is comprised of two branches, the canonical 
and alternative NF-B pathways. Signaling through the alternative NF-B pathway culminates in 
the activation of the downstream transcription factor subunits, RELB and NF-B2. The biological 
roles of RELB and NF-B2 within the B cell lineage have been obscured in constitutional 
knockout mice by the diverse functions of these subunits in non-B cell types. To overcome 
these limitations, conditional alleles were generated to investigate the roles of RELB and NF-
B2 in B cell development. These alleles allowed the identification of complex functional 
requirements for RELB and/or NF-B2 in naïve B cells, germinal center (GC) B cells and 
plasma cells (PCs). These functional requirements may have implications for B cell 
malignancies that display mutations that constitutively activate the alternative NF-B pathway.  
A large body of work has demonstrated that B cell activating factor (BAFF) signaling is 
critical for the maintenance of mature B cells. However, the contribution of the alternative NF-B 
subunits that are activated downstream of BAFF remained unclear, especially in regards to their 
specific target genes. We have identified critical, B cell-intrinsic roles for RELB and NF-B2 in 
the maintenance of mature B cells. In response to BAFF, these subunits were found to control 
the expression of anti-apoptotic genes, genes that ensure correct positioning within the B cell 
niche, and genes involved in promoting B–T cell interactions that allow effective antigen-
mediated activation.  
 
During the GC B cell reaction, light zone (LZ) B cells undergo affinity-based selection 
mediated by T follicular helper (Tfh) cells. A subset of LZ B cells show activation of the NF-B 
signaling cascade, suggesting a critical role for NF-B in the selection of high-affinity GC B 
cells. We here report that GC B cell development occurred normally in mice with conditional 
deletion of either relb (RELB) or nfkb2 (NF-B2) in GC B cells. In contrast, the simultaneous 
ablation of both subunits caused rapid involution of established GCs, similar to what has been 
observed for ablation of the canonical NF-B transcription factor subunit c-REL. Intriguingly, 
RNA-sequencing analysis of relb/nfkb2-deleted GC B cells revealed no overlap between the 
genes controlled by RELB/p52 and c-REL within GC B cells. This suggests that signaling 
through the separate NF-B pathways in GC B cells results in the expression of different 
biological programs that are independently required for the maintenance of the GC reaction. 
In addition, we observed that human PCs and PC precursors within the LZ showed high 
protein levels of NF-B2 compared to surrounding lymphocytes, suggesting a biological role for 
this subunit in PCs. Indeed, ablation of nfkb2 alone in GC B cells led to a dramatic decrease in 
antigen-specific serum IgG1 and antigen-specific IgG1-secreting cells. Interestingly however, 
the mice developed normal frequencies of PCs, suggesting a role for NF-B2 in PC physiology 
rather than differentiation. 
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Section 1.1: OVERVIEW OF B CELLS IN ADAPTIVE IMMUNITY  
Following exposure to a foreign pathogen, the innate branch of the immune system is engaged 
to mount an early response. This response is coordinated by a range of cell types, which may 
include macrophages, neutrophils and/or natural killer cells, depending on the nature of the 
pathogen. Early responses are rapid and characterized by lack of antigen specificity to the 
invading pathogen. Following this first wave of innate immunity, an antigen-specific immune 
response is mounted. This adaptive immune response enables both effective pathogen 
clearance and protection against future encounters with the invading pathogen via the 
generation of immunological memory.  
The mediators of adaptive immunity are B and T lymphocytes. T lymphocytes (T cells) 
lyse infected cells and provide activation signals to B lymphocytes (B cells).  B cells differentiate 
into plasmablasts or plasma cells (PCs) that secrete antibodies, also known as immunoglobulin 
(Ig), which are crucial for protection against microorganisms. This is best exemplified by the 
immunodeficiency syndromes that occur when B cells are absent or function abnormally. 
Antibodies allow binding to antigenic structures on the surface of microbes enabling 
neutralization, opsonization and clearance. They are comprised of two identical heavy chains 
and two identical light chains which consist of variable and constant regions. The variable 
regions of the heavy and light chain mediate binding to antigens whereas the constant regions 
of the heavy chain impart various effector functions on the antibody that tailor it to optimally 
combat particular microbes.  
Antibodies are the secreted form of the B cell-receptor (BCR) that is assembled and 
expressed on the surface of B cells undergoing B cell development in the bone marrow.  
Developing B cells progress through the pro, pre and immature B cell stages during which BCR 
assembly occurs through a process of somatic DNA recombination known as VDJ 
recombination. VDJ recombination assembles the variable region of an antibody via the 
juxtaposition of distinct gene segments encoded within the heavy and light chain Ig loci. 
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Variable (V), diversity (D) and joining (J) segments are combined in the case of the heavy chain, 
whereas V and J gene segments are combined in the case of the light chain. As the heavy and 
light chain Ig loci within germ-line DNA encode many different V, D and J gene segments, a 
multitude of combinations are possible during VDJ recombination. The addition of non-germline 
encoded nucleotides (N-nucleotides) by terminal nucleotidyl transferase (TdT) inbetween the 
VD, DJ or VJ gene segments further contribute to the diversity of the antibody repertoire. As 
early B cell development proceeds within the bone marrow, processes of positive and negative 
selection ensure the survival of only those immature B cells expressing a functional BCR that is 
not strongly reactive to self.  An enormous repertoire of B cells, each expressing a BCR with a 
unique antigenic specificity, is produced during B cell development. This repertoire is 
theoretically capable of recognizing any foreign antigen.  
Section 1.2: MATURE B CELL DEVELOPMENT 
B cell developmental processes lead to the generation of three subsets of mature B cells, 
namely follicular B cells, marginal zone (MZ) B cells and B1 cells1,2. B1 cells develop during fetal 
life3. In contrast, follicular and MZ B cells, also known as B2 cells or conventional B cells, are 
derived from immature B cells completing B cell development within the bone marrow (Fig. 1.1). 
B1 cells and MZ B cells survey sensitive sites that experience continual exposure to microbial 
antigens and provide a first line of defense. In the case of B1 cells, these are the peritoneal and 
pleural cavities, whereas MZ B cells reside within a specialized compartment of the spleen 
where they monitor the blood. Follicular B cells are named for their primary localization within 
the B cell follicles of lymphoid tissues; however, these cells recirculate between the follicles of 
the spleen, lymph nodes and Peyer’s patches via the blood and lymph. Follicular B cells are 
also known as naïve B cells, as they have not yet encountered antigen. Upon antigen 
encounter, follicular B cells become activated, ultimately leading to their differentiation into PCs 
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that secrete high affinity antibodies (Fig. 1.1). The development, localization and function of B2 
cells is discussed in this section. 
Transitional B cell stages prior to mature B cell development 
Immature B cells developing within the bone marrow progress through two transitional stages 
(T1 and T2) prior to becoming a mature B cell4 (Fig. 1.1). B cells expressing BCRs with 
intermediate reactivity to self can progress through these transitional stages; however, these 
cells are removed prior to final maturation5-7. T1 and T2 B cells retain the B cell lineage marker 
of immaturity, CD93/AA4.1, and as T1 cells transition into T2 B cells, they acquire the ability to 
recirculate1. The final maturation of T2 B cells into mature B cells occurs within the bone marrow 
environment for approximately one quarter of immature B cells, whereas the majority of 
developing B cells traffic to the spleen to complete maturation8,9. T2 B cells are able to follow 
two distinct mature B cell developmental pathways resulting in the generation of either follicular 
B cells or MZ B cells (Fig. 1.1). Follicular B cells are characterized by high expression of the 
antibody isotypes IgM and IgD and intermediate expression of the complement receptor CD21, 
whereas MZ B cells have high expression of IgM and CD21 and low expression of IgD. Most T2 
B cells develop into follicular B cells and only a small proportion of cells follow the MZ B cell 
developmental path.  
Follicular vs. MZ B cell fate commitment  
The integration of several signals dictates the decision to follow a follicular vs. MZ B cell fate, 
and these signals often represent a balance between opposing regulatory factors. NOTCH2 
signaling is required for commitment to the MZ B cell fate as MZ B cells do not develop in the 
absence of NOTCH2 or a DNA binding molecule critical for NOTCH signaling, recombination 
signal binding protein for immunoglobulin kappa J region (RBP-J)10,11. The physiologically 
relevant ligand of NOTCH2 that activates signaling in B cells is delta-like 1 (DL1), which is 
absent from the bone marrow and is highly expressed in the splenic venules12. MSX2-
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interacting protein (MINT) is a protein capable of competing with the intracellular domain of 
NOTCH for binding to RBP-J and is therefore an inhibitor of NOTCH signaling. While low 
expression of MINT is observed in MZ B cells, it is highly expressed in follicular B cells and 
inactivation leads to expansion of MZ B cells13.  
The follicular vs MZ B cell fate is also governed by a similar dichotomy between the 
transcription factor E2A and its antagonist, inhibitor of DNA binding 3 (ID3). Low levels of E2A 
and high levels of ID3 promote MZ B cell development, whereas high levels of E2A and low 
levels of ID3 are associated with follicular B cell development14. The transcription factor friend 
leukemia integration 1 (FLI1) further regulates this balance15 and NOTCH signaling may also 
have a regulatory role via the degradation of E2A16.  
Persistent, weak BCR signaling is required throughout B cell development (discussed 
later in this section). The strength of the signal through the BCR at the T2 stage of development 
is thought to influence the decision to differentiate into either a follicular or MZ B cell. In this 
signal-strength model, weak BCR signaling is believed to promote MZ B cell differentiation, 
whereas strong signaling favors follicular B cell differentiation17-19. This signaling strength is 
linked to the balance between Bruton’s tyrosine kinase (BTK), which is activated by BCR 
signaling, and the transcription factor Aiolos, which may negatively regulate BTK. Therefore, in 
the absence of Aiolos, strong BCR signaling is present and follicular B cell development is 
favored, whereas MZ B cell development is promoted in the absence of BTK.  However, 
NOTCH2 signaling may be sufficient to drive the MZ fate as constitutive NOTCH2 signaling can 
promote the differentiation of MZ B cells in a BCR-independent manner20.  
Follicular vs. MZ B cell localization 
Splenic structure  
The spleen is comprised of red pulp and white pulp. Whereas the red pulp functions to filter the 
blood and remove aged erythrocytes, the white pulp is lymphoid tissue comprised of B cell 
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follicles that are bordered by T cell areas21 (Fig. 1.2). Blood is supplied to the spleen via the 
splenic artery which branches into central arterioles that further divide into smaller arterioles. 
These branching arterial vessels are sheathed by white pulp. Branching arterioles penetrate the 
marginal sinus, a fenestrated vessel with low resistance21. Circulating blood enters the marginal 
sinus and filters slowly into an adjacent region, the MZ, before entering the red pulp and the 
general circulation21 (Fig. 1.2). While the spleen and lymph nodes differ in a number of structural 
ways, the basic organization of the splenic white pulp into T cell areas and B cells follicles is 
very similar to that observed within lymph nodes22.   
Follicular B cell localization 
B cells travelling in the circulation to the spleen migrate into the B cell follicles of the white pulp 
through the marginal sinus following a gradient of the chemokine, CXCL13. This movement is 
directed by the expression of the chemokine receptor, CXCR5, which is expressed on mature B 
cells and is essentially absent on immature B cells23,24,25. CXCR5 is required for homing of 
mature B cells into splenic follicles as mice lacking CXCR5 do not form splenic follicles and B 
cells are instead present as a ring at the boundary of the T cell area25,26.  Together with adjacent 
stromal cells27, CXCL13 is also produced by follicular dendritic cells (FDCs) that form a network 
within the B cell follicles25. FDCs sequester antigen within the follicle and present it in antigen-
antibody complexes using Fc receptors and complement receptors28. FDCs are non-
haematopoietic in origin and are named for their dendritic morphology rather than relation to 
dendritic cells (DCs)29. B cells and FDCs reinforce their respective localizations, as signaling 
through CXCR5 induces the expression of lymphotoxin-α1β2 (LT-α1β2) on B cells, which in turn 
promotes both FDC differentiation and CXCL13 expression25.   
The T cell areas of the white pulp are comprised of T cells and DCs, and these cells are 
attracted to the T cell area via the chemokines CCL19 and CCL21 that bind the chemokine 
receptor CCR730,31. T cells are activated upon the entry of activated DCs bearing antigen into 
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the white pulp. This activation leads to upregulation of CXCR5 expression together with a 
downregulation of CCR7 expression; these events result in the migration of T cells towards the 
border of the B cell follicles32. Within B cell follicles, binding of antigen to BCRs induces the 
upregulation of CCR7 on the surface of B cells, promoting their migration to the boundary of the 
B cell follicles33-35. At this B/T interface B cells receive signals from activated T cells that initiate 
their activation33-35; this T cell-dependent activation leads to the initiation of a germinal center 
(GC) response (see Section 1.3).  
MZ B cell localization 
Murine MZ B cells are found only in the splenic MZ, a region that separates the outer rim of the 
white pulp from the red pulp (Fig. 1.2). The architecture of the spleen ensures that the MZ is 
exposed to blood from the circulation21.  It consists of a reticular fibroblast framework that is 
continuous with the reticular network of the red pulp, and the MZ is therefore considered an 
open compartment21. MZ macrophages and MZ B cells reside within this reticular network, while 
DCs, lymphocytes and granulocytes transit through this area21.  
Sphingosine-1-phosphate (S1P) is a lysophospholipid present in blood that binds to the 
S1P receptors, S1P1 and S1P3. The MZ has a high concentration of S1P as it is a blood-rich 
environment whereas low concentrations are found in the follicles and T cell areas of lymphoid 
tissues36,37. The S1P receptors S1P1 and S1P3 are expressed on MZ B cells at higher levels 
than those observed on follicular B cells38. In addition to this S1P ligand/receptor distribution, 
although follicular B cells and MZ B cells express similar levels of CXCR5, the ligand for this 
receptor, CXCL13, is found in abundance within the follicles, whereas CXCL13 transcripts are 
absent in the MZ27,38,39. As such, while follicular B cells home to the follicles following a CXCL13 
gradient, the S1P ligand/receptor interaction (principally through S1P1) is able to overwhelm this 
attraction resulting in the migration of MZ B cells into the MZ38,40.  Once MZ B cells enter the 
MZ, they are retained within this environment due to their high expression of several integrins 
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that enable them to resist the strong sheer forces created by the flow of blood. These include 
the integrin, lymphocyte function-associated antigen 1 (LFA1, comprised of αL and β2 chains), 
which binds to intracellular adhesion molecule 1 (ICAM1), and the integrin, very late antigen 4 
(VLA4, comprised of α4 and β1 chains chains), which binds to vascular cell adhesion molecule 1 
(VCAM1)41. ICAM1 and VCAM1 are expressed on stromal cells in the MZ. Finally, in addition to 
directing MZ B cell development, continued expression of NOTCH2 is also important for the 
retention of MZ B cells within the MZ42.  
MZ B cell function 
MZ B cells are situated at the interface between the circulatory system and the lymphoid tissue 
of the white pulp and are thereby ideally located to survey the blood and respond rapidly to 
blood-borne pathogens. MZ B cells are activated upon interaction with antigen captured by 
metallophilic macrophages that line the marginal sinus, resident MZ macrophages or circulating 
DCs and granulocytes43,44. Activation can also occur by direct interaction with antigen opsonized 
with complement45,46. MZ B cells are particularly well equipped to respond rapidly to antigen in a 
T-independent (TI) fashion. They have a lower antigen-activation threshold than follicular B cells 
and high expression of Toll-like receptors (TLRs)47. TLR signaling can integrate with BCR 
signaling to promote optimal MZ B cell activation48-50 and TLR stimulation alone is also capable 
of driving the differentiation of MZ B cells into plasmablasts49. MZ B cells also have high 
expression of the complement receptors CD21 and CD35, allowing efficient binding of antigens 
opsonized by complement45,51,52.  
Upon antigen activation, MZ B cells rapidly differentiate into plasmablasts primarily via a 
TI response to carbohydrate antigens44,45,53-55. Mice that lack MZ B cells10,45 and asplenic 
individuals56-58 are therefore particularly susceptible to infection with encapsulated bacteria. 
Antibodies secreted by these plasmablasts generally have low affinity for antigen; however, as 
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the generation of a high-affinity response by follicular B cells requires one week to develop (see 
Section 1.3), MZ B cells contribute to bridging this temporal gap in immunity. 
MZ B cells are also capable of differentiating into plasmablasts under homeostatic 
conditions, giving rise to “natural” antibodies. These natural antibodies are capable of 
recognizing conserved molecular patterns present on self and foreign antigen59. MZ B cells are 
therefore involved in the recognition of bacteria, including commensal bacteria, and host cell 
debris59. B1 cells provide an additional source of natural antibodies59.   
Signals required for mature B cell survival 
Only those B cells that have assembled a functional BCR survive to maturity60. Mature B cells 
are then dependent on BCR signaling for survival, as conditional or inducible ablation of the 
BCR or BCR associated components leads to the rapid death of mature B cells in vivo61,62. 
Persistent BCR signaling is therefore a requirement for mature B cell maintenance and is 
termed “tonic” signaling. The nature of this BCR stimulation, however, remains unclear and may 
occur due to low-affinity interactions with self antigens or proceed in a ligand-independent 
manner63.  
An additional survival signal is required from the T2 stage of B cell development 
onwards as B cells enter the follicular environment. This signal is derived from binding of the B 
cell activating factor-receptor (BAFF-R) to the ligand BAFF. The importance of this signal is 
exemplified by the severe reduction in mature B cells observed in mice deficient for either the 
BAFF-R or BAFF and the rapid death of mature B cells following BAFF neutralization64-73. B cell 
expansion is also observed in mice with transgenic BAFF expression or following BAFF 
administration74-77. The BAFF-R is first expressed in T2 B cells and sensitivity to BAFF-mediated 
survival signals begins at this stage64,67,78-81. BAFF is a soluble factor produced by FDCs and 
other cell types within the B cell follicle82 and the level of available BAFF serves as a limiting 
factor for B cell survival and determines the size of the B cell pool. BAFF signaling activates 
10 
 
many pathways that promote survival83-87, including the NF-B signaling cascade which will be 
explored further in Section 1.5.  
Section 1.3: THE GERMINAL CENTER (GC) REACTION 
GCs are transient structures that form within peripheral lymphoid organs in response to T-
dependent (TD) antigens88. Within the GC, mutational processes lead to the generation of 
mutant clones possessing a broad spectrum of affinity for the immunizing antigen. Highly 
effective selection processes within the GC then ensure that inferior antibody-mutants or those 
with autoreactive specificities are outcompeted by higher affinity competitors89. The GC reaction 
is remarkably efficient as antigen-specific memory and PCs appear within one week after 
antigen-encounter90. Over time, several iterative rounds of Darwinian-like mutation and selection 
occur, ultimately resulting in the generation of memory B cells and PCs that exit the GC reaction 
expressing an antibody repertoire whose affinity increases in a stepwise manner. This 
phenomenon is known as affinity maturation and drives the effective clearance of invading 
pathogens, which is best illustrated by the immunodeficiency syndromes observed in patients 
who are unable to form GCs91. Discussed in this section are the events leading to the formation 
of the GC, processes that drive mutation and selection within the GC and molecular regulators 
that coordinate the GC reaction. 
Initiation of the GC B cell reaction 
GCs form within the B cell follicles of lymphoid organs (Fig. 1.2). The first step in GC formation 
is the activation of naïve B cells by exogenous antigen within the follicle92 (Fig. 1.3). Intravital 
imaging93,94 has demonstrated that at day 1 post-immunization, antigen-activated B cells 
migrate to the border of the T cell/B cell zone or the interfollicular region in the lymph nodes 
where they proliferate and form long-lived interactions with antigen-specific T cells to become 
fully activated34,95. At this time, T cells, which have committed to T follicular helper (Tfh) cell 
development through priming by DCs96, begin to upregulate B cell lymphoma 6 (BCL6)93,97, a 
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critical regulator of both the Tfh98-100 and GC B cell program (discussed later in this section). In 
contrast, low expression of BCL6 is only detectable in interacting B cells at day 2. At day 3, Tfh 
cells migrate from the interfollicular area into the follicle, and pre-GC B cells follow at day 4 and 
form a primordial GC at the center of the follicle. This movement is dependent on 
downregulation of the chemotactic receptor Epstein-Barr virus induced molecule-2 (EBI2), which 
drives B cell localization to the outer follicle by responding to oxysterol ligand101-105. The S1P 
receptor, S1P2, is also required for GC-confinement of B cells by inhibiting migration to the outer 
follicle106. 
The formation of the dark and light zones of the GC 
Primordial GCs can be identified histologically at day 4 after immunization within follicles. At this 
time, B cells grow and differentiate into blasts that rapidly divide and begin to fill the network of 
FDCs in center of the follicle88. During this process, the blasts displace the IgM+IgD+ B cells 
resulting in the formation of the mantle zone around the GC. From day 5-6 post-immunization, 
the GC increases in size due to the rapid proliferation of the blasts, which continues until day 7, 
the time-point at which the GC has been fully established and is polarized into two 
microenvironments known as the dark and light zones88,107 (Fig. 1.3). The dark zone (DZ) is 
named for its histological appearance and consists of densely packed GC B cells that proliferate 
within a recently identified interconnected network of reticular cells that express the chemokine 
CXCL12108. These reticular cells are morphologically similar to the FDCs of the light zone (LZ). 
The LZ is more sparsely populated by B cells than the DZ and is comprised of several cell 
types, including Tfh cells, FDCs and macrophages107.  
Generation of mutant GC B clones 
Antibody-dependent immune responses are characterized by affinity maturation of the immune 
response. The mechanism of affinity maturation is centered on somatic hypermutation (SHM) of 
the variable regions of the Ig loci within proliferating GC B cells in the DZ89,109 (Fig. 1.3). The GC 
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is the primary site of SHM; however, extrafollicular SHM has been reported110.  The process of 
SHM is driven by activation-induced cytidine deaminase (AID)111,112 and involves the induction of 
DNA strand breaks resulting primarily in the introduction of single nucleotide exchanges113,114. 
While undergoing SHM, GC B cells proliferate at a rate unparalleled in mammalian tissues115. 
The estimated mutational rate within the variable regions of the Ig loci is 10-3 per base pair per 
generation which is 10-6 fold higher than the rate of spontaneous mutation at other loci115. SHM 
is therefore a second point of diversification of the Ig loci, following VDJ recombination within 
the bone marrow, and is generally limited to the proliferative GC B cells within the DZ116. Robust 
division and SHM produces a pool of mutant GC B cell clones possessing a large spectrum of 
affinities to the immunizing antigen (Fig. 1.3).  
Movements of B cells between the DZ and LZ of GCs 
The DZs and LZs of the GC are organized by the expression of the chemokine receptors 
CXCR4 and CXCR5117. CXCR4 is expressed on DZ B cells and is responsive to CXCL12 
produced in the DZ108, and CXCR5 is expressed on LZ B cells (and follicular B cells) and is 
responsive to CXCL13 within the LZ (and throughout the follicle)117. An important advance in the 
field has been the ability to identify DZ vs. LZ B cells phenotypically using CXCR4 and the 
activation markers CD83 and CD86117-119. DZ B cells can be identified as CXCR4hiCD83loCD86lo 
and LZ B cells as CXCR4loCD83hiCD86hi. Classical models of the GC define the existence of 
two distinct GC B cell differentiation states88. Centroblasts were thought to reside within the DZ 
and differentiate into smaller centrocytes upon entry into the LZ. However, this classical model 
has been challenged by findings derived from studies that incorporated the use of intravital 
microscopy and photoactivation to visualize the movements of GC B cells for the first time119-122. 
Rapid flux of GC B cells was observed between the DZ and LZ, and GC B cells in the DZ and 
LZ were found to have similar morphology and a great overlap in gene expression. These cells 
13 
 
are therefore perhaps more accurately described as transient states that are associated with 
positioning in the DZ and LZ107,123.  
Recirculation between the DZ and LZ is known as cyclic reentry. Mutant GC B cell 
clones move to the LZ where high affinity mutants are selected and several iterative rounds of 
cyclic reentry drive affinity maturation (Fig. 1.3). In the absence of CXCR4, GC B cells are 
restricted to the LZ and affinity maturation is inefficient108. GC polarization into DZs and LZs is 
therefore critical for optimal GC function and it is likely that the spatial separation of SHM and 
the selection of high-affinity GC B cells is required for efficient rounds of affinity maturation. In 
the absence of this polarization, inappropriate or premature selection may occur. The 
importance of the unique zonal structure of GCs is perhaps most strongly evidenced by its 
conservation in humans118,124. 
Selection of high-affinity GC B cells  
Tfh cells drive selection of high-affinity GC B cells  
Following SHM within the DZ, high-affinity GC B cell mutants must be selected in the LZ before 
undergoing further rounds of hypermutation in the DZ. Traditionally, it was believed that the 
selection of high-affinity GC B cells was largely driven by a process of direct competition for 
antigen acquired from FDCs88. High-affinity GC B cells would sequester all available antigen via 
their BCRs and thereby deprive lower-affinity competitors of survival signals triggered by BCR 
ligation. However, using an experimental system in which antigen is delivered directly to GC B 
cells independent of the BCR, it was recently demonstrated that Tfh cells promote selection 
within the LZ119. GC B cells capture antigen via the BCR and present the processed antigen on 
major histocompatibility complexes (MHCs) to Tfh cells (Fig. 1.3). Higher BCR affinity is directly 
associated with greater antigen-capture and leads to a higher density of MHC-peptide 
presentation on the surface of the B cell. This results in the greatest share of T cell help, which 
in turn drives selection. Active BCR signaling is also largely quiescent within B cells125. 
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Therefore, within the context of the GC, it appears that the role of the BCR is primarily to 
capture and internalize antigen rather than induce BCR signaling. Visualization of these 
selection processes in vivo demonstrated that Tfh cells patrol GC B cells and form the largest 
and longest contacts with those cells presenting the highest density of antigen on MHC 
complexes126. These contacts are transient, thereby allowing Tfh cells to continuously survey 
many different LZ B cells, resulting in the selection of the antibody mutants with the highest 
affinity on a population level.  
Mechanism of selection of high-affinity GC B cells  
Tracking of cell division within the GC demonstrated that B cells that receive the greatest 
magnitude of T cell help are programmed to divide the greatest number of times upon reentry 
into the DZ127. As SHM and proliferation are intimately linked128, GC B cells that undergo the 
greatest number of divisions harbor significantly more affinity-enhancing mutations in their Ig 
variable region (IgV) genes compared to less proliferative competitors. Therefore, in a “feed-
forward” loop, the GC B cells with the highest affinity are repeatedly instructed to recirculate to 
the DZ to undergo further rounds of division and SHM (Fig. 1.3). As a result of this iterative 
process, GC B cells with the highest affinity dominate the population of B cells participating in 
the GC reaction over time.  
Signals derived from T cells during selection within the LZ 
As outlined above, Tfh cells provide crucial signals to high-affinity GC B cells to allow their 
selection, transit back to, and division in the DZ. The exact nature of these signals and their 
downstream effects remains unclear and is being actively explored in the field. Murine and 
human LZ B cells are enriched for several early activation signatures, including CD40, BCR, 
nuclear factor-B (NF-B) and c-MYC signatures, suggesting that these pathways are activated 
during selection119,124,129. CD40 stimulation is achieved via ligation of the CD40 receptor, which 
is expressed on B cells, by CD40 ligand (CD40L), expressed on the surface of Tfh cells. An 
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additional T cell/B cell interaction is mediated by inducible T cell co-stimulator (ICOS) ligand 
(ICOSL) which is expressed on GC B cells and promotes transient yet expansive ‘entanglement’ 
with Tfh cells that express the surface receptor ICOS. This interaction stimulates the increased 
display of CD40L on the surface of Tfh cells, thereby providing GC B cells with CD40-
stimulation130. CD40-stimulation also leads to the upregulation of ICOSL on GC B cells, resulting 
in a feed-forward loop that enables high-affinity B cells to reiteratively acquire a greater share of 
T cell help than lower-affinity competitors130. T cell-mediated CD40 stimulation and BCR 
signaling lead to the activation of several downstream pathways, including NF-B activation, 
which will be discussed in Section 1.5. Contact between Tfh and GC B cells has also been 
shown to induce increased calcium signaling and co-expression of IL-4 and IL-21 in Tfh cells, 
both of which are cytokines that augment GC B development126.  
An additional DNA-modifying event occuring within the GC is Ig class switch 
recombination (CSR). Like SHM, this process is driven by AID111,112. CSR allows B cells to 
switch the constant region of the heavy chain Ig locus, enabling Ig isotype switching from IgM 
and IgD to other classes such as IgG, IgE or IgA, while retaining the same BCR specificity. This 
switch occurs via DNA recombination of switch regions that intercede the constant region gene 
segments of the Ig heavy chain locus. Different isotypes are associated with specific effector 
functions. While CSR can occur both in a TI or TD manner131, it is believed that within the GC, 
signals that induce CSR are derived from Tfh cells located in LZ132 (Fig. 1.3). CSR to various 
isotypes is promoted by co-stimulatory signals, such as CD40 and ICOSL stimulation from T 
cells133-135, and exposure to cytokines, such as IL4 which drives switching to IgG1136. It is 
believed that SHM and CSR are temporally separated. However, the precise developmental 
stage at which CSR occurs is unclear, as class-switched cells can be observed among DZ cells 
and post-GC memory B cells and PCs, suggesting that CSR can occur prior to cyclic reentry 
and/or post-GC differentiation137.  
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Molecular control of the GC reaction 
The GC-reaction is a highly complex process involving several distinct, timed events that are 
segregated topographically within the GC microenvironment. The coordination of this complex 
cascade of events is underpinned by precise molecular control achieved by a series of 
transcription factors, epigenetic mediators and post-transcriptional mechanisms138,139. The 
function of the major regulators of these processes is discussed below.  
BCL6 
Within the B cell lineage, BCL6 is specifically expressed in GC B cells and is rapidly upregulated 
upon antigen activation140,141. BCL6 is essential during GC responses, since BCL6-deficient 
mice fail to form GCs142,143. During GC initiation, BCL6 controls a transcriptional program within 
pre-GC B cells that facilitates the migration of these cells to the center of the follicle via the 
downregulation of both EBI2 and S1P1
94,144, and the upregulation of CXCR494. BCL6-
upregulation in pre-GC B cells also appears to enhance integrin-dependent conjugation of B 
and T cells94. 
BCL6 is a transcriptional repressor that is responsible for the specialized physiology of 
GC B cells, including all DZ B cells and most LZ B cells. BCL6 represses the expression of 
genes encoding a range of targets that are involved in B cell activation and post-GC activation 
including CD80145, which promotes T cell interactions via the binding of CD28. BCL6 also 
represses genes encoding factors that drive PC development such B lymphocyte-induced 
maturation protein 1 (BLIMP1) and interferon regulatory factor 4 (IRF4)146-149 (see Section 1.4) 
and genes encoding several factors that modulate chemokine and cytokine responses146,150.  
GC B cells are tolerant of SHM-induced DNA damage as BCL6 inhibits DNA damage-induced 
apoptosis by inhibiting the expression of the tumor suppressor p53151 and other DNA damage-
response factors146,152-154. Repression of p53 also promotes rapid proliferation, which is further 
facilitated by BCL6 via the transcriptional repression of the cell cycle regulator p21152. BCL6 also 
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modulates a range of apoptotic genes146,147 and has been shown to directly target the gene 
encoding the anti-apoptotic factor B cell lymphoma 2 (BCL2)147,155. GC B cells express a pro-
apoptotic transcriptional profile156 and are particularly prone to apoptosis ex vivo157-159; this 
susceptibility is thought to enable the rapid elimination of mutant GC B clones that are not 
rescued by survival signals provided during LZ selection. BCL6 therefore controls a broad 
genetic program that maintains and promotes the DZ phenotype by collectively ensuring that 
GC B cells do not undergo premature activation or differentiation, are permissive to genotoxic 
stress induced by SHM and can be rapidly eliminated if they are not selected by T cells in the 
LZ.  
c-MYC 
c-MYC exerts a critical role in virtually all proliferating cells. Through both transcriptional and 
non-transcriptional mechanisms, c-MYC supports robust proliferation by regulating diverse 
processes including cell-cycle progression, metabolism and telomere maintenance160. Despite 
the highly proliferative nature of DZ B cells, it was believed that GC B cells do not express c-
MYC156,161 as BCL6 represses transcription of the MYC locus162. Recently however, it was 
observed that the primordial GC arising at day 4 post-immunization is characterized by the 
appearance of a sizable fraction of c-MYC+BCL6+ blasts, and ablation of c-MYC in activated B 
cells shortly after immunization (day 2) inhibits GC formation163. These findings demonstrate an 
essential function for c-MYC in GC initiation. At day 4, the c-MYC+BCL6+ GC B cells, in contrast 
to their c-MYC–BCL6+ counterparts, transcribed the known direct c-MYC target gene ccnd2 
(encoding Cyclin D2) in addition to ccnd3 (encoding Cyclin D3)163, the DZ-specific D-type 
cyclin164,165. As c-MYC+BCL6+ cells appear to be the precursors of c-MYC–BCL6+ GC B cells163, 
this finding suggests that c-MYC establishes a Ccnd2-dependent proliferation program in GC-
precursor B cells that is replaced by the typical Ccnd3-dependent proliferation program of DZ B 
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cells164,165 upon c-MYC downregulation. From this point onwards, c-MYC is virtually absent in 
DZ B cells until it is reexpressed at day 7162,163.  
c-MYC expression occurs within a small subset of LZ B cells within mature GCs that 
have segregated into DZs and LZs at day 7 post-immunization162,163. This pattern of expression 
coincides with the time-point at which selection of high-affinity mutants is thought to begin90,166. 
Moreover, c-MYC+ GC B cells demonstrated evidence of T cell-mediated selection as they 
possessed an activated phenotype similar to that described by gene expression profiling of LZ B 
cells119,162,163, were actively cycling, expressed high-affinity BCRs, and T cell help was found to 
induce c-MYC expression in LZ B cells prior to cyclic reentry162,163. These findings collectively 
suggest that c-MYC+ B cells within the LZ are undergoing affinity-based positive selection.  
MCL1 
Despite the general pro-apoptotic nature of GC B cells, one antiapoptotic BCL2 family member, 
myeloid cell leukemia 1 (MCL1), has recently been identified as the principal regulator of cell 
survival during GC-formation167. The conditional deletion of mcl1 early after immunization (d2) 
prevented the formation of GCs, suggesting a continuous requirement of MCL1 throughout GC 
development. In contrast, the pro-survival factor BCL2-like 1 (BCL-XL) is dispensable within this 
context167 and antagonizing BCL-XL and BCL2 leads to a reduction in naïve B cells, but has no 
effect on GC B cells168.  
Section 1.4: PLASMA CELL (PC) DEVELOPMENT 
Upon completion of GC development, GC B cells exit the GC as either memory B cells or PCs 
(Fig. 1.3). Memory B cells have the capacity to rapidly differentiate into PCs that secrete high 
affinity antibody upon reencounter with the immunizing antigen. The molecular events that drive 
memory B cell development remain largely unknown; however, it is clear that extensive 
heterogeneity exists within this cell population169. In contrast, PC development is understood in 
greater depth. All B cell subpopulations are capable of differentiating into ASCs upon antigen 
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encounter. ASCs include plasmablasts and PCs. Plasmablasts are short-lived and actively 
cycling and can further mature into PCs, which are long-lived and non-proliferative. The kinetics 
of this differentiation and the type of antibodies secreted can differ depending on the nature and 
location of the antigen, the type of responding B cell and the co-stimuli present. During a TD 
response, an initial low affinity wave of antibody production provides immediate protection. 
Following a GC response, PCs are generated that produce a high affinity, persistent antibody 
response. The B cell—PC transition can be considered a lineage switch, and PCs are terminally 
differentiated as they have permanently extinguished the genetic program of the B cell. 
Described in this section are early antibody responses, the mutually repressive genetic 
programs that govern B cell/GC B cell vs. PC fate and PC survival within the bone marrow.  
Early antibody responses 
As mentioned in Section 1.2, antibody responses can occur even in the absence of infection via 
the secretion of natural antibodies by PCs derived from MZ B cells or B1 cells170. Following 
infection, MZ B cells respond rapidly to blood-borne pathogens by differentiating into 
plasmablasts that secrete large amounts of low-affinity antibody. These plasmablasts develop 
as early as 1-3 days following microbial exposure, reside within the red pulp and are short-
lived53,59. The antibody class these cells secrete is generally of the IgM subtype; however, 
switching via CSR to IgA and IgG can occur45,171. Movement to the red pulp is achieved via 
downregulation of S1P receptors, CXCR5 and CCR7 and upregulation of CXCR4, allowing 
plasmablasts to enter the red pulp following a CXCL12 gradient that is produced by stromal and 
innate immune cell types within the red pulp38,171-173.  
Follicular B cells can also differentiate into plasmablasts and contribute to an early 
antibody response, as not all antigen-activated B cells enter the GC reaction170. Following 
interaction with T cells, a subset of B cells differentiates into short-lived plasmablasts that 
secrete low-affinity antibodies directed against the invading pathogen174. Among the pool of 
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responding B cells, it appears to be those with high-affinity antigen specificities that 
predominantly differentiate into plasmablasts175,176. Plasmablastic differentiation occurs in 
extrafollicular sites and movement to these sites is dependent on the expression of EBI2101,102. 
In the lymph nodes, these extrafollicular sites are the medullary cords; in the spleen, foci of 
plasmablasts form in the red pulp170. Two days following immunization with a TD antigen, foci of 
plasmablasts appear and expand until day 8, when they recede and die via apoptosis177,178. 
Following this initial wave of low affinity antibody, PCs derived from the GC reaction begin to 
secrete high affinity antibody.   
Antagonism of the PC fate in B cells  
In the bone marrow, B cells develop from haematopoietic stem cells. The master regulator of 
commitment to the B cell fate is the transcription factor paired box 5 (PAX5)179. Expression of 
PAX5 is consistent throughout all stages of B cell development and preservation of B cell 
identity is dependent on continued expression, as removal of PAX5 from mature B cells leads to 
dedifferentiation back to a progenitor stage180,181. PAX5 binds thousands of genomic sites within 
B cells, and by acting as either a transcriptional activator or repressor, directs a broad 
transcriptional program182-184. PAX5 activates genes involved in BCR signaling (such as the IgH 
locus and Igα), adhesion and migration (such as CD44), immune receptors (such as CD19, 
CD21, CD40) and important B cell transcriptional regulators (such as IRF4, interferon regulatory 
factor 8 (IRF8), BTB and CNC homology 2 (BACH2), Aiolos and SPIB). In addition, PAX5 
represses a range of lineage inappropriate genes that are associated with driving a T cell or 
myeloid fate185. PAX5 also represses the expression of several PC regulators including X-box 
binding protein 1 (XBP1), BLIMP1 and joining (J) antibody chain185-188 (Fig. 1.4), and PC 
differentiation is associated with a loss of B cell identity via the inhibition of PAX5185,187,189. It was 
believed that repression of PAX5 in PCs was induced by BLIMP1, a critical regulator of PC 
development190. However, an early “pre-plasmablast” stage, characterized by PAX5 inhibition, 
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can develop in the absence of BLIMP1191. These pre-plasmablasts secrete low amounts of 
antibody likely due to the derepression of the genes encoding XBP1 (a factor that drives the PC 
secretory phenotype) and J chain191. Therefore, it appears that the repression of PAX5 is the 
earliest event in PC differentiation. Subsequent expression of essential regulators of PC 
development, BLIMP1 and IRF4, then drive the development of mature PCs, that secrete large 
amounts of antibody, and PAX5 repression is reinforced by BLIMP1 (Fig. 1.4). The molecular 
events that initiate PAX5 repression remain to be determined.  
In addition to PAX5, several other B cell factors also repress drivers of PC development. 
For example, in addition to establishing the DZ phenotype, BCL6 also guards against premature 
PC differentiation by repressing the transcription of PRDM1 (the gene encoding BLIMP1)148,149 
(Fig. 1.4). In addition, BACH2 cooperates with BCL6 to promote the repression of PRDM1192,193 
and in naïve B cells, microphthalmia-associated transcription factor (MITF) represses irf4194.   
Molecular drivers of the PC fate  
Regulators of B cell and GC B cell identity repress drivers of PC development, and in turn 
regulators of PC development repress both B cell and GC B cell genetic programs to reinforce 
the PC fate195 (Fig. 1.4). The function of the major regulators of these processes is discussed 
below.  
IRF4 
IRF4 has diverse, context-dependent functions in GC B cell and PC development196,197. 
Together with various co-factors, IRF4 has roles in promoting very early GC initiation198,199, CSR 
and PC differentiation200,201, and in the T cell lineage IRF4 regulates the differentiation of Tfh 
cells202. Its function appears to be dose-dependent as low levels are associated with GC 
formation and CSR, whereas high, sustained levels are associated PC development201.  The 
role of IRF4 in GC formation appears to be confined to a very early initiation stage when pre-GC 
B cells still reside in the outer follicle, as GCs develop normally in the absence of IRF4 from day 
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2 of the GC reaction onwards200. At this pre-GC stage, IRF4 induces the expression of BCL6 
and AID198. In GC B cell and PC development, IRF4 has a biphasic activation pattern during 
which it is required for early GC initiation, before it is silenced throughout the majority of GC B 
cell development, and is then reactivated in late GC differentiation. High expression of IRF4 is 
essential for PC differentiation201 and may direct PC differentiation either in parallel with200 or 
upstream201 of another essential regulator, BLIMP1. High expression of IRF4 also results in 
inhibition of BCL6, thus extinguishing the GC B program, while also indirectly inducing BLIMP1 
expression by alleviating BCL6-mediated repression of PRDM1201,203 (Fig. 1.4).  
BLIMP1 
BLIMP1 is a transcriptional repressor, and within the B cell lineage BLIMP1 is uniquely 
expressed in PCs, with PCs expressing higher levels than plasmablasts204-206. While BLIMP1 is 
not required for initiation of PC development191, it is essential for the generation of mature 
PCs207, and the expression of exogenous BLIMP1 can induce plasmablast differentiation208. 
Continuous expression of BLIMP1 is also required for the maintenance of long-lived PCs209. 
BLIMP1 acts upstream of another important PC factor, XBP1210 (see below), and represses the 
genes encoding B cell and GC B cell factors PAX5, c-MYC and BCL6190,211-213 (Fig. 1.4). In 
response to activation, B1 and MZ B cells upregulate BLIMP1 more rapidly than follicular B 
cells; this kinetic difference may underlie the swift differentiation of these cell types into 
plasmablasts upon activation49,214.  
XBP1 
PCs are essentially factories of antibody production and secretion, creating conditions that 
induce endoplasmic reticulum (ER) stress. When a cell experiences ER stress caused by 
unfolded proteins, it induces the unfolded protein response (UPR) in order to tolerate these 
conditions. The key mediator of this response is the transcription factor XBP1215. While PCs 
form in the absence of XBP1, these cells secrete reduced amounts of antibody, and fail to 
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undergo the ER remodeling that creates the characteristic morphology of PCs210,216-219. The 
expression of XBP1 may be activated by IRF4200 and BLIMP1210. 
Long term survival of PCs 
Long-lived PCs primarily reside within the bone marrow. Within this niche, their survival is 
maintained by several trophic signals220 and PCs are dependent on these non-intrinsic trophic 
factors for survival. Only a subset of plasmablasts generated in secondary lymphoid organs will 
travel via the blood to the bone marrow to become long-lived PCs221. The expression of the S1P 
receptor S1P1 is required for the migration into the blood
221, after which expression of CXCR4 
together with other chemokine receptors promotes homing to and retention within the bone 
marrow environment172,222-225. This movement is also associated with reduced expression of 
CXCR5 and CCR7, allowing PCs to leave the B cell follicles and T cell areas172. Retention within 
the bone marrow environment involves the interactions of several integrins and adhesion 
molecules226,227, including VLA4-mediated interactions with VCAM1-expressing epithelial 
cells228. BLIMP1 at least in part drives these events as it has been shown to repress CXCR5211, 
while inducing CXCR4 and VLA4 expression229. The cell types that make up the bone marrow 
PC niche remain somewhat unclear226, but include a CXCL12-producing stromal cell type222 and 
eosinophils that colocalize with bone marrow PCs230. PCs express high levels of the receptor B 
cell maturation protein (BCMA)231 in a BLIMP1-independent manner232, and low levels of the 
BAFF-R relative to follicular B cells81,231. The bone marrow niche produces the B cell survival 
factors a proliferation-inducing ligand (APRIL) and BAFF which are critical for the survival of 
bone marrow PCs231,233,234. BAFF and APRIL are both able to bind and signal through BCMA, 
and the survival of long-lived PCs is impaired in the absence of BCMA or following 
sequestration of APRIL or BAFF231,232,235. Signaling through BCMA induces high levels of the 
anti-apoptotic factor MCL1, and PCs are depleted in vivo upon removal of MCL1232. Several 
other important factors are produced within the bone marrow niche that support PC survival227, 
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including IL-6236,237. Signals within the bone marrow niche also promote survival via the 
activation of the NF-B signaling cascade, which will be discussed in Section 1.5.  
Section 1.5: THE GC AND LYMPHOMAGENESIS 
The mutational processes occurring within the GC drive the generation of a high affinity immune 
response that is critical for effective pathogen clearance. However, the advantage of these Ig 
remodeling processes for immunity is counterbalanced by the threat of malignant transformation 
when these events, that induce DNA strand breaks, are dysregulated and create genomic 
aberrations. Indeed, the vast majority of mature B cell lymphomas are derived from GC B cells 
at various stages of GC development238,239. Genomic sequencing of human lymphomas has 
revealed that most cases develop as a result of genetic lesions involving loci encoding key 
regulators of normal GC development240-245. Therefore, genetic programs important for normal 
GC differentiation are frequently hijacked during lymphomagenesis. Understanding the 
molecular control of the GC reaction therefore provides the basis for the development of 
therapies aimed at the treatment of lymphoma. In turn, recurrent mutations identified in 
lymphoma may provide clues that identify novel pathways that function within the GC, and this 
has been the case for many factors now recognized as critical for normal GC development. 
Lymphoma classification and recurrent genetic lesions are discussed in this section, with 
particular focus on mutations in NF-B signaling components. 
Dysregulation of Ig remodeling mechanisms  
B cell non-Hodgkin lymphomas (B-NHLs) comprise several different lymphoma subtypes with 
distinct genetic and phenotypic composition and heterogenous prognosis. The majority of these 
lymphomas are of GC origin, as evidenced by the presence of somatically mutated Ig 
genes238,246. A major type of genetic alteration observed in B-NHLs are chromosomal 
translocations and these translocations frequently involve the Ig loci. The analysis of 
translocation breakpoints has revealed that chromosomal translocations can be caused by 
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errors in SHM or CSR. These processes normally induce DNA lesions in Ig switch regions or in 
regions targeted by SHM and can aberrantly induce these lesions in non-Ig loci247-249. These 
errors can result in the juxtaposition of the coding region of a proto-oncogene with Ig regulatory 
elements, leading to dysregulated expression of the corresponding gene. A second major type 
of genetic lesion observed in B-NHLs is aberrant SHM (ASHM). Under normal conditions the 
process of SHM acts almost exclusively on the variable regions of the Ig loci; during ASHM, 
however, several non-Ig loci are targeted250,251. These mutations can target 5’ regulatory regions 
and coding regions leading to nucleotide and amino acid exchanges, respectively250. A direct 
link between the Ig DNA remodeling events operating within the GC and lymphomagenesis has 
been provided via the demonstration that AID, the enzyme that directs SHM and CSR, is 
required for the development of GC-derived B-NHL in mouse models of B cell lymphoma252,253.  
B-NHL classification  
Comparison of the transcriptional profiles of normal GC B cell types and lymphoma subtypes 
has revealed that different B-NHLs subtypes can often be traced back to specific cells of origin 
within the GC, suggesting that these lymphomas are stalled at particular phases of GC 
development124,254,255. In addition, while there are several commonalities, different subtypes of 
B-NHL are often characterized by the recurrence of characteristic genetic lesions that frequently 
involve known regulators of the GC reaction. A selection of representative examples are 
discussed below.  
Burkitt lymphoma 
The cell of origin in Burkitt lymphoma is believed to be a DZ B cell124,254, and virtually all cases 
are associated with translocations between the Ig and MYC loci256. MYC was the first gene 
associated with GC-derived lymphomagenesis257,258 and encodes the transcription factor c-
MYC. c-MYC is an important example of a critical regulator of the GC whose role in 
lymphomagenesis was appreciated long before a physiological function within the GC could be 
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identified. Only recently, as outlined in Section 1.3, have important roles for c-MYC been 
defined specifically in early GC initiation and during T cell-mediated selection; in all other 
phases of the GC reaction, the expression of c-MYC is tightly controlled by BCL6-mediated 
repression162,163. Oncogenic activation of c-MYC expression allows escape from BCL6-mediated 
repression and is likely to promote lymphomagenesis by driving inappropriate cell growth and 
also via the induction of genomic instability, which may facilitate the acquisition of additional 
genetic aberrations160,259,260.  
Diffuse large B cell lymphoma (DLBCL)  
DLBCL is the most common B-NHL, comprising ~40% of adult B-NHLs256. Transcriptional 
analysis of DLBCL has further segregated this type of lymphoma into two distinct forms known 
as GC B cell-like DLBCL (GCB-DLBCL) and activated B cell-like DLBCL (ABC-DLBCL). GCB-
DLBCL is characterized by the expression of GC B cell genes, whereas genes associated with 
the in vitro activation of B cells are expressed in ABC-DLBCL255. Recently, additional work 
further defined this distinction and it is now believed that the cell of origin in GCB-DLBCL is a LZ 
B cell, whereas ABC-DLBCL appears to derive from a cellular stage at which a LZ B cell has 
initiated post-GC plasmablastic differentiation124,255. These distinctions have important clinical 
implications, as GCB-DLBCL is associated with a more favorable prognosis than ABC-
DLBCL255,261. One of the most common oncogenic events observed in DLBCLs is dysregulation 
of BCL6 expression which affects ~30% of cases256,262 and can occur via several mechanisms. 
Translocations involving BCL6 frequently occur263,264, and mice engineered to express an Ig-
BCL6 translocation develop a lymphoproliferative disease that closely mirrors human DLBCL265. 
In addition, binding sites within the BCL6 promoter that normally mediate repression of BCL6 
transcription are frequently rendered non-functional by mutations in DLBCL203,266. These genetic 
aberrations collectively lead to constitutive BCL6 expression and thus prevent the silencing of 
BCL6 that is necessary for post-GC differentiation, as described in Section 1.4. These types of 
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aberrations are therefore thought to cause a block in development and consequently lock GC B 
cells into a DZ B cell phenotype characterized by rapid proliferation and tolerance of DNA 
damage, which in turn create opportunities for further, potentially transforming, genetic hits267.  
Distinctive genetic lesions are also observed in GCB-DLBCL vs. ABC-DLBCL256,262. 
GCB-DLBCL is associated with translocations involving the MYC and BCL2 loci and mutations 
in the genes encoding polycomb methyltranferase enhancer of zeste homolog 2 (EZH2)241,268-270 
and regulators of GC confinement271, including the chemokine receptor S1P2
106,272. Genetic 
lesions resulting in the inhibition of the PC regulator BLIMP1 are observed in ~30% of ABC-
DLBCL cases256,262. Bi-allelic inactivation can occur via a variety of mechanisms including 
deletions, mutations and epigenetic silencing273-275. These lesions are likely to contribute to 
lymphomagenesis by creating a block in PC differentiation, thereby trapping LZ B cells in a state 
of early plasmablastic differentiation. Indeed, conditional removal of BLIMP1 in B cells promotes 
the generation of a lymphoproliferative disorder with several phenotypic similarities to human 
ABC-DLBCL275. Finally, in the last several years, a range of mutations that converge on 
activation of the NF-B signaling cascade were identified in ~95% of ABC-DLBCL cases256,262, 
providing an explanation for the predominant expression of NF-B target genes observed in 
ABC-DLBCL vs. GCB-DLBCL that had been noted in early studies276. Constitutive activation of 
NF-B signaling is therefore a hallmark of ABC-DLBCL. The normal function of NF-B and the 
consequences of lymphoma-associated mutations are discussed below. 
The NF-B signaling cascade 
The NF-B signaling transduction pathway can be divided into two major branches, a canonical 
and an alternative pathway that are activated through specific cell surface receptors277,278 (Fig. 
1.6). The canonical NF-B pathway has been intensively studied over the past 29 years, with 
critical roles defined in both innate and adaptive immune cell types. The range of functions 
ascribed to the canonical NF-B pathway can be inferred from the diverse range of signals 
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known to activate this pathway. These include exposure to pathogen-associated molecular 
patterns (PAMPs) that bind TLRs, pro-inflammatory cytokines such as tumor necrosis factor 
(TNF) that binds the TNF-receptor (TNF-R) and IL-1 which binds the IL-1-receptor (IL1-R). 
Canonical NF-B activation also occurs following T cell-receptor (TCR) and BCR antigen 
stimulation. In response to signaling through this array of immune receptors, canonical NF-B 
activation induces the expression of a range of host defense genes including cytokines, growth 
factors and other effector molecules that augment the immune response. In addition, canonical 
NF-B signaling also induces the expression of genes with pro-proliferative and anti-apoptotic 
functions, promotes effector cell activation and regulates the development of various 
lymphocyte subpopulations279. In contrast, the alternative NF-B pathway is associated with a 
specific set of functions280. This pathway was discovered more recently than the canonical 
pathway with the first reports defining the alternative pathway appearing in the early 2000s. The 
alternative NF-B pathway is activated by signals through a limited number of receptors 
including the LT β-receptor (LTβR)281,282, CD40283,284, receptor activator of NF-B (RANK)285 and 
the BAFF-R286-288, all of which to varying degrees also have some capacity to activate the 
canonical pathway. CD40 stimulation in particular is capable of strongly activating both NF-B 
pathways283,284,289,290. Alternative NF-B pathway activation in response to signaling through 
each of these receptors leads to heterogeneous outcomes280.  LTβR signaling promotes the 
organization of lymphoid architecture by stromal cells, while CD40 signaling induces T cell-
mediated activation of B and T cells, DCs and monocytes. Signaling through RANK has 
important roles in osteoclast development, and BAFF-R signaling is required for the survival of 
mature B cells. The role of alternative NF-B signaling in mature B cell survival will be further 
discussed in the introduction to Chapter 2 (Section 2.1). As outlined below, under physiological 
conditions, activation of the NF-B cascade occurs only in response to inducing signals and is 
subject to tight regulation. Therefore, under normal circumstances, NF-B activation is transient, 
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and the constitutive activation that occurs as a result of genetic alternations in lymphoma is an 
aberrant, pathogenic event.  
The canonical NF-B pathway 
The downstream mediators of the canonical NF-B pathway are the transcription factors 
reticuloendotheliosis oncogene (c-REL), v-rel reticuloendotheliosis viral oncogene homolog A 
(RELA) and p50 (which is derived from constitutive, co-translational processing of the precursor, 
p105, also known as NF-B1) that mainly occur as heterodimers277,278 (Fig. 1.6). In B cells, 
translocation of canonical NF-B heterodimers from the cytoplasm to the nucleus occurs in 
response to BCR, TLR and CD40 stimulation291,292. These signals are relayed through a series 
of kinases and adaptor proteins that differ depending on the initiating signal but culminate in the 
activation of the inhibitory BIB) kinase β subunit (IKKβ)277,278. IKKβ is present in a complex 
with another catalytic subunit, IKKα, and the regulatory subunit IKKγ, together these three 
subunits from the IKK complex. Activated IKKβ phosphorylates inhibitory IBmolecules (IBα, 
IBβ or IBε), an event which marks these subunits for polyubiquitylation and subsequent 
proteasomal degradation (Fig. 1.6). IB degradation represents the rate limiting step in the 
activation of the canonical NF-B pathway277,278. Under steady state, unstimulated conditions, 
IBs hold the canonical heterodimers in an inactive form in the cytoplasm by masking nuclear 
localization sequences. Following proteasomal degradation of IBs, homo- or heterodimers of c-
REL, RELA and p50 (usually c-REL-p50 and RELA-p50) are free to enter the nucleus and bind 
to B binding sites in the regulatory regions of target genes. c-REL and RELA contain 
transactivation domains (TADs) that enable these subunits to drive the transcription of target 
genes277,278. IBα can also serve to inhibit DNA binding and promote the export of NF-B dimers 
from the nucleus. Transcription of the gene encoding IBα is a frequent event following 
30 
 
canonical NF-B activation, providing a mechanism by which NF-B signaling can be rapidly 
extinguished in order to restore steady-state conditions293,294.  
The alternative NF-B pathway 
The corresponding downstream mediators of the alternative NF-B pathway are avian 
reticuloendotheliosis viral (v-rel) oncogene related B (RELB) and p52 (which is generated by 
proteolytic cleavage of the precursor p100, also known as NF-B2) and these subunits mainly 
occur as heterodimers280 (Fig. 1.6). In B cells, alternative NF-B signaling is activated by soluble 
BAFF or CD40 stimulation283,286. These signals activate the alternative NF-B pathway via the 
release of NF-B-inducing kinase (NIK) from continuous turnover mediated by a complex 
comprised of TNF receptor-associated factor 2 and 3 (TRAF2 and TRAF3) and baculoviral IAP 
repeat-containing 2 and 3 (cIAP1/2), allowing its stabilization295-302. NIK activates IKKα 
homodimers, which phosphorylate and subsequently induce proteasomal processing of p100 
that is bound to RELB303,304. This results in the removal of an inhibitory C-terminal ankyrin 
domain of p100, resulting in both the generation of p52 and the release of RELB from p100-
mediated inhibition and retention within the cytoplasm303,304 (Fig. 1.6). The processing of p100 to 
p52 therefore represents the rate limiting step in the activation of the alternative NF-B pathway 
and allows the nuclear translocation of RELB/p52 heterodimers280. RELB, but not p52, contains 
a TAD and is thus capable of activating transcription280. 
NF-B mutations in ABC-DLBCL  
Activating mutations in canonical NF-B signaling components 
Mutations affecting NF-B signaling components observed in ABC-DLBCL predominantly 
converge on constitutive activation of the canonical NF-B pathway (Fig. 1.7). BCR signaling 
activates the canonical NF-B pathway, and chronic BCR signaling is observed in ABC-
DLBCL305. Mutations in the genes encoding the intracellular components of the BCR signaling 
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complex, CD79A and CD79B, prevent receptor internalization and inhibit Yamaguchi sarcoma 
viral (v-yes-1) oncogene homolog (LYN), a negative regular of BCR signaling305. Mutations in 
the gene encoding coiled-coil domain of the scaffolding protein caspase recruitment domain 
family, member 11 (CARD11), which is a downstream signaling component of the BCR present 
in a complex with mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) 
and B cell lymphoma 10 (BCL10), lead to constitutive oligomerization and canonical NF-B 
activation independent of antigen stimulation306-308. Mutations in the gene encoding myeloid 
differentiation primary response gene 88 (MYD88), an adaptor protein that mediates signaling 
downstream of TLRs and the IL-1 receptor, were also observed309. Mutant MYD88 complexes 
with the adaptors proteins interleukin-1 receptor-associated kinase 1 and 4 (IRAK1 and IRAK4) 
in a spontaneous manner, thereby leading to constitutive downstream pathway activation309,310. 
Mutant MYD88 promotes survival via the constitutive activation of several signaling pathways in 
addition to the canonical NF-B pathway, including the Janus kinase (JAK), signal transducer 
and activator of transcription 3 (STAT3) and type I interferon (IFN) pathways309. Finally, tumor 
necrosis factor, alpha-induced protein 3 (TNFAIP3, also known as A20), a negative regulator of 
the canonical NF-B signaling cascade, is frequently subjected to bi-allelic inactivation311,312.  
Functional validation of addiction to constitutive canonical NF-B activation 
The addiction of ABC-DLBCL to constitutive canonical NF-B signaling has been directly 
demonstrated using both in vitro and in vivo approaches. Suppression of  canonical NF-B 
activation via the introduction of a super-repressor form of IBα or a dominant negative form of 
IKKβ leads to cell death and growth arrest in ABC-DLBCL but not GCB-DLBCL cell lines276. The 
oncogenic function of mutant CARD11 was demonstrated using complementation assays in 
which ABC-DLBCL lines expressing CARD11 mutants could be rescued from cell death 
following CARD11 knockdown via the introduction of mutant CARD11, but not wild-type 
CARD11308. In addition, the reintroduction of A20 into ABC-DLBCL cell lines with bi-allelic 
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inactivation of TNFAIP3 induced apoptosis and cell growth arrest. In vivo, tumorigenicity was 
also observed, demonstrating a tumor suppressor role for A20311,312. Finally, constitutive 
activation of NF-B signaling cooperated with BLIMP1 inactivation in mouse GC B cells to drive 
the development of a lymphoma closely resembling human ABC-DLBCL313.  
Activating mutations in alternative NF-B signaling components 
Mutations that activate the NF-B signaling cascade in ABC-DLBCL do so predominantly via the 
canonical pathway. However, mutations leading to activation of the alternative NF-B pathway 
were also observed in DLBCL with a frequency of ~15%242,314,315. Nuclear p52 was however 
observed in ~30% of cases, suggesting a more expansive role for this pathway311. These 
genetic lesions occurred in DLBCL irrespective of the GCB or ABC subtype, and were either 
mutations or mono- or bi-allelic deletions of TRAF3 or TRAF2242,314 that abrogated the ability of 
these factors to degrade NIK, resulting in constitutive alternative NF-B pathway activation (Fig. 
1.7). Finally, NIK overexpression in GC B cells cooperated with deregulated BCL6 to promote 
the development of DLBCL in mice, thereby demonstrating an oncogenic role for the alternative 
NF-B pathway in this disease315.  
NF-B mutations in multiple myeloma (MM)  
MM is a post-GC malignancy of PCs during which a monoclonal PC population accumulates in 
the bone marrow316. The disease has several subtypes defined by particular genetic and 
cytogenetic alterations; however, it is believed that dysregulation of Cyclin D (Cyclin D1, D2 or 
D3) may be a unifying event317. Multiple mutations in NF-B signaling components have also 
been identified in this disease with a frequency of ~17%318-320. However, in contrast to ABC-
DLBCL, most of these mutations affected signaling components of the alternative NF-B 
pathway318-320 (Fig. 1.7).  
Activating mutations in alternative NF-B signaling components 
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Several mutations that lead to the overexpression of NIK were observed in MM318,320 (Fig. 1.7). 
Overexpression of NIK was achieved both directly via amplification or translocations and 
indirectly via mechanisms that lead to protein stabilization318,320. Indirect mechanisms involved 
mutations in the region of NIK targeted by TRAF3 for NIK destabilization. Inactivation of several 
negative regulators of NIK protein stability were also observed, including bi-allelic deletion, 
truncating mutations and epigenetic silencing of TRAF3 and TRAF2 and BIRC2/BIRC3 (genes 
encoding the ubiquitin ligases c-IAP2/3, which promote NIK degradation)318,320.  Copy number 
amplifications of CD40, LTBR and TACI (another receptor which can activate NF-B signaling) 
and homozygous deletion of cylindromatosis (CYLD), a negative regulator of NF-B signaling, 
were also observed318,320. Similar to the canonical pathway mutations observed in B-NHL, most 
of these aberrations therefore affected upstream components of the alternative NF-B pathway, 
with a few exceptions such as truncating mutations of NFKB2 (the gene encoding p100)318,320. 
These NFKB2 mutations disrupt the C-terminal ankryin repeats that serve as an inhibitory 
domain that maintains cytoplasmic localization. Similar mutations have previously been reported 
for MM and other lymphoid malignancies321,322. Finally, amplification of NFKB1 (the gene 
encoding p105, a canonical pathway component) was also observed318,320.  
Cross-talk between the canonical and alternative NF-B pathways 
While the majority of these mutations in MM affect upstream components of the alternative NF-
B pathway, analysis of MM cell lines revealed that these mutations were found to constitutively 
activate both the alternative and canonical pathways in the majority of cases318,319,323. In 
addition, toxicity was induced in many of these cell lines following inhibition of the canonical NF-
B pathway via treatment with a specific inhibitor of IKKβ318. Knockdown of NIK in NIK-
overexpressing cell lines induced toxicity and reduced both canonical and alternative pathway 
activation and induction of TRAF3 in TRAF3-deficient lines had similar effects318,319,323. Indeed, 
the toxicity induced by NIK inhibition may be dependent on the canonical pathway, since it was 
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observed that knockdown of IKKα, downstream of NIK in the alternative pathway, in NIK-
overexpressing lines did not affect viability318.  
This dual activation is likely a result of cross-talk between the two pathways. For example, in 
certain cellular contexts, NIK has been shown to activate the canonical pathway in response to 
particular stimuli, including CD40L and BAFF290 (Fig. 1.7). In addition, overexpression of NIK is 
associated with canonical pathway activation via activation of the IKK complex324-327. It is 
possible therefore that elevated NIK may promote MM survival primarily via activation of the 
canonical pathway318. However, as nuclear localization of alternative subunits was also 
observed in these cases, it is likely that both pathways are utilized318,319,323.  
Role of the bone marrow niche in MM 
The findings described above collectively demonstrate that constitutive NF-B activation has an 
important role in MM pathogenesis.  A unique aspect of MM, in comparison to B-NHLs, is 
dependence on the bone marrow microenvironment. As outlined in Section 1.4, PCs rely on 
signals from bone marrow niches for long term survival. These signals include BAFF and 
APRIL, related molecules that can activate the NF-B signaling cascade by binding to the 
BCMA receptor expressed on PCs231,232,234,235. Normal PCs are therefore characterized by 
activated NF-B signaling and the magnitude of this signaling may be the highest observed 
among B cell subpopulations318. MM cells also reside within the bone marrow environment and 
rely on bone marrow trophic signals for survival328-332. It has been suggested that mutations 
causing constitutive NF-B activity may allow MM cells to escape the survival limitations 
imposed by the bone marrow environment, thus leading to growth that is independent of bone 
marrow factors333,334. 
NF-B mutations in other B cell malignancies  
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In addition to the mutations in NF-B signaling components observed in DLBCL and MM, other 
types of B cell malignancies also display similar aberrations. These B cell malignancies include 
Hodgkin lymphoma, splenic marginal zone lymphoma, mantle cell lymphoma, mediastinal large 
B cell lymphoma and chronic lymphocytic leukemia (reviewed in ref.335). Mutations activating the 
canonical pathway and/or the alternative NF-B pathway were identified in most cases. The 
acquisition of activating mutations in NF-B signaling components is therefore common among 
B cell malignancies. These activating mutations appear to be a rare feature as constitutive NF-
B signaling is commonly achieved via infection and inflammatory environmental stimuli in other 
contexts of cancer336,337.    
Function of NF-B activation in GC and B cell development? 
The selection of mutations converging on NF-B activation in various GC-derived lymphomas 
suggests that the NF-B signaling cascade may have an important biological role during normal 
GC development. Understanding the biological function of NF-B may therefore provide insights 
into the oncogenic function of this signaling cascade. Cross-talk between the canonical and 
alternative NF-B pathways necessitates analysis of the downstream transcription factors of the 
NF-B cascade in order to assign specific functions to either the canonical or alternative NF-B 
pathway. As such, the role of the canonical subunits c-REL and RELA in the GC reaction was 
the subject of a project within the lab that was recently published338 (discussed in Section 4.1). 
The importance of the subunits of the alternative NF-B pathway, RELB and p52, during GC 
development however remained an open question and is the focus of this thesis in Chapters 3 
and 4. In contrast, the alternative NF-B pathway has been extensively studied within the 
context of mature B cell survival. However, specific questions remained, regarding B cell 
intrinsic functions and the events that occur downstream of BAFF-mediated activation of the 
alternative NF-B pathway, and these issues are addressed in Chapter 2.  
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Figure 1.1. Stages of mature B cell development. Immature B cells expressing a functional B 
cell receptor (BCR) complete development within the bone marrow and progress through two 
transitional stages (T1 and T2) prior to becoming a mature B cell. For the majority of immature B 
cells, these transitional stages occur in the spleen. T2 B cells mature into either follicular B cells 
(also known as mature B cells) or marginal zone (MZ) B cells. Mature B cells activated via 
antigen (red) in the presence of T cell help enter the germinal center (GC) reaction, GC B cells 








Figure 1.2. Structure of the spleen. Blood is supplied to the spleen by the splenic artery which 
branches into arterioles (not depicted). These arterioles penetrate a vessel called the marginal 
sinus. From the marginal sinus, blood filters into the marginal zone (MZ) prior to reentering the 
general circulation. The white pulp of the spleen is lymphoid tissue comprised of B cell follicles 
that are bordered by T cell areas. B cells travelling in the blood migrate into the B cell follicles 
from the MZ. This splenic structure is shown schematically (top) and via immunohistochemical 
analysis of mouse spleen for the expression of IgM (bottom, image provided by Nicole Heise). 
Germinal centers (GCs) form within B cell follicles and are marked by BCL6 expression 





Figure 1.3. Dynamics of the GC reaction and selection of high-affinity antibody mutants. 
Antigen-activated germinal center (GC) precursor B cells form the early GC at day 4, during 
which they differentiate into blasts that undergo clonal expansion over the following days until 
the mature GC, that is characterized by a dark zone (DZ) and light zone (LZ), forms at day 7. 
During proliferation, the process of somatic hypermutation (SHM) introduces base-pair changes 
into the V(D)J region of the rearranged immunoglobulin variable region (IgV) genes (red lines); 
some of these base-pair mutations lead to a change in the amino acid sequence. DZ B cells 
then move to the LZ, where the modified B cell receptor (BCR) of the LZ B cell, with help from 
immune cells, including T follicular helper (Tfh) cells and follicular dendritic cells (FDCs), is 
selected for improved binding to the immunizing antigen. Among the newly generated LZ B cells 
that express BCR mutants resulting from SHM in the DZ, higher BCR affinity is directly 
associated with greater antigen capture and leads to a higher density of peptide–major 
histocompatibility (MHC) complexes presented on the surface of the B cell. This results in the 
greatest share of T cell help, in the form of CD40 stimulation and other signals, which in turn 
drives positive selection. Newly generated LZ B cells that produce an unfavourable antibody are 
rendered unable to capture sufficient antigen and undergo apoptosis. Following positive 
selection, a subset of LZ B cells is instructed to recirculate to the DZ. LZ B cells may undergo Ig 
class switch recombination (CSR) before LZ–DZ recirculation, whereas other cells switch and 
directly differentiate. Back in the DZ, these cells undergo further proliferation and SHM, thus 
potentially generating antibody mutants with an improved affinity. Recirculation between the DZ 
and the LZ facilitates several iterative rounds of mutation and selection, and within a short time, 
leads to the generation of high-affinity memory B cells and plasma cells (PCs). Antigen-selected 
LZ B cells eventually differentiate into memory B cell precursor cells and plasmablasts, which 






Figure 1.4. Mutually repressive genetic programs govern the B cell/GC B cell vs. PC fate.  
In B cells and/or germinal center (GC) B cells, the transcription factors PAX5, BACH2 and BCL6 
inhibit plasma cell (PC) development by repressing the transcription of genes encoding the PC 
regulator BLIMP1. PC development is further inhibited by BCL6-mediated repression of the 
gene encoding IRF4, PAX5-mediated repression of the genes encoding J chain and XBP1 and 
repression of the gene encoding IRF4 by MITF. In PCs, BLIMP1 represses the genes encoding 
the B cell/GC B cell factors PAX5, c-MYC and BCL6. In addition, IRF4 represses the gene 
encoding BCL6. Repression of the PC genetic program in B cells and GC B cells prevents 
premature PC differentiation and repression of the B cell and GC B cell genetic program in PCs 





Figure 1.5. The NF-B signaling cascade. The NF-B signaling cascade is comprised of two 
pathways, the canonical and alternative NF-B pathways. Signaling through the T cell receptor 
(TCR), B cell receptor (BCR), Toll-like receptors (TLRs), interleukin 1-receptor (IL1-R) and 
tumor necrosis factor-receptors (TNF-Rs) lead to activation of the canonical NF-B pathway. 
Signaling through these receptors culminates in the activation of IKKβ. IKKβ is present in a 
complex with another catalytic subunit, IKKα, and the regulatory subunit IKKγ. Activated IKKβ 
phosphorylates inhibitory IBmolecules, marking these subunits for proteasomal degradation. 
Under unstimulated conditions, these IBs hold the canonical heterodimers in an inactive form 
in the cytoplasm. Following proteasomal degradation of IBs, homo- or heterodimers of the 
transcription factor subunits c-REL, RELA and p50 (usually c-REL-50 and RELA-p50) are free 
to enter the nucleus and bind to B binding sites in the regulatory regions of target genes to 
drive transcription. Activation of the alternative NF-B pathway is induced by a more limited set 
of signals, including the lymphotoxin β-receptor (LTβR) and B cell activating factor-receptor 
(BAFF-R). CD40 stimulation is capable of activating both the canonical and alternative NF-B 
pathways. Signaling through these receptors releases NIK from continuous turnover mediated 
by a complex comprised of TRAF2, TRAF3 and cIAP1/2. NIK activates IKKα homodimers, 
which phosphorylate and subsequently induce proteasomal processing of p100 which is bound 
to the transcription factor subunit, RELB. This results in the generation of the transcription factor 
subunit p52 and the release of RELB from p100-mediated inhibition and retention within the 
cytoplasm. RELB-p52 heterodimers then enter the nucleus and activate transcription of target 





Figure 1.6. Genetic aberrations in multiple components of the NF-B signaling cascade 
are observed in B cell malignancies. Mutations in genes encoding multiple components of the 
NF-B signaling cascade are observed in various B cell malignancies. These mutations lead to 
constitutive activation of the canonical and/or alternative NF-B pathway. Activating mutations 
are marked with a red asterisk. Inactivating mutations, including bi-allelic mutations and/or 
deletions, are marked with a blue asterisk. Figure adapted from ref.335. The publications 









Impairment of mature B cell maintenance upon combined ablation of the 
alternative NF-B transcription factors RELB and NF-B2 in B cells  
50 
 
Section 2.1: INTRODUCTION 
As mentioned in Section 1.2, it is clear that the maintenance of mature B cells is dependent on 
tonic BCR signaling61,62 and signaling induced by binding of BAFF to the BAFF-R64-73. The 
downstream events that orchestrate this dependence are however convoluted and have been 
the subject of intense investigation.  
As BCR stimulation via cognate antigen during B cell activation is known to activate 
canonical NF-B signaling, it was believed that the canonical NF-B pathway was also activated 
within the context of tonic BCR signaling. A role for the canonical pathway in tonic signaling was 
further supported by the observation that mature B cells were greatly reduced upon B cell-
specific ablation of the canonical pathway components IKKγ and IKKβ339,340. However, removal 
of downstream components of the BCR pathway that are necessary for canonical NF-B 
activation, CARD11, MALT1 and BCL10, had minimal impact on the resting peripheral B cell 
pool306,341-345. Furthermore, BCR signaling is capable of activating many pathways346, including 
the phosphoinositide 3-kinase (PI3K) pathway, and it was demonstrated that BCR-deficient 
mature B cells could be completely rescued by PI3K activation in vivo347. In contrast, minimal 
rescue was observed following activation of canonical NF-B signaling using a constitutively 
active IKKβ347. These results suggest that B cell survival mediated by tonic BCR signaling does 
not critically involve signaling through the canonical NF-B pathway. Tonic BCR signaling is 
therefore functionally distinct from BCR signaling induced by cognate antigen interactions. This 
is further supported by the inability of mitogen-activated protein kinase (MAPK) activation, 
another pathway involved in antigen-dependent B cell activation, to rescue BCR deficiency347.  
Genetic ablation of BAFF or the BAFF-R results in a dramatic reduction in peripheral B 
cells due to maturation arrest at the T1 developmental stage348. In terms of NF-B activation, 
BAFF-BAFF-R signaling is predominantly associated with activation of the alternative NF-B 
pathway286-288. However, the phenotypes of mice deficient for the alternative NF-B signaling 
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components IKKα303,349 or NIK350 did not fully recapitulate the severe B cell defects observed in 
BAFF-R deficient mice. In these mice, B cell numbers were reduced, although not to the 
dramatic extent observed in the absence of BAFF survival signals. This indicates that BAFF 
also mediates B cell survival via pathways other than the alternative NF-B pathway. BAFF has 
been reported to activate several downstream signaling routes including protein kinase B (PKB 
or AKT), PI3K, extracellular signal-regulated kinase (ERK) and protein kinase Cβ (PKCβ) 
signaling axes which sustain B cell survival and metabolic fitness and may be a means of 
crosstalk with tonic BCR signaling83-87. Indeed, sustained activation of the PI3K pathway is able 
to partially restore B cell maturation in the absence of BAFF83. In regards to NF-B activation, it 
has been reported that activation of the canonical pathway may also contribute to BAFF-
mediated pro-survival functions351,352. Most strikingly, BAFF-R deficiency can be fully rescued by 
constitutive canonical NF-B activation353. It appears therefore that the canonical pathway can 
replace signals derived from BAFF-mediated activation of the alternative NF-B pathway as well 
as pathways. These findings suggest that BAFF-mediated activation of the canonical NF-B 
pathway may explain in part the importance of canonical NF-B signaling to mature B cell 
maintenance339,340. 
The body of literature described above highlights the involvement of several signaling 
routes in maintaining the survival of mature B cells in the periphery. These signaling routes 
appear to direct overlapping functions, suggesting that mechanisms driving mature B cell 
survival are highly reinforced. In order to determine the function of alternative NF-B signaling in 
BAFF-mediated B cell survival, many studies have focused on analyzing upstream components 
of the alternative pathway and have confirmed that this pathway has a critical role in maintaining 
B cell homeostasis. Constitutional deletion of these upstream components produces dramatic 
phenotypes often associated with severe lymphoid architectural defects. These defects are 
likely due to disrupted activation of the alternative NF-B pathway by LTβ in non-hematopoietic 
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cell types354. Due to these severe phenotypes, described below are studies in which radiation 
chimeras were utilized to investigate the function of upstream components of the alternative 
NF-B pathway in hematopoietic cells, or studies in which these components were 
conditionally deleted in B cells. First, adoptive bone marrow transfers involving alymphoplasia 
(aly) mice, which harbor a defective NIK, resulted in a marked reduction in mature B cells350. 
Second, conditional deletion of TRAF2 or TRAF3 and double deletion of cIAP1 and cIAP2, 
which are negative regulators of NIK, led to peripheral B cell hyperplasia and conferred 
independence from BAFF survival signals355-357. Third, fetal liver cell transfer studies reported 
that inactivation of IKKα was associated with a marked decrease in the number of peripheral B 
cells303,349. However, this issue requires further investigation as more recent work using 
conditional alleles found that while deletion of ikkα in early B cell development led to a reduction 
in the number of peripheral B cells due to a partial block in B cell maturation at the T2 stage, 
inducible deletion of ikkα in mature B cells had little effect, and p100 processing was not 
impaired83. Finally, it is important to note that, while NIK and IKKα have critical roles in inducing 
the processing of p100 and thereby facilitating nuclear translocation of RELB/p52 heterodimers, 
these factors can have additional functions. In certain cell systems, NIK has been found to also 
activate the canonical pathway290,324-327, and IKKα has NF-B-independent roles358. These 
alternative NF-B pathway-independent functions of NIK and IKKα make it difficult to 
conclusively identify the biological role of RELB/p52-mediated target gene transcription via the 
study of NIK or IKKα. 
Similar to constitutional deletion of the upstream alternative NF-B components 
described above, ablation of relb or nfkb2 produces severe phenotypes. In the absence of 
RELB or NF-B2 (p100/p52), disrupted lymphoid organization was observed, and RELB-
deficient mice in addition were characterized by multiorgan inflammation359-362. Due to these 
limitations, the roles of RELB and NF-B2 in mature B cell development have been investigated 
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with bone marrow chimeras360,362. Relb–/–→wild-type (WT) chimeras displayed a strong 
reduction in MZ B cells, suggesting that RELB is required in hematopoietic cells for the 
generation of this B cell subset362. Reduced peripheral B cells and a distorted MZ were 
observed in nfkb2–/– mice360,361; however, the study of nfkb2–/–→RAG-1 (recombination 
activating gene 1) chimeras did not specifically report reduced B cell numbers or impaired MZ B 
cell development360. Finally, combined constitutive ablation of RELB and NF-B2 has not been 
undertaken. As such, similar experiments with hematopoietic cells from relb–/–nfkb2–/– mice to 
determine the biological consequences of the combined deletion of RELB and NF-B2 in B cells 
have not been conducted.   
The studies outlined above have revealed much information about the role of the 
alternative NF-B pathway in BAFF-mediated B cell homeostasis; however, several issues 
remain to be clarified. First, the cell-intrinsic requirement of the NF-B2 or RELB subunits for 
mature B cell maintenance has not been determined using conditional alleles that can be 
deleted specifically in B cells. Second, knockout of either relb or nfkb2 alone does not allow 
complete ablation of the alternative NF-B pathway. Indeed, in the absence of either RELB or 
NF-B2, the remaining alternative NF-B subunit may be able to drive transcription by binding 
to canonical NF-B subunits. Furthermore, in nfkb2 knockout mice, lack of NF-B2 not only 
prevents the generation of p52, but also eliminates the p100 inhibitor. NF-B2 retains RELB in 
the cytoplasm, and in its absence, inappropriate translocation of RELB into the nucleus may 
occur, potentially resulting in target gene transcription via the formation of heterodimers with 
other NF-B subunits. Therefore, identification of the biological consequences of complete 
inactivation of the alternative NF-B pathway requires ablation of both RELB and NF-B2 
subunits. Finally, the transcriptional program activated by the alternative NF-B pathway in B 
cells following stimulation with BAFF has not been defined. To address these issues, we have 
generated conditional relb and nfkb2 alleles. We found that combined deletion of relb and nfkb2 
54 
 
in B cells had a markedly stronger effect on the survival of mature B cells compared to the 
single gene deletions. These results reveal the extent to which the activity of the alternative NF-
B pathway controls B cell homeostasis in vivo, and provide new insights into the biological 
program controlled by the alternative NF-B pathway in response to BAFF. 
Section 2.2: MATERIALS AND METHODS 
Generation of mice carrying a floxed relb or nfkb2 allele 
The targeting vector used to target relb and nfkb2 has been described previously in the context 
of targeting the irf4 gene200. The relb and nfkb2 vectors were constructed such that upon Cre-
mediated deletion, the promoter regions and the exons comprising the first ATG of relb or nfkb2 
were deleted with simultaneous activation of eGFP expression (Fig. 2.1-2.3). The conditional 
relb and nfkb2 alleles were backcrossed to C57BL/6 mice (n ≥ 7). CD19-Cre mice have been 
described363. Mice were housed and treated in compliance with the US Department of Health 
and Human Services Guide for the Care and Use of Laboratory Animals and in accordance with 
the guidelines of the Institute of Comparative Medicine at Columbia University (New York). The 
animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of 
Columbia University. 
B cell isolation and culture 
Single cell suspensions of mouse spleen were subjected to hypotonic lysis and B cells were 
purified by depletion of magnetically labeled non-B cells using the MACS B cell isolation kit 
(Miltenyi Biotec). Purified B cells from the indicated genotypes were cultured in the presence of: 
1 g/ml anti-mouse CD40 (clone HM40-3; BD Pharmingen) or 25 ng/mL BAFF (R&D Systems). 
Cell density in CD40 and BAFF stimulation experiments was 1.5 x 106 cells/mL using RPMI with 
15% FBS. For the RNA-seq analysis, cell pellets were lysed with TRIzol reagent (Life 
Technologies) for RNA isolation. For Western blot analysis, purified B cells were washed twice 
with PBS and subjected to NP40-based lysis.  
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Flow cytometry  
Spleen cell suspensions or cultured B cells were stained on ice in PBS/0.5% BSA with the 
following antibodies. From BD Pharmingen: APC-conjugated anti-IgM (clone II/41), PE-
conjugated anti-IgD (clone 11-26c.2a) and PE-conjugated anti-CD23 (clone B3B4). From 
Biolegend: PerCP-conjugated anti-B220 (clone RA3-6B2), APC-conjugated anti-CD21 (clone 
7E9), PE-conjugated anti-β2 (clone M18/2), PE-conjugated anti-CD93 (clone AA4.1), biotin-
conjugated anti-ICOSL (clone HK5.3) followed by streptavidin-PerCP (BD Pharmingen) and PE-
conjugated anti-BCL2 (clone BCL/10C4). Intracellular BCL2 was detected using the BD 
Cytofix/Cytoperm Fixation Permeabilization Kit. Annexin V/7-AAD stainings were conducted 
using the APC Annexin V Apoptosis Detection Kit with 7-AAD (Biolegend). For DNA content 
analysis, cells were lysed and stained with propidium iodide (PI). The cells or nuclei were 
washed and analyzed on a FACSCalibur or LSRII (BD). Data were analyzed using FlowJo 
software.  
Immunohistochemistry 
Sections of 2-3 m in thickness were cut from spleen tissue that was fixed overnight in 10% 
formalin and embedded in paraffin. Sections were stained with either H&E, unlabeled anti-CD3 
rabbit antibody (Thermo Scientific, clone SP7), or anti-GFP rabbit antibody (Molecular Probes, 
Invitrogen). Antibodies were incubated overnight at 4°C, stained with anti-rabbit HRP-labeled 
polymer (Dako) and developed in aminoethylcarbazole (AEC; Sigma). These slides were then 
counterstained for IgM by overnight incubation at 4°C with alkaline peroxidase (AP)-conjugated 
anti-IgM antibody (Southern Biotech). IgM stainings were developed in nitro blue tetrazolium 
chloride–5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; Roche, New York, NY). The images 
were acquired by means of a Digital Sight camera (Nikon) mounted on a Nikon Eclipse E600 




Purified B cells were subjected to NP40-based lysis, separated by SDS-PAGE and blotted on 
nitrocellulose membranes (GE Healthcare). Samples were incubated with the following primary 
antibodies overnight at 4°C: rabbit anti-RELB (Santa Cruz, clone C-19), rabbit anti-p100/p52 
(Cell Signaling Technologies, CST), mouse anti-β-actin (Sigma, clon: AC-15), rabbit anti-pAKT 
(Cell Signaling Technologies, CST, clone D9E) and rabbit anti-AKT (Cell Signaling 
Technologies, CST). Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit IgG, 
GE Healthcare and anti-mouse IgG, Thermo Scientific) and ECL Western Blotting Substrate or 
SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) were used for 
detection.   
RNA-seq 
RNA was harvested from 3 culture replicates/genotype of BAFF-stimulated B cells and 
submitted for RNA-sequencing at the Columbia University Genome Center. 30 million single-
end, 100bp reads were sequenced per sample on the Illumina HiSeq2000/2500 V3 instrument. 
DESeq analysis was used to identify differentially expressed genes and determine fold 
expression changes between genotypes. Padj is the p value for the statistical significance of the 
corresponding fold changes adjusted for multiple testing correction to control the false discovery 
rate (FDR).  
Statistical analysis 
P values were obtained using unpaired Student’s t test. P values < 0.05 were considered 
significant. 
Section 2.3: RESULTS 
Conditional deletion of relb and nfkb2 in B cells  
To determine the B cell-intrinsic functions of RELB and NF-B2 in the maintenance of B cells in 
vivo, we generated transgenic mouse strains carrying loxP-flanked alleles of relb and nfkb2, 
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respectively. The region of the relb or nfkb2 genes flanked by loxP sites comprised the promoter 
region and the exon encoding the translational start site, thus allowing the creation of relb or 
nfkb2 null alleles upon Cre-mediated recombination of loxP sites. A previously described 
targeting vector was utilized to generate these alleles200. To generate a relb targeting vector, 3 
DNA fragments were successively inserted into the cloning sites of this targeting vector – (1) 
2.2kb of the region upstream of the relb promoter region; (2) the relb promoter region and exon 
1 which contains the translation start site and exon 2 (overall 2.8kb); and (3) 3.8 kb of the region 
downstream of exon 2 (Fig. 2.1). Likewise, to generate a nfkb2 targeting vector, the following 
DNA fragments were successively inserted into the targeting vector – (1) 2.0 kb of the region 
upstream of the nfkb2 promoter region; (2) the nfkb2 promoter region and exon 1 and exon 2, 
which contains the translational start site (overall 2.4kB); and (3) 4.6 kb of the region 
downstream of exon 2 (Fig. 2.2). The linearized vectors were electroporated into KV1 embryonic 
stem (ES) cells (a 129:B6 hybrid ES cell line), and correctly targeted ES cell colonies were 
identified after selection with gancyclovir and G418 via a PCR-based screening strategy 
followed by confirmation via Southern blot analysis (Fig. 2.1, Fig. 2.2). 288 ES cell clones 
transfected with the relb targeting vector were screened via PCR for integration of the 5’ and 3’ 
regions of the targeting vector. 20 (6.9%) of the screened ES cell clones were positive for 5’ 
integration, and of these, 5 (25.0%) were positive for 3’ co-integration.  The frequency of 
correctly targeted ES cell clones was therefore 1.7% with a total of five clones identified, which 
were expanded and correct integration was confirmed via Southern blot analysis (Fig. 2.1). 2 ES 
cell clones were subsequently injected into blastocysts derived from C57BL/6 mice and one of 
the 2 injections yielded chimeras. 188 ES cell clones transfected with the nfkb2 targeting vector 
were screened via PCR for integration of the 5’ and 3’ region of the targeting vector. 18 (9.6%) 
of the screened ES cell clones were positive for 5’ integration, and of these, 8 (44.4%) were 
positive for 3’ co-integration. The frequency of correctly targeted ES cell clones was therefore 
4.3% with a total of 8 clones identified. 6 of these ES cell clones were expanded and correct 
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integration was confirmed via Southern blot analysis (Fig. 2.2). 2 ES cell clones were 
subsequently injected into blastocysts derived from C57BL/6 mice and chimeras were obtained 
from 1 of the 2 injections. Following breeding of chimeras to C57BL/6 females, mice with the 
‘conditional’ relb or nfkb2 alleles in the germ-line were obtained.  
To enable B cell-specific ablation of relb and nfkb2, these mice were crossed to CD19-
Cre mice which express Cre recombinase specifically in B cells from the pre-B stage of bone 
marrow development363. The targeting vector used to generate the relb and nfkb2 alleles was 
constructed such that the recombination of loxP sites is accompanied by the expression of an 
enhanced green fluorescent protein (eGFP), thus enabling tracking of relb or nfkb2-deleted cells 
in the tissues (Fig. 2.1, 2.2, 2.3). To achieve this, an eGFP minigene was placed upstream of 
the relb or nfkb2 promoter regions in the opposite orientation; this minigene is silent in the 
targeted locus. However, following recombination of loxP sites, a phosphoglycerate kinase 
(PGK) promoter (placed in intron 2 of relb or nfkb2) is placed proximal to the eGFP gene, 
allowing transcription. A similar strategy was previously used for the conditional deletion of irf4, 
rel (the gene encoding c-REL) and rela200,338. In this system, gene deletion is directly linked to 
induction of eGFP expression, and therefore eGFP positivity is a marker for gene deletion. In 
addition, eGFP expression is quantitative, as B cells from mice heterozygous or homozygous for 
the floxed allele can be distinguished by their mean eGFP fluorescence200,338 (also see Fig. 
2.4A,B lower panels).  
Western blot analysis of B cells isolated from relbfl/flCD19-Cre and nfkb2fl/flCD19-Cre 
mice demonstrated that the protein levels of RELB and p52 were strongly reduced compared to 
B cells from littermate controls (Fig. 2.3B,E), confirming the creation of null alleles upon 
recombination of the loxP-flanked relb and nfkb2 alleles. The remaining protein is likely to be 
derived from eGFP– B cells that have escaped Cre-mediated deletion. This possibility was 
confirmed by the complete absence of RELB protein in flow-sorted eGFP+ B cells from 
relbfl/flCD19-Cre mice (Fig. 2.3C). The low eGFP expression in B cells of nfkb2fl/flCD19-Cre mice 
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prevented us from unambiguously separating eGFP+ and eGFP– B cells; we were therefore 
unable to perform a similar experiment for NF-B2. B cells from relbfl/+CD19-Cre and 
nfkb2fl/+CD19-Cre mice respectively showed reduced protein expression of RELB and p52 
relative to the CD19-Cre controls, indicating haploinsufficiency of RELB and p52 expression in B 
cells (Fig. 2.3B,C,E). Importantly, in the absence of Cre, the unrearranged conditional relb and 
nfkb2 alleles produced physiological amounts of RELB and p52 protein, respectively (Fig. 
2.3B,E).  
Reduced fractions of splenic B cells in the absence of alternative NF-B subunits  
To assess the B cell-intrinsic functions of the alternative NF-B subunits in B cell maintenance, 
we determined the fraction of mature splenic B cells present in mice with B cell-specific ablation 
of RELB or NF-B2 individually, or combined RELB and NF-B2 inactivation. Upon B cell-
specific ablation of RELB in relbfl/flCD19-Cre mice, we observed a slight but significantly reduced 
fraction of splenic B cells compared to relbfl/+CD19-Cre and CD19-Cre control mice (Fig. 2.4A; 
for cell numbers, see Fig. 2.5A). B cell-specific ablation of NF-B2 was associated with a 
marked reduction in the fraction of splenic B cells; B220+ cells comprised 28% of total 
splenocytes in nfkb2fl/flCD19-Cre mice compared to 46% and 50% in nfkb2fl/+CD19-Cre and 
CD19-Cre control mice, respectively (Fig. 2.4B; for cell numbers, see Fig. 2.5B). In order to 
obtain complete ablation of RELB/p52, the major heterodimer of the alternative NF-B pathway, 
the conditional relb and nfkb2 alleles were interbred to generate relbfl/flnfkb2fl/flCD19-Cre mice to 
allow simultaneous deletion of relb and nfkb2 in B cells. The fraction of splenic B cells in these 
mice was similar to that observed following ablation of NF-B2 alone (B220+ cells comprised 
30% of total splenocytes in relbfl/flnfkb2fl/flCD19-Cre mice compared to 45% and 50% in 
relbfl/+nfkb2fl/+CD19-Cre and CD19-Cre control mice, respectively; Fig. 2.4C; for cell numbers, 
see Fig. 2.5C). However, analysis of eGFP expression among B cells of relbfl/flnfkb2fl/flCD19-Cre 
mice identified two distinct eGFP+ and eGFP– peaks of approximately equal proportions (Fig. 
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2.4C; bottom panel). The presence of a sizable eGFP– population in mice with combined 
ablation of RELB and NF-B2 indicates that eGFP+ B cells deficient for both RELB and NF-B2 
are outcompeted by eGFP– B cells that escaped Cre-mediated deletion. As a result, relb/nfkb2-
deleted eGFP+ B cells were present at a frequency of only 15% of total splenocytes in 
relbfl/flnfkb2fl/flCD19-Cre mice compared to the B cell fraction of 50% observed in CD19-Cre 
control mice.   
The unique eGFP-expression pattern in relbfl/flnfkb2fl/flCD19-Cre mice contrasts with the 
single eGFP+ peak observed in B cells from relbfl/flCD19-Cre mice (Fig. 2.4A; bottom panel), 
suggesting that there is virtually no counter-selection against RELB-deficient B cells in these 
mice. Due to the generally low eGFP-expression in B cells from nfkb2fl/flCD19-Cre mice, a clear 
distinction between eGFP+ and eGFP– populations is not possible; however, the eGFP 
expression of B cells from nfkb2fl/flCD19-Cre mice is generally higher than that of B cells from 
mice with heterozygous deletion of nfkb2 (nfkb2fl/+CD19-Cre mice) (Fig. 2.4B; bottom panel). In 
addition, Western blot analysis (Fig. 2.3E) demonstrated that the majority of B cells from 
nfkb2fl/flCD19-Cre mice do not express p52 protein. Together, these observations argue against 
extensive counter-selection of NF-B2-deficient B cells in these mice, unlike what is observed in 
relbfl/flnfkb2fl/flCD19-Cre mice. Nonetheless, deletion of nfkb2 alone led to a strong reduction in 
the fraction of B cells that was considerably higher than that observed in relbfl/flCD19-Cre mice, 
indicating that functionally, p52 appears to be the major subunit downstream of the alternative 
pathway in B cells.   
Immunohistochemical staining analysis of spleen sections for IgM and CD3 revealed that 
in accordance with the reduced B cell fraction observed by flow cytometry, relbfl/flnfkb2fl/flCD19-
Cre mice displayed fewer B cell follicles within the white pulp compared to relbfl/+nfkb2fl/+CD19-
Cre and CD19-Cre control mice (Fig. 2.6). The size of these B cell follicles was also more 
heterogeneous in relbfl/flnfkb2fl/flCD19-Cre mice compared to the controls. In summary, 
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combined B cell-specific deletion of relb and nfkb2 results in a greatly reduced fraction of B cells 
that is reflected by abnormalities in splenic white pulp architecture. Moreover, the severity of the 
B cell phenotype upon relb/nfkb2 deletion appears to surpass that observed with the 
corresponding single gene deletions.  
Marked counter-selection against relb/nfkb2-deleted MZ B cells  
The bone marrow compartment is comprised of immature B cells and mature B cells that have 
yet to exit into the periphery. Mice with B cell-specific ablation of both RELB and NF-B2 
compared to controls displayed reduced frequencies of mature B cells (B220+CD93–) in the 
bone marrow, whereas immature B cells were present at normal frequencies (Fig. 2.7A). This is 
in agreement with published observations from relb–/– and nfkb2–/– mice which concluded that B 
cell development in the bone marrow is not impaired in these mice359,360. In addition, we 
observed that ~70% of immature CD93+B220int B cells in the bone marrow were positive for 
eGFP, which is a readout for gene deletion (Fig. 2.7B). This frequency is in the range of the 
deletion efficiency observed for CD19-Cre in immature B cells (77%±8%)363 which is lower than 
the frequency observed in splenic B cells (93%±4%)363; therefore, there does not appear to be 
counter-selection against relb/nfkb2-deleted immature B cells. In contrast, the fraction of mature 
B cells in the bone marrow that are positive for eGFP was ~40% (Fig. 2.7B), indicating that 
during the transition from the immature to the mature B cell stage, the fraction of relb/nfkb2-
deleted B cells is strongly reduced. This transition is also the timeframe during which BAFF 
responsiveness is initiated64,67,78-81, and the counter-selection against relb/nfkb2-deleted B cells 
observed following this transition is likely due to the requirement of the alternative NF-B 
pathway to transmit BAFF signals286-288. As such, eGFP– B cells successfully outcompeted 
eGFP+ B cells (i.e. relb/nfkb2-deleted) and became a significant population comprising 
approximately half of splenic peripheral B cells (Fig. 2.4C; bottom panel).  
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Among the splenic B cell subsets in relbfl/flnfkb2fl/flCD19-Cre mice, a slightly reduced 
fraction of follicular B cells (CD23+CD21int) and an increased fraction of MZ B cells 
(CD21hiCD23–) was observed compared to CD19-Cre mice (~70% vs. ~83% follicular B cells 
and ~11% vs. ~6% MZ B cells) (Fig. 2.8A). Similar observations were made when analyzing 
IgM+IgD+ and IgMhiIgDlo B cell subsets (data not shown). However, the extent of counter-
selection against relb/nfkb2 deleted B cells differed considerably between the follicular and MZ 
B cell fractions (Fig. 2.8B), with the strongest counter-selection observed in the MZ B cell 
compartment. Analysis of eGFP expression within MZ B cells (Fig. 2.8B) demonstrated that only 
~25% of MZ B cells were eGFP+ compared to ~57% of follicular B cells. The observed dramatic 
counter-selection against relb/nfkb2-deleted MZ B cells is consistent with previous publications 
that invoked roles for RELB or NF-B2 in the development of MZ B cells from the study of 
constitutional knockout mice352,362. Curiously, morphologic evaluation of hematoxylin & eosin 
stained splenic sections from relbfl/flnfkb2fl/flCD19-Cre mice demonstrated focal MZ enlargement 
in these mice compared to the controls (Fig. 2.9; left panels). The prominent MZs presumably 
reflect the higher fractions of MZ vs. follicular B cells that were observed among splenic B cells 
by flow cytometric analysis (see Fig. 2.8A). These observations suggest that while there is an 
overall reduction in both follicular B cells and MZ B cells in relbfl/flnfkb2fl/flCD19-Cre mice, of the 
B cells that remain, the fraction of MZ B cells is increased relative to follicular B cells. 
Importantly, immunohistochemical staining analysis of splenic sections revealed that the 
majority of the B cells in the enlarged MZs of relbfl/flnfkb2fl/flCD19-Cre mice did not stain for 
eGFP, whereas eGFP+ follicular B cells were readily observed (Fig. 2.9; right panels), a finding 
which is in accordance with the flow cytometric results (Fig. 2.8B). In summary, 
relbfl/flnfkb2fl/flCD19-Cre mice show strong counter-selection against relb/nfkb2-deleted MZ B 
cells.  
Identification of BAFF-responsive genes controlled by the alternative NF-B pathway  
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The data outlined above demonstrate that the alternative NF-B pathway controls a biological 
program that promotes B cell maintenance. In order to gain insight into this program, we sought 
to identify genes that are transcriptionally regulated by the alternative NF-B subunits in B cells 
stimulated with BAFF in vitro. A time-course analysis of BAFF stimulation on normal B cells 
revealed that at 6h, the majority of p100 was processed to p52, demonstrating robust activation 
of the alternative NF-B pathway (Fig. 2.10A). Phosphorylation of AKT, an additional event 
known to occur downstream of BAFF stimulation85, was observed after 24h of stimulation (Fig. 
2.10A). We chose to stimulate B cells for 6h in order to identify early BAFF-responsive genes. B 
cells purified by magnetic cell separation from nfkb2fl/flCD19-Cre mice were used for this 
transcriptional profiling experiment as these mice showed a marked reduction in mature B cells 
without evidence of strong counter-selection against nfkb2-deleted B cells, unlike what is 
observed in relbfl/flnfkb2fl/flCD19-Cre mice. B cells isolated from three nfkb2fl/flCD19-Cre and 
CD19-Cre mice each were stimulated with BAFF for 6 hours (6h) in vitro, and RNA harvested 
from the cultures was subjected to RNA sequencing.  
Differentially expressed sequence analysis (DESeq) of NF-B2-proficient vs. NF-B2-
deficient BAFF-stimulated B cells identified 150 genes with reduced (Fig. 2.10B), and 174 genes 
with increased expression in the absence of NF-B2 at a significance threshold of padj<0.05 
(Appendix A). The fold changes were mostly small, but highly significant. Genes were assigned 
to putative functional categories (Fig. 2.10B and Appendix A), including B cell markers, 
apoptosis, cellular trafficking, and immune response–T-dependent (Fig. 2.10C). A transcriptional 
profile analysis of BAFF-responsive genes controlled by the alternative NF-B pathway has not 
previously been undertaken. However, cd23 (encoding FcεRII) is a known BAFF-controlled 
gene in B cells364, and the gene encoding inducible costimulator ligand (ICOSL) has been 
identified as a bona fide target of the alternative subunits in response to BAFF-R stimulation in 
murine B cells365. In the RNA-seq analysis, we observed reduced expression of mRNA encoding 
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cd23 and icosl in NF-B2-deficient vs. control B cells (Fig. 2.10C). Accordingly, following BAFF 
or CD40 stimulation, ICOSL protein was expressed at significantly reduced levels on eGFP+ (i.e. 
relb/nfkb2-deleted) B cells derived from relbfl/flnfkb2fl/flCD19-Cre mice, whereas eGFP– B cells 
from the same mice displayed surface levels of ICOSL similar to those observed on WT B cells 
(Fig. 2.12A). These results validated our strategy for identifying BAFF-responsive targets. The 
major findings of the RNA-seq analysis are presented below.  
Control of BAFF-mediated survival by the alternative NF-B pathway  
We observed reduced expression of mRNA encoding the anti-apoptotic gene bcl2 in NF-B2-
deficient vs. control B cells (Fig. 2.10C). In accordance, flow cytometric analysis revealed lower 
BCL2 protein expression by B220+ B cells in relbfl/flnfkb2fl/flCD19-Cre mice compared to CD19-
Cre control mice (Fig. 2.11A). In addition, the genes encoding the pro-apoptotic factors BCL2 
modifying factor (BMF) and BCL2 binding component 3 (BBC3, PUMA) were expressed at 
higher levels in BAFF-stimulated relb/nfkb2-deleted vs. WT B cells (see Appendix A). Together, 
these findings suggest that B cells with impaired signaling through the alternative NF-B 
pathway have an increased propensity to undergo apoptosis. In agreement, following BAFF-
stimulation, increased cell death of B cells that express a RELB mutant protein which is unable 
to bind DNA has previously been demonstrated compared to WT controls366. To assess the 
survival capacity of RELB/NF-B2-deficient B cells in vitro, we stimulated B cells from 
relbfl/flnfkb2fl/flCD19-Cre or CD19-Cre control mice with either BAFF or CD40 for three days, as 
both BAFF and CD40 are strong activators of the alternative NF-B pathway283,286-288. The 
results showed significantly enhanced cell death in the cultures of RELB/NF-B2-deficient vs. 
control B cells in response to BAFF stimulation (~63% vs. ~23% by propidium iodide (PI) 
staining and ~66% vs. ~21% by annexin V/7AAD staining) (Fig. 2.11B,C). In contrast, cell 
viability was comparable among the genotypes in response to CD40 stimulation (~22% vs. 
~14% by PI staining and ~20% vs. ~17% by annexin V/7AAD staining), although the small 
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difference observed in the PI staining reached significance (Fig. 2.11B,C). These findings 
suggest that CD40 stimulation activates a transcriptional program in RELB/NF-B2-deficient B 
cells that is able to overcome the viability defect observed in response to BAFF.   
Control of B cell trafficking by the alternative NF-B pathway  
Both relb–/– and nfkb2–/– mice show altered lymphoid organization359-362, and analysis of total 
splenic mRNA from RELB-deficient mice revealed reduced expression of the chemokines 
CXCL13, CCL19 and CCL21, and mildly reduced expression of the chemokine receptors 
CXCR5 and CCR7 compared to controls362. These findings provided the first suggestion that the 
alternative pathway may be required for proper lymphoid organization by controlling the 
expression of chemokines or chemokine receptors in stromal and/or other cell types. In support 
of this notion, RNA-seq analysis revealed reduced mRNA expression of the genes encoding the 
chemokine receptors CXCR5, CCR7 and EBI2 (Gpr183), as well as the adhesion molecule L-
selectin (encoded by sell) in NF-B2-deficient B cells compared to controls following BAFF 
stimulation (Fig. 2.10C). These findings suggests that in B cells, the alternative NF-B pathway 
controls a gene expression program that permits homing to and positioning within B cell follicles 
in response to cues from stromal cells.   
Since the absence of alternative NF-B subunits correlated with a reduction in the 
fraction of MZ B cells (ref.352,362, and Fig. 2.8B, Fig. 2.9), we determined the surface protein 
expression of the integrin chains αL and β2, that together form the LFA-1 complex, on 
relb/nfkb2-deleted and WT control B cells. LFA-1 is important for the retention of B cells within 
the splenic MZ41. Whereas we detected no significant differences in the expression level of αL 
between eGFP+ (i.e. relb/nfkb2-deleted) B cells from relbfl/flnfkb2fl/flCD19-Cre and CD19-Cre 
control mice, relb/nfkb2-deleted B cells showed strongly reduced surface expression of β2 
compared to B cells from CD19-Cre control mice (Fig. 2.12B). This observation is likely to be 
relevant to the strong counter-selection against eGFP+ MZ B cells observed in 
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relbfl/flnfkb2fl/flCD19-Cre mice (Fig. 2.8B, Fig. 2.9), and may suggest an impaired retention of 
these cells in the MZ compartment (see discussion, Section 2.4). 
CD21 has been identified as a target of BAFF receptor signaling364. We observed lower 
protein levels on the surface of eGFP+ relb/nfkb2-deleted B cells in comparison to CD19-Cre 
control mice (Fig. 2.12C), suggesting that BAFF mediates expression of CD21 via the 
alternative NF-B pathway. CD21 is a complement receptor and high expression of CD21 is a 
marker of MZ B cells59. Reduced expression of CD21 may therefore result in less efficient 
binding to complement opsonized antigens, an important function of MZ B cells45,51,52. It is also 
possible that reduced expression of CD21 on RELB/NF-B2-deficient MZ B cells impairs the 
antigen-stimulation properties of those cells as the CD19/CD21 co-receptor complex has been 
implicated in lowering the threshold of BCR signaling367.  
Genes involved in T cell-B cell interactions regulated by the alternative NF-B pathway  
As mentioned above, the alternative NF-B pathway has been implicated in the regulation of 
ICOSL expression on B cells365. ICOSL is involved in facilitating interactions with T cells368 and 
its expression on B cells is required for the development of Tfh cells365. In addition to decreased 
expression of icosl in BAFF-stimulated NF-B2-deficient vs. control B cells, our RNA-seq 
analysis revealed reduced expression of several genes involved in MHC class-II (MHCII) 
antigen presentation (Fig. 2.10C). These included the genes ctss, h2-dmb2 and h2-oa, which 
respectively encode cathepsin S, H2-DMb2 and H2-Oa and are involved in the processing and 
removal of invariant chain peptide (CLIP) from MHCII molecules to allow loading of antigenic 
peptides369. In addition, cd83 was expressed at lower levels in NF-B2-deficient B cells 
compared to WT B cells (Fig. 2.10C). CD83 is a member of the Ig superfamily that is associated 
with B cell activation, and CD83-deficient splenic B cells also have reduced MHCII antigen 
presentation370. Thus, it appears that besides regulating ICOSL expression, the alternative NF-
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B pathway may have a more substantial role in activating the expression of genes required for 
optimal T cell-dependent B cell responses in response to BAFF. 
Section 2.4: DISCUSSION  
BAFF-mediated activation of the alternative NF-B pathway has long been implicated in the 
survival of mature B cells. However, the B cell-intrinsic roles of transcription factors downstream 
of the pathway, RELB or NF-B2, have not as yet been identified. Perhaps most importantly, it 
is unknown how the combined deletion of relb and nfkb2 affects the development and function 
of B cells. We here crossed newly generated conditional relb and nfkb2 alleles, either separately 
or in combination, to CD19-Cre mice in order ablate these subunits specifically in B cells. We 
found that the individual gene deletions led to a decrease in the fraction of mature B cells; 
however, the most dramatic reduction in peripheral B cells was observed upon simultaneously 
ablating RELB and NF-B2. Thus, by ablating the downstream transcription factors of the 
alternative NF-B pathway in B cells, our results for the first time define the extent to which this 
pathway regulates mature B cell homeostasis. In addition, we identified BAFF-responsive target 
genes of the alternative NF-B pathway that are involved in the survival and trafficking of 
peripheral B cells and their interaction with T cells.  
Similar to what has been described in mice with conditional B cell ablation of major 
regulators of the canonical pathway, IKKβ or IKKγ339,340, we observed a marked counter-
selection of relb/nfkb2-deleted B cells in mice with B cell-specific RELB/NF-B2 deficiency, 
which was strongest in the MZ B cell compartment. Nevertheless, none of these mouse models 
showed a complete disappearance of ikkβ, ikkγ or relb/nfkb2-deleted B cells, indicating that the 
B cell phenotypes are less severe than those observed in mice deficient in BAFF signaling that 
show a virtually complete absence of B cells. One possibility to explain these findings is that 
downstream of BAFF, the canonical and alternative NF-B pathways may complement each 
other to a certain extent during B cell development and maintenance, as suggested by the 
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observation that adoptive transfer of bone marrow from nfkb1–/–nfkb2–/– mice into RAG-1-
deficient animals resulted in the generation of only few mature B cells371. Of note, ablation of the 
canonical subunits c-REL or RELA in B cells does not appear to impact mature B cell numbers 
(Nicole Heise (Klein lab), unpublished findings), which may be suggestive of redundancy 
between these two subunits. The generation of mice with B cell-specific double ablation of c-
REL and RELA will clarify this issue. Finally, it is known that non-NF-B-mediated effects of 
BAFF signaling contribute to the survival of mature B cells83-87 and these effects may also 
promote the survival of relb/nfkb2-deleted B cells.  
In order to make a comparative assessment of the severity of the B cell maintenance 
defects that manifest in the absence of NF-B pathway components, the experimental systems 
should be comparable. In regards to the alternative NF-B pathway, CD19-Cre has been used 
to ablate TRAF2, TRAF3 and cIAP1/2 which all result in B cell expansion355-357. CD19-Cre-
mediated ablation of IKKα has also been conducted and the reduction in peripheral B cells, 
while similar to what we report here for combined ablation of RELB and NF-B2, is slightly less 
severe83. Also, no counterselection against ikkα-deficient B cells was evident83. Moreover, while 
deletion of ikkα in early B cell development using CD19-Cre (which deletes prior to the 
expression of the BAFF-R) led to a reduction in peripheral B cells due to a partial block in B cell 
maturation at the T2 stage, inducible deletion in mature B cells had little effect on peripheral B 
cell survival83. This study highlights an important distinction between a defect in the 
differentiation of T2 B cells into mature B cells and a defect in the maintenance of mature B cells 
once they have passed this transitional developmental stage. It is therefore possible that IKKα is 
required for progression through the T2 stage, while it is not required for continued maintenance 
of mature peripheral B cells83. Most studies aimed at understanding the roles of both canonical 
and alternative NF-B pathway components in B cell maintenance, including our study, cannot 
clearly distinguish between these two possibilities due to the use of bone marrow transfers or a 
69 
 
Cre expressed in early B cell development. While we cannot make such a distinction without the 
use of an inducible Cre, this issue can be further investigated by determining the effect of 
RELB/NF-B2 deficiency on transitional B cell subsets in the spleen, as to date we have only 
broadly characterized immature vs. mature B cells in the bone marrow of relb/nfkb2-deleted 
mice. Of note, the maintenance of mature B cells was recently assessed following inducible 
ablation of NIK372. However, in contrast to the IKKα report described above83, NIK ablation was 
induced ubiquitously in all cell types372. Reduced B cells were observed over time in mesenteric 
lymph nodes and Peyer’s patches upon inducible ablation of NIK, demonstrating that continued 
NIK expression is important for the survival of mature B cells in these sites372.  
In in vitro-cultures, relb/nfkb2-deleted B cells were sensitive to apoptosis when 
stimulated with BAFF, suggesting that the alternative NF-B pathway controls an anti-apoptotic 
program in normal B cells that is activated in response to BAFF stimulation. BAFF signaling has 
long been implicated in controlling B cell survival78, at least in part through the regulation of 
BCL2 expression373. In agreement with this notion, ectopic expression of BCL2 led to the 
accumulation of B cells in BAFF-R-deficient mice67,374,375. Our observation that peripheral B cells 
in mice with combined B cell-specific deletion of relb and nfkb2 died rapidly in vitro following 
BAFF stimulation and showed reduced protein levels of BCL2 suggests that bcl2 expression is 
at least partially mediated via the alternative NF-B pathway. Indeed, bcl2 has been described 
to be a target of nfkb2 in a cell line376. It is interesting to note that activation of relb/nfkb2-deleted 
B cells with CD40, also a strong inducer of p100 processing283, did not lead to increased cell 
death. This result may indicate that CD40 signaling can transmit survival signals by a different 
route, presumably via the canonical NF-B pathway377. Similarly, while B cells derived from 
mice with inducible ablation of NIK were found to exhibit greater susceptibility to cell death 
following BAFF stimulation, proliferation in response to CD40 stimulation was comparable to 
control B cells372. By means of exploring CD40 signaling in further detail we plan to conduct 
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gene expression profiling on CD40-stimulated nfkb2-deficient B cells, similar to the approach 
used to identify BAFF-responsive genes.  
BCL2 overexpression does not fully rescue the loss of B cells in BAFF-R-deficient mice 
as only follicular B cells with an immature surface phenotype develop in these mice. These B 
cells display improper follicular organization67,374,375, indicating that BAFF stimulation has 
additional functions besides providing pro-survival signals. In accordance, our RNA-seq analysis 
identified several BAFF responsive genes controlled by the alternative NF-B pathway that are 
involved in lymphocyte trafficking, including adhesion molecules and chemokine receptors. Two 
previous studies have implicated the alternative pathway in the regulation of B cell homing to 
the lymphoid follicles and the MZ, respectively. Based on an RT-PCR analysis of mRNA derived 
from whole spleen of relb–/– mice, Weih et al. reported slightly reduced mRNA levels of the 
genes encoding the chemokine receptors CXCR5 and CCR7362. Expression of CXCR5 is 
required for homing of B cells to the follicle25,26, while CCR7 directs positioning at the B-T cell 
boundary following antigen stimulation34,35. We found both receptors to be expressed at lower 
mRNA levels in BAFF-stimulated NF-B2-deficient B cells compared to controls. In addition, we 
observed reduced expression of the chemokine receptor EBI2, which guides B cell localization 
to the outer follicle and must be downregulated to enable GC formation101-105, and the adhesion 
molecule L-selectin (CD62L), which mediates the entry of lymphocytes from the blood into 
lymphoid tissue378. These results suggest that RELB/NF-B2-deficient B cells that fail to express 
chemokine receptors and adhesion molecules at physiological levels may be impaired in their 
homing to and organization within the follicle. In agreement with this notion, mice with B cell-
specific deletion of both relb and nfkb2 have a decreased number of splenic B cells and fewer B 
cell follicles (Fig. 2.4C, Fig. 2.5C, Fig. 2.6). In vitro migration assays that assess the ability of 
RELB/NF-B2-deficient B cells to travel towards the CXCR5 ligand CXCL13 may lend further 
support to a role for the alternative NF-B pathway in B cell migration.  
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A critical role for the alternative NF-B pathway in the development of MZ B cells has 
been suggested based on two observations: First, relb–/–→WT chimeras show a significant 
reduction of MZ B cells compared to the controls362. Second, BAFF-transgenic mice, mice with 
inactivation of upstream components of the alternative pathway (that induce processing of p100) 
and mice that lack p100 but still express p52, are characterized by MZ hyperplasia75,302,355-357,379. 
As reported by Enzler et al., the latter phenotype is likely due to the upregulation of the integrin 
chains αLβ2 (LFA-1) and α4β1 (VLA-4)352 that facilitate homing to the MZ41. The expression of 
these genes was found to be at least partially impaired in BAFF-Tg/nfkb2–/– mice that presented 
with a strongly reduced fraction of MZ B cells relative to BAFF-Tg mice352. In light of these 
findings, our observation that, compared to the controls, relb/nfkb2-deleted B cells had 
significantly reduced surface-expression of the β2 integrin chain suggests that these cells might 
have defects in homing to and retention within the MZ. In turn, this may contribute to the strong 
reduction in RELB/NF-B2-deficient MZ B cells observed in the spleens of relbfl/flnfkb2fl/flCD19-
Cre mice. It is possible that relb/nfkb2-deleted MZ B cells that fail to be retained by the stroma 
are flushed out into the blood and eventually disappear due to the lack of stroma-associated 
survival signals, similar to what has been observed in various other experimental 
systems41,42,352.  
Adding to a previous report365, we observed reduced protein expression of ICOSL on the 
cell surface of B cells upon BAFF as well as CD40 stimulation in relb/nfkb2-deleted B cells. Our 
RNA-seq analysis in addition revealed that several genes involved in MHC class II-antigen 
presentation failed to be expressed at physiological levels in BAFF-stimulated NF-B2-deficient 
B cells. These findings further suggest that the alternative NF-B pathway appears to control 




Figure 2.1. Generation of a conditional relb allele. Relb (RELB) targeting strategy. (Top) 
Shown from top to bottom i) the relb locus with the promoter region, exons and translational 
start site in exon 1 (E1); ii) the targeting vector comprising an enhanced green fluorescent  
protein (eGFP), a triple simian virus 40 (SV40) polyA site (tpA), a phosphoglycerate kinase 
(PGK) neomycin (neopA) cassette, a PGK promoter (P) downstream of exon 1, a thymidine 
kinase (TK) gene, and loxP and frt sites; arrows denote the orientation; iii) the targeted relb 
locus and iv) the locus after Cre-mediated recombination of loxP sites. Restriction sites, probes 
used for detection and the expected fragments detected by Southern blot analysis are indicated. 
(Bottom) Correctly targeted embryonic stem (ES) cell lines were identified by Southern blot 
analysis of EcoRV-digested DNA that displayed the 5.9 kb band of the integrated transgene 
along with the 11.4 kb wild-type (WT) band. Co-integration of the 3’ loxP site was verified by the 





Figure 2.2. Generation of a conditional nfkb2 allele. Nfkb2 (NF-kB2) targeting. (Top) Shown 
from top to bottom i) the nfkb2 locus with the promoter region, exons and translational start site 
in exon 2 (E2); ii) the targeting vector comprising an enhanced green fluorescent  protein 
(eGFP), a triple simian virus 40 (SV40) polyA site (tpA), a phosphoglycerate kinase (PGK) 
neomycin (neopA) cassette, a PGK promoter (P) downstream of exon 2, a thymidine kinase 
(TK) gene, and loxP and frt sites; arrows denote the orientation; iii) the targeted nfkb2 locus and 
iv) the locus after Cre-mediated recombination of loxP sites. Restriction sites, probes used for 
detection and the expected fragments detected by Southern blot analysis are indicated. 
(Bottom) Correctly targeted embryonic stem (ES) cell lines were identified by Southern blot 
analysis of PvuII-digested DNA that displayed the 8.3 kb band of the integrated transgene along 
with the 5.2 kb wild-type (WT) band. Co-integration of the 3’ loxP site was verified by PCR 
analysis using primers that hybridize in a unique region spanning the PGK promoter and the 3’ 





Figure 2.3. Generation of mice with conditional deletion of relb or nfkb2 in B cells and 
simultaneous expression of eGFP. (A and D) Targeting strategy showing the status of relb 
and nfkb2 before (top) and after (bottom) Cre-mediated recombination. Numbers indicate the 
respective exons. (B and E) Western blot analysis of RELB and p52 protein levels in purified 
splenic B cells of the indicated genotypes, and (C) of flow-sorted eGFP+ B cells from 





Figure 2.4. Reduced fractions of splenic B cells in the absence of alternative NF-B 
subunits. (A-C, top) The fractions of splenic B cells from relbfl/flCD19-Cre, nfkb2fl/flCD19-Cre or 
relbfl/flnfkb2fl/flCD19-Cre mice and the corresponding heterozygous and CD19-Cre control mice 
were determined by flow cytometry. Each symbol represents a mouse. Data are shown as mean 
± standard deviation. Statistical significance was determined by Student’s t test (*, P<0.05; **, 
P<0.01; ***, P<0.001). (A-C, bottom) Flow cytometry of eGFP expression in splenic B cells of 
the indicated genotypes. The number above the gate indicates the percentage of eGFP+ B cells 
among B220+ B cells of relbfl/flnfkb2fl/flCD19-Cre mice. The “eGFP+” arrow denotes the fraction of 







Figure 2.5. Reduced numbers of splenic B cells in the absence of alternative NF-B 
subunits. (A-C) Absolute numbers of splenic B cells from relbfl/flCD19-Cre, nfkb2fl/flCD19-Cre or 
relbfl/flnfkb2fl/flCD19-Cre mice and the corresponding heterozygous and CD19-Cre control mice. 
Data are shown as mean ± standard deviation. Statistical significance was determined by 
Student’s t test (*, P<0.05; ***, P<0.001). The “eGFP+” arrow denotes the number of eGFP+ B 





Figure 2.6. relbfl/flnfkb2fl/flCD19-Cre mice display fewer B cell follicles within the white 
pulp, and exhibit more heterogeneity in the size of B cell follicles, compared to control 
mice. Spleen sections from relbfl/flnfkb2fl/flCD19-Cre mice and the corresponding heterozygous 
and CD19-Cre control mice were analyzed via immunohistochemistry for the expression of CD3 
and IgM. One representative mouse out of 3 per group is shown. 40x magnification (left) and 





Figure 2.7. Reduced fraction of mature B cells in the bone marrow in relbfl/flnfkb2fl/flCD19-
Cre mice. (A) B220 and CD93 expression of bone marrow lymphocytes from 
relbfl/flnfkb2fl/flCD19-Cre mice and the corresponding heterozygous and CD19-Cre control mice 
were analyzed by flow cytometry. Numbers beside each gate indicate the percentage of 
immature (CD93+B220int) and mature (B220+CD93–) bone marrow B cells (top). Summary of the 
frequencies of immature and mature bone marrow B cells (bottom). (B) The fractions of eGFP+ 
cells among immature (CD93+B220int) and mature (B220+CD93–) bone marrow B cells in 
relbfl/flnfkb2fl/flCD19-Cre mice was determined by flow cytometry. Numbers above the gates 
indicate the percentage of eGFP+ B cells among the indicated B cell subsets (top). Summary of 
the frequency of eGFP+ cells among the corresponding B cell subsets (bottom). Each symbol 
represents a mouse. Data are shown as mean ± standard deviation. Statistical significance was 





Figure 2.8. Counter selection against relb/nfkb2-deleted MZ B cells in relbfl/flnfkb2fl/flCD19-
Cre mice (flow cytometry). (A) CD21 and CD23 expression of splenic B cells from 
relbfl/flnfkb2fl/flCD19-Cre mice and the corresponding heterozygous and CD19-Cre control mice 
was analyzed by flow cytometry. Numbers beside each gate indicate the percentage of follicular 
(CD23+CD21int) and marginal zone (MZ) (CD21hiCD23–) B cells (top). Summary of the 
frequencies of follicular and MZ B cells (bottom). (B) The fractions of eGFP+ cells among splenic 
follicular (CD23+CD21int) and MZ (CD21hiCD23–) B cells in relbfl/flnfkb2fl/flCD19-Cre mice was 
determined by flow cytometry. Numbers above the gates indicate the percentage of eGFP+ B 
cells among the indicated B cell subsets (top). Summary of the frequency of eGFP+ cells among 
the corresponding B cell subsets (bottom). Each symbol represents a mouse. Data are shown 
as mean ± standard deviation. Statistical significance was determined by Student’s t test (*, 





Figure 2.9. Counter selection against relb/nfkb2-deleted MZ B cells in relbfl/flnfkb2fl/flCD19-
Cre mice (immunohistochemistry). (left) Hematoxylin & eosin (H&E) stained splenic sections 
from relbfl/flnfkb2fl/flCD19-Cre mice and CD19-Cre control mice demonstrating focal MZ 
enlargement (arrows) in the former mice. 40x. (right) Spleen sections from mice of the indicated 
genotypes were analyzed for the expression of eGFP and IgM by immunohistochemistry. FO, 






Figure 2.10. Identification of BAFF-responsive genes controlled by the alternative NF-B 
pathway by RNA-seq analysis of BAFF-stimulated nfkb2-deleted and WT B cells. (A) 
Western blot analysis of purified WT B cells ex vivo (day 0), after 3 hours (h) of culture in 
medium only, and stimulated for 6h and 24h with BAFF. (B) Differentially expressed sequence 
analysis (DESeq) of NF-B2-proficient vs. NF-B2-deficient B cells stimulated with BAFF for 6h 
identified 150 genes with reduced expression in the absence of NF-B2 at a significance 
threshold of padj<0.05. Genes were assigned to putative functional categories. For the identity 
of the corresponding genes, fold-change and padj values, see Appendix A. (C) Genes of 





Figure 2.11. Control of BAFF-mediated survival by the alternative NF-B pathway. (A) 
(left) Flow cytometric analysis of ex vivo B cells from relbfl/flnfkb2fl/flCD19-Cre and CD19-Cre 
mice for BCL2 expression. (right) Summary of the results obtained for relbfl/flnfkb2fl/flCD19-Cre 
mice represented as percentage median fluorescence intensity (MFI) of CD19-Cre mice. (B) 
Flow cytometric analysis of BAFF or CD40-stimulated purified B cells from relbfl/flnfkb2fl/flCD19-
Cre and CD19-Cre mice at day 3 for DNA content by propidium iodide (PI) staining (top) and 
summary of the corresponding percentage Sub-G1 (bottom). (C) Flow cytometric analysis of 
BAFF or CD40-stimulated purified B cells from relbfl/flnfkb2fl/flCD19-Cre and CD19-Cre mice at 
day 3 for apoptotic/dead cells by annexin V/7AAD staining (top) and summary of the 
corresponding percentage of annexin V/7AAD+ cells (bottom). Each symbol represents a 
mouse. Data are shown as mean ± standard deviation. Statistical significance was determined 





Figure 2.12. Differential expression of BAFF-responsive genes controlled by the 
alternative NF-B pathway. (A) Flow cytometric analysis of BAFF or CD40-stimulated B cells 
from relbfl/flnfkb2fl/flCD19-Cre and CD19-Cre mice at day 3 for the expression of ICOSL. Staining 
of eGFP+ and eGFP– B cells from relbfl/flnfkb2fl/flCD19-Cre mice and B cells from CD19-Cre mice 
(top). Summary of the corresponding median fluorescence intensities (MFI) (bottom). (B) Flow 
cytometric analysis of ex vivo B cells from relbfl/flnfkb2fl/flCD19-Cre and CD19-Cre mice for β2 
expression (left) and summary of the corresponding MFIs (right). (C) Flow cytometric analysis of 
ex vivo B cells from relbfl/flnfkb2fl/flCD19-Cre and CD19-Cre mice for CD21 expression (left) and 
summary of the corresponding MFIs (right).  eGFP+ and eGFP– identifies relb/nfkb2-deleted and 
non-deleted B cells from relbfl/flnfkb2fl/flCD19-Cre mice, respectively. Each symbol represents a 
mouse. Data are shown as mean ± standard deviation. Statistical significance was determined 









Activation of the alternative NF-Bpathway in human GC B cells
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Section 3.1: INTRODUCTION 
Although the NF-B signaling cascade has been extensively studied within the context of 
mature B cell development, very little is understood about the role of this cascade in GC 
development. As described in a Section 1.5, recurrent, activating mutations in both canonical 
and alternative NF-B pathway components are observed in various GC-derived B cell 
malignances (summarized in ref.335). These mutations are suggestive of a physiological role of 
the NF-B cascade in GC B cells that is hijacked during lymphomagenesis. However, initial 
gene expression profiling studies revealed that NF-B signature genes are not expressed in GC 
B cells, which was thought to reflect the pro-apoptotic nature of these cells156,161. In addition, a 
CD40 signaling signature, which includes several NF-B target genes, as CD40 activates the 
NF-B signaling cascade283,284,289,290, was not detectable in gene expression data obtained from 
purified human GC B cells129.  This observation was surprising since the importance of the 
CD40/CD40L interaction during the GC reaction was well established: first, GCs do not develop 
in mice or humans with nonfunctional CD40 or CD40L380; second, established GCs collapse 
upon CD40L inhibition381; and third, CD40 stimulation can prevent the rapid apoptosis of GC B 
cells ex vivo157. Immunofluorescence analysis of human lymphoid tissue confirmed that the vast 
majority of GC B cells are not subject to active NF-B signaling as evidenced by the 
predominantly cytoplasmic rather than nuclear localization of NF-B subunits within these 
cells129. Nuclear localization of NF-B subunits was however detectable in a subset of LZ B 
cells129.  Indeed, this finding was supported by recent gene expression profiling analyses of 
mouse and human LZ B cells that revealed the presence of CD40, BCR and NF-B gene 
signatures119,124. As LZ B cells are subject to T cell-mediated selection, these findings suggest 
that while NF-B activation is silent in the bulk of GC B cells, it is induced in a subset of LZ B 
cells that receive activation signals during T cell-mediated selection. These activation signals 
are likely to include both CD40 and BCR stimulation, which converge on NF-B activation291,292, 
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resulting in the nuclear translocation of NF-B subunits. In the case of CD40 stimulation, this 
pattern of activation is consistent with the localization of T cells only within the LZ of GCs. Of 
note, only the canonical subunits c-REL and RELA were tested in the immunofluorescence 
analyses described above129. Therefore, the expression and activation pattern of alternative NF-
B subunits within the GC remained unknown.  
Following this initial description of NF-B activation in LZ B cells, Saito et al. defined a 
signaling axis in human Burkitt lymphoma cell lines, in which CD40-mediated activation of NF-
B led to the repression of BCL6 expression203. In a step-wise series of events, activated 
canonical NF-B subunits were found to directly transactivate IRF4, and, in turn, IRF4 bound to 
the promoter of BCL6 leading to its transcriptional repression203. These signaling events were 
also observed upon CD40 stimulation of native human GC B cells and may therefore represent 
an important pathway by which the GC program, which is directed by BCL6267, can be 
extinguished. This presumably occurs during the selection of LZ B cells, in order to allow GC 
exit. Since NF-B activation can be induced by BCR signaling, BCR signals may also activate 
this signaling axis during selection. BCR signals are also able to extinguish BCL6 expression via 
MAPK-mediated phosphorylation of BCL6, which leads to its ubiquitin-mediated proteasomal 
degradation382. The NF-B-IRF4-BCL6 signaling axis, in addition to extinguishing the GC 
program, is also likely to promote PC development. As mentioned in Section 1.4, IRF4 drives 
PC development200,201 and loss of BCL6 would be predicted to relieve BCL6-mediated 
transcriptional repression of BLIMP1149, another key regulator of the PC fate207. In turn, BLIMP1 
would further reinforce silencing of BCL6 expression and the B cell program190,211.  Additional 
evidence that is supportive of this NF-B-IRF4-BCL6 signaling axis include the coexpression of 
IRF4 and BLIMP1 in BCL6-negative LZ B cells205,383. However, GCs are not expanded in mice 
with GC B cell-specific ablation of IRF4200, which would be a possible consequence of IRF4-
deficiency in these cells due to the unrestricted expression of BCL6. It therefore appears that 
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the NF-B-IRF4-BCL6 axis identified by Saito et al. may promote GC exit and PC development 
in some, but not all, contexts of GC development.  
The body of literature described above provides evidence that the canonical NF-B 
pathway is active in LZ B cells. It appears likely that the alternative NF-B pathway is also 
activated during the GC reaction, as CD40 stimulation is known to induce both the canonical 
and alternative NF-B pathways and appears to be a critical signal during B cell selection in the 
LZ. In addition, as described in Section 1.5, NF-B mutations that activate the canonical 
pathway are predominantly associated with ABC-DLBCL, while MM is associated with mutations 
that activate both the canonical and alternative NF-B pathways318,319,335. Since ABC-DLBCL is 
believed to originate from the malignant transformation of a LZ B cell that has initiated 
plasmablastic differentiation256, whereas the cell of origin of MM is a bona fide PC316, the 
mutational pattern suggests the possibility that the canonical and alternative NF-B pathways 
may have distinct physiological functions in GC and post-GC cell types. These distinct functions 
may explain the selection of genetic mutations in either canonical or alternative NF-B pathway 
components in B cell malignancies of different cellular origin. For these reasons we assessed 
the expression and activation pattern of both the canonical and alternative NF-B subunits in 
normal GC B cells. Similar to the canonical NF-B subunits, nuclear translocation of alternative 
NF-B subunits was observed following CD40 stimulation of human GC B cells. A unique 
expression pattern of alternative vs. canonical NF-B subunits was revealed within human PCs.  
We next attempted to identify specific gene targets of the alternative NF-B pathway via 
chromatin immunoprecipitation (ChIP) and gene expression profiling in various human cellular 
systems. These experiments were however unsuccessful due to technical limitations.  
Section 3.2: MATERIALS AND METHODS 
Isolation of GC B cells from human tonsil 
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Tonsils were obtained from children undergoing routine tonsillectomies at the Babies and 
Children’s Hospital of Columbia-Presbyterian Medical Center. Residual material was obtained 
after diagnosis and was exempt from informed consent as samples were fully anonymized. 
Approval from the Institutional Review Board (IRB) was obtained for all procedures. Biopsies 
were transferred to ice immediately upon surgical removal and tonsillar mononuclear cells were 
obtained via mincing of the tissue in RPMI medium followed by Ficoll-Isopaque density 
centrifugation. Human GC B cells were isolated via magnetic labelling of CD77+ cells followed 
by magnetic cell separation using the MidiMACS system (Miltenyi Biotec).   
Cell culture 
Human GC B cells and the CD40L-expressing mouse feeder cell lines157 were cultured in RPMI 
with 10% FBS. The P3HR1, SUHDL2 and JJN3 cell lines were cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM) with 10% FBS. The U266 line was cultured in IMDM with 20% FBS. 
LY10 was cultured in IMDM with 15% human serum obtained from the New York Blood Center.  
Immunoblot analysis 
Cell lines or human GC B cells were subjected to NP40-based lysis, separated by SDS-PAGE 
and blotted on nitrocellulose membranes (GE Healthcare). Samples were incubated with the 
following primary antibodies overnight at 4°C. From Santa Cruz: rabbit anti-RELB (clone C-19), 
rabbit anti-BCL6 (clone N-3), rabbit anti-RELA (clone C-20), and rabbit anti-c-REL (clone C). 
From Cell Signaling Technologies (CST): rabbit anti-p100/p52, mouse anti-Phospho-IB(clone 
5A5), rabbit anti-IB, rabbit anti-p105/p52. From Sigma, mouse anti-β-actin (clone AC-15) and 
from Abcam, rabbit anti-RELA (clone ab7970). Horseradish peroxidase-conjugated secondary 
antibodies (anti-rabbit IgG, GE Healthcare and anti-mouse IgG, Thermo Scientific) and ECL 
Western Blotting Substrate or SuperSignal West Dura Extended Duration Substrate (Thermo 




For single cell staining, cells were spun onto slides using a cytospin machine and fixed in 10% 
formalin for 20 minutes followed by an additional 20 minutes of methanol fixation. Nuclear 
permeabilization was achieved via incubation with 0.2% triton in PBS. Cytospin slides were 
incubated overnight with each of the antibodies specific for NF-B subunits followed by 
incubation with a secondary anti-rabbit Cy3 antibody (Cy3-conjugated AffiniPure Donkey anti-
rabbit IgG; Jackson ImmunoResearch Laboraties). During slide mounting, slides were 
counterstained with DAPI (Prolong Gold antifade reagent with DAPI; Molecular Probes by Life 
Technologies). The images were acquired by means of an Eclipse E400 microscope (Nikon) 
with a Spot2 charge-coupled device camera (Diagnostic Instruments) mounted on top. Images 
were acquired in monochromatic JPEG format prior to merging as two-color images in 
Photoshop (Adobe Systems).  
Chromatin immunoprecipitation (ChIP) 
Cells were subjected to cross-linking via incubation with 1% formaldehyde for 10 minutes at 
room temperature. The reaction was stopped with glycine. The following steps were completed 
via the use of buffers and reagents provided by the ChIP-IT Express Kit (Active Motif). Nuclei 
were released following resuspension in lysis buffer followed by dounce homogenization. 
Chromatin was then sonicated in a Bioruptor sonicator (Diagenode) for 15-30 minutes, 
depending on the cell type, in order to achieve  sheared fragments of 200-1000bp. Sheared 
chromatin was used in ChIP reactions with the anti-RELA, anti-c-REL and anti-RELA antibodies 
detailed above together with protein G magnetic beads and immunoprecipitated chromatin was 
isolated using a magnetic stand. Immunoprecipitated chromatin was then subjected to cross-link 
reversal and isolated DNA was analyzed via PCR or quantitative PCR (qPCR) for various target 
genes. Primer sets were designed to flank NF-B “B” binding sites in putative target genes 
identified using a web based transcription factor binding site search tool, available at: 
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http://diyhpl.us/~bryan/irc/protocol-online/protocol-cache/TFSEARCH.html. The forward (F) and 
reverse (R) primer pairs used were: BCL6 (F: gccacgtagcagtggtaaag, R: tgtccggcctttcctagaaac), 
BFL1 (F: agctgggattacaggcacac, R: agcactttgggaggacaagg), CD44 (F: cttgcttgggtgtgtccttc, R: 
aaacttgtccatggtgtccggag), CCR7 (F: actgagcagagcaagggaag, R: cagaagaaaggtgacagagggtg), 
CXCR5 (F: caagtgccctaacttgccag, R: cacgcaaagtcagcaggttg), IBa (F: agaaactccctgcgatgagc, 
R: agggacaggattacagggtg), β-ACTIN (F: tgtaatcccagctactcaggagg, R: tgtgttagccaggatggtctcg), 
BCL2 (F: gcatcacagaggaagtagactg, R: gctttgcattcttggacgagg), IRF4 (F: 
agctcaacgggtgaaagctcag, R: tacttgagaggacgagccacgag) and PDX1 (F: agcacttgcaaatgctggctc, 
R: tctaactgtgaccaaac).  
shRNA knockdown 
Hairpins were designed against the mRNA sequences of RELA, c-REL and RELB using a 
















c-REL 1:  
tgctgttgacagtgagcgaccgtatatagagataattgaatagtgaagccacagatgtattcaattatctctatatacgggtgcctactgc
ctcgga 






























These hairpins were cloned into a viral vector (pMSCV-mir30-Luci.1309-PIG (MLP))385 and 
transfected using polyethylenimine into an amphotropic retroviral packaging cell line385 to create 
retroviral particles. These viral particles were used to infect cell lines via three rounds of spin 
infection in the presence of polybrene. Successfully infected cells were then selected using 
puromycin.  
Section 3.3: RESULTS 
Expression and activation of the alternative NF-B subunits in human GC B cells 
To assess the activation of the alternative NF-B pathway within the context of human GC B 
cells we began by stimulating a human cell line with CD40 in vitro. P3HR1 is a Burkitt lymphoma 
cell line that was used to define the NF-B-IRF4-BCL6 signaling axis described in the 
introduction to this chapter203 (Section 3.1). Since P3HR1 is believed to originate from a DZ B 
cell256, NF-B signaling is expected to be quiescent in this cell line. Indeed, in the absence of 
stimulation, minimal phosphorylation of IBα, a readout of canonical NF-B activation, was 
observed (Fig. 3.1A). Accordingly, the canonical NF-B subunits RELA, c-REL and p50 were 
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present in a cytoplasmic, inactive state (Fig. 3.1C). In regards to the alternative NF-B pathway, 
expression of the p100 precursor itself was not detectable via Western blot analysis (Fig. 3.1B). 
The alternative NF-B subunits RELB and NF-B2 (p100/p52) were detected in the cytoplasm 
by immunofluorescence analysis, confirming a quiescent signaling state (Fig. 3.1C). CD40-
stimulation of the P3HR1 cell line was achieved via co-culture with a feeder cell line engineered 
to express CD40L157. 6h and 24h of stimulation resulted in the accumulation of phosphorylated 
IBα (Fig. 3.1A), and after 24h of stimulation, nuclear translocation of canonical NF-B subunits 
was observed (Fig. 3.1C), in accordance with the results presented by Saito et al.203. 6h of 
CD40-stimulation resulted in both the expression of the p100 precursor and its processing to 
p52, demonstrating activation of the alternative NF-B pathway (Fig. 3.1B). This activation was 
further increased following 24h of stimulation, and nuclear translocation of the alternative NF-B 
subunits was observed (Fig. 3.1B,C). The activation of the alternative pathway was 
accompanied by downregulation of BCL6 expression, as predicted by the NF-B-IRF4-BCL6 
signaling axis described in Section 3.1203.  
We next determined whether alternative NF-B activation was also detectable in CD40-
stimulated native GC B cells. Native GC B cells can be isolated from human tonsils obtained 
during routine tonsillectomies performed on children experiencing recurrent infections. Freshly 
isolated tonsillar GC B cells were devoid of activation of the alternative NF-B pathway, as 
evidenced by the presence of unprocessed p100 (Fig. 3.2A; left panel). Following 24h of CD40-
stimulation, p100-p52 processing was observed, which was accompanied by BCL6 
downregulation (Fig. 3.2A; left panel). Accordingly, the p52 subunit along with the canonical NF-
B subunit p50 translocated into the nucleus of GC B cells (Fig. 3.2A; right panel). These results 
demonstrate that the alternative NF-B pathway is activated in human GC B cells in response to 
CD40-stimulation. CD40-stimulation is a signal thought to be important during the selection of 
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LZ B cells; our data suggest that both the alternative and canonical NF-B pathways may be 
activated in LZ B cells during selection.  
To further investigate the expression pattern of canonical and alternative NF-B subunits 
in lymphoid tissue we performed immunofluorescence analysis on human tonsil sections (Fig. 
3.2B, data generated by Amanda Carette, a technician in the Klein lab). In the tonsillar 
subepithelium where PCs reside, strong cytoplasmic staining of the alternative NF-B subunit 
p100/p52 (NF-B2) and weak staining of the canonical NF-B subunit p105/p50 (NF-B1) was 
observed in PCs, which were identified by BLIMP1 expression (Fig. 3.2B, top panel). In 
contrast, strong cytoplasmic staining of the canonical NF-B subunit p105/p50 and weak 
staining of the alternative subunit p100/p52 was observed in surrounding lymphocytes (Fig. 
3.2B, top panel). The same trend was also evident in the LZ of GCs, as BLIMP1+ PC precursors 
demonstrated strong cytoplasmic staining of the alternative subunit p100/p52 and weak staining 
of the canonical subunit p105/p50 (Fig. 3.2B; bottom panel). Weak staining of the canonical 
subunit c-REL was also observed in PCs and PC precursors (data not shown). These data 
suggest that the expression of the alternative NF-B subunit p100/p52 is upregulated in PCs 
and their precursors, whereas the expression of the canonical NF-B subunit p105/p50 is 
downregulated.  
We were also able to identify differential activity of canonical vs. alternative NF-B 
subunits when analyzing subunit expression in selected ABC-DLBCL and MM cell lines. The 
ABC-DLBCL lines SUDHL2 and LY10 have mutations that constitutively activate the canonical 
NF-B pathway (mutations in MYD88, CD79A, amplification of REL and TNFAIP3 deletions242), 
whereas the MM lines U266 and JJN4 have mutations in alternative NF-B pathway 
components that result in dual activation of the canonical and alternative pathways (mutations in 
NIK and TRAF3)319,318. In the MM cell lines, we observed strong processing of p100 to p52, 
denoting alternative NF-B activation, and weak activation was observed in the ABC-DLBCL 
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cell lines (Fig. 3.2C), as previously reported311,319. No significant expression differences in the 
alternative subunit RELB and the canonical subunits RELA and p50 could be detected among 
the cell lines. Strikingly however, c-REL protein levels were virtually absent in the MM lines, 
whereas robust expression could be detected in the ABC-DLBCL lines (Fig. 3.2C).  
Collectively, the data presented in Figures 3.1 and 3.2 demonstrate that the subunits of 
the alternative NF-B pathway are activated in response to CD40 stimulation, and there 
appears to be preferential expression of alternative over canonical subunits in PCs and PC 
precursors, which could also be identified in MM cell lines. This differential expression NF-B 
subunits could be suggestive of distinct functional roles for the canonical vs. alternative 
pathways during the GC reaction and in post-GC development.  
Attempts to identify NF-B target genes 
The identification of the target genes activated by alternative NF-B subunits in GC B cells is an 
important step towards understanding the downstream functional events that occur following 
activation of this pathway during the GC reaction. In light of the apparent preferential expression 
of an alternative NF-B subunit in PC and PC precursors, we were interested in identifying 
target genes of both the canonical and alternative NF-B subunits in order to detect potential 
differential targets. As the ABC-DLBCL cell lines presented in Fig. 3.2C demonstrated 
preferential expression and activation of the canonical NF-B subunits242, these cell lines may 
provide a cellular system suitable for the identification of specific canonical NF-B target genes. 
Similarly, since the MM lines shown in Fig. 3.2C demonstrate dual activation of the canonical 
and alternative pathways (Fig. 3.2C and ref.319) and low expression of the canonical subunit c-
REL (Fig. 3.2C), these cell lines may prove amenable to the identification of specific alternative 
NF-B targets. ChIP sequencing (ChiP-seq) in combination with gene expression profiling 
represents a suitable approach to identify transcriptionally active, direct NF-B target genes. 
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We sought to assess the robustness of our ChIP protocol using an anti-BCL6 antibody 
that had been successfully used in ChIP assays on the Burkitt lymphoma line P3HR1266. BCL6 
modulates its expression via binding to its own promoter, thus repressing transcription266. We 
assayed for this interaction following immunoprecipitation (IP) of cross-linked P3HR1 chromatin 
with the validated anti-BCL6 antibody and were able to detect binding of BCL6 to the BCL6 
promoter at 6-fold enrichment over binding of a control IgG to this region (Fig. 3.3A). When 
calculated over binding of the anti-BCL6 antibody to the β-ACTIN locus, a fold enrichment of 12-
fold was detected (Fig. 3.3A; bottom panel). These experiments demonstrated the functionality 
of our ChIP protocol.  
NF-B antibodies specific for the three NF-B subunits that possess TAD domains and 
thereby directly drive transcription – RELA, c-REL and REL – were utilized in subsequent ChIP 
experiments. These antibodies were previously used by Saito et al. in Burkitt lymphoma cell 
lines to elucidate the NF-B-IRF4-BCL6 signaling axis described in Section 3.1203. ChIP 
experiments were conducted on CD40-stimulated P3HR1 to replicate the ChIP assays 
presented by Saito et al. and assayed for binding to an NF-B “B” binding site in the IBα loci, 
which had been used as a positive control region that was strongly bound by all NF-B subunits 
tested. RELA was found to bind to the IBα loci at ~4-fold enrichment over binding of a control 
IgG to the same region (Fig. 3.3B). In addition, binding of RELA to another predicted NF-B 
target gene that was shown to be induced by CD40 stimulation in B cells, BFL1386, was also 
tested by designing primers to flank predicted B sites within the gene that were identified by a 
web-based transcription factor binding site predictor. Binding of RELA to BFL1 was detected at 
a fold enrichment of ~2-fold over control IgG (Fig. 3.3B). Binding to β-ACTIN was also assayed 
as a negative control and a fold enrichment of ~5-fold was detected over IgG (Fig. 3.3B). 
Perhaps unexpectedly, this locus contained several putative B binding sites; however, binding 
by RELA was detected despite designing primers around these sites. Since binding of greater 
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than 10-fold over a negative control is preferred before the submission of ChIP samples for 
deep sequencing, the IBα and BFL1 enrichments over IgG were not sufficient, and larger 
enrichments were also not observed for binding of c-REL or RELB to these loci (data not 
shown). Similar observations were made in ChIP assays on CD40-stimulated native tonsil GC B 
cells. Via PCR assay, binding of NF-B subunits to the BFL1 and IBα loci and to the defined 
B binding site in the IRF4 loci203 was observed, however, binding to β-ACTIN was also 
detected (Fig. 3.3C).  
In order to remove one variable from these assays - the efficiency and strength of CD40-
mediated induction of NF-B subunits into the nucleus - RELA ChIP assays were conducted on 
two ABC-DLBCL lines that harbor mutations which lead to strong constitutive canonical NF-B 
activation (LY10 and SUDHL2). High levels of RELA protein were detected upon Western blot 
analysis of chromatin derived from these cell lines following cross-link reversal, confirming the 
nuclear presence of the RELA subunit (Fig. 3.3D). However, significant binding of RELA to a 
range of both defined and predicted targets in either the LY10 or SUDH2 cell lines could not be 
detected (Fig. 3.3E; top panel). In addition, quantitative analysis of these ChIP reactions 
revealed essentially no enrichment over binding to the “negative control” target gene PDX1, a 
pancreatic developmental gene not expressed in B cells which was also found to lack any 
predicted B binding sites (Fig. 3.3F). This negative control was utilized due to problems with 
using β-ACTIN as a negative control (Fig. 3.3E; bottom panel). To determine if another anti-
RELA antibody may be more efficient in the ChIP assays, another Western blot test was 
performed in which RELA was immunoprecipitated from cross-linked CD40-stimulated P3HR1 
chromatin with the anti-RELA clone c-20 antibody (Santa Cruz) and an additional anti-RELA 
clone ab7970 antibody (Abcam), that had been used in a published ChIP analysis of 
macrophages387 (Fig. 3.4A).  Following cross-link reversal, immunoprecipitated chromatin was 
probed via Western blot and the anti-RELA c-20 antibody appeared to be more efficient at 
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immunoprecipitating RELA than the anti-RELA ab7970 antibody. The Western blot analysis also 
confirmed that the anti-RELA c-20 antibody was capable of recognizing its corresponding RELA 
epitope following cross-linking, which can be a concern in ChIP assays as epitopes can be 
altered via exposure to the cross-linking agent formaldehyde. Neither the anti-RELA c-20 or 
ab7970 antibody was capable of binding to a range of targets with significant enrichment over 
binding of these targets by an IgG control or over binding of RELA to PDX1 (Fig. 3.4B-C). For 
these later tests, an expanded list of target gene candidates was utilized by designing primers 
flanking predicted B binding sites in several genes that were strongly induced in response to 
CD40 stimulation in a Burkitt lymphoma line – CD44, BCL2, CCR7 and CXCR5129.  
Finally, the ability of anti-c-REL and anti-RELB antibodies to immunoprecipitate c-REL 
and RELB, respectively, from cross-linked chromatin was tested, as shown for RELA in Fig. 
3.4A. The anti-c-REL antibody was able to immunoprecipitate its target from CD40-stimulated 
P3HR1 chromatin (Fig. 3.5A; middle panel). The specificity of c-REL IP was confirmed by the 
inability to detect RELA or RELB protein (Fig. 3.5A; middle and right panel). Furthermore, no c-
REL protein could be detected following c-REL IP of chromatin from unstimulated P3HR1, 
where c-REL is localized in the cytoplasm (Fig. 3.1C and Fig. 3.5A; left panel). Similar results 
were observed using an anti-RELB antibody, which was able to immunoprecipitate its target 
from chromatin derived from the MM cell line U266 (Fig. 3.5B; left panel), which is characterized 
by strong activation of the alternative NF-B pathway (Fig. 3.2C). RELB, but not RELA, was 
detected in this IP (Fig. 3.5B; right panel). Collectively, the Western blot analyses (Fig. 3.4A and 
3.5) demonstrate that the NF-B antibodies used were capable of binding their targets in cross-
linked chromatin, and that the antibody-target interactions survive the washing and cross-link 
reversal steps of the ChIP protocol. Despite these data that suggest that the employed ChIP 
protocols and antibodies were suitable for this assay, we observed no consistent enrichment for 
a range of known and predicted NF-B targets over negative controls. In the absence of this 
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form of validation, we did not have the confidence to submit any samples for deep sequencing 
and therefore pursued different approaches for the identification of NF-B target genes.  
Knockdown of NF-B subunits in human cell lines 
To develop an alternative strategy for identifying NF-B target genes within a human system, 
we adopted a knockdown strategy. Using a shRNA prediction algorithm, five hairpins were 
designed to target c-REL, RELA and RELB mRNAs. The efficacy of each hairpin was tested in 
the P3HR1 cell line. In each case, hairpins that produced effective knockdown of their target 
protein could be identified (Fig. 3.6). As NF-B signaling in P3HR1 is quiescent, this cell line 
presented an ideal system to test these hairpins without the risk of inhibiting growth or cell 
survival. We next tested a selection of effective c-REL hairpins in LY10, an ABC-DLBCL cell line 
with constitutive canonical NF-B signaling, and effective knockdown of c-REL was observed 
(Fig. 3.6B). Knockdown of RELB in the MM cell line U266, which displays constitutive alternative 
NF-B activation, was also evident (Fig. 3.6C). Following knockdown, however, this cell line 
grew poorly. This observation is in accordance with a publication reporting the toxicity of RELB 
knockdown in U266 that was published while these experiments were being conducted388. Gene 
expression profiling of ABC-DLBCL cell lines following knockdown of canonical NF-B subunits, 
and MM cell lines following knockdown of alternative NF-B subunits, appears to be a valid 
strategy for identifying canonical and alternative NF-B target genes, respectively. This 
approach is being pursued by another member of the Klein lab using inducible targeting vectors.  
Section 3.4: DISCUSSION 
NF-B-activating mutations identified in various GC-derived lymphomas suggest a functional 
role for NF-B signaling during the GC reaction335. Early studies, perhaps surprisingly, found no 
detectable NF-B activity in the vast majority of normal GC B cells156,161. However, it was later 
revealed that NF-B activation occurs in a subset of LZ B cells129. In addition, CD40 and NF-B 
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gene signatures were found to be enriched in LZ B cells119,124.  It is therefore likely that CD40 
stimulation occurs during the selection of high affinity LZ B cells. Via CD40 stimulation of both 
native and transformed human GC B cells we were able to detect activation of both the 
canonical and alternative NF-B pathway. Therefore, T cell help afforded to LZ B cells in the 
form of CD40L-CD40 interactions appears to activate both pathways of the NF-B signaling 
cascade.  
While CD40 stimulation clearly mediates activation of the canonical and alternative NF-
B pathways in LZ B cells, it is possible that additional signaling events contribute to NF-B 
activation in these cells. BCR signaling is known to specifically activate the canonical NF-B 
pathway291,292; therefore, antigen binding to the BCR during selection may induce canonical NF-
B activation. However, recent evidence suggests that BCR signaling within murine GC B cells 
is quiescent, suggesting that the sole function of the BCR during the GC reaction is to enable 
antigen capture for presentation on MHC-II molecules in order to acquire T cell help125. 
Nevertheless, the same study did report a defined window in which active BCR signaling could 
be detected, specifically in the G2/M phase of the cell cycle
125. This observation suggests that 
transient BCR signaling can occur within the GC reaction, which is further supported by the 
enrichment of a BCR gene signature in the gene expression profile of murine LZ B cells 
compared to DZ B cells119. Activation of BCR signaling may have a role in testing that the 
signaling capacity of mutant BCRs has “survived” the SHM process and could potentially also 
function as a selection signal in LZ B cells. An additional signal occurring in LZ B cells that may 
be involved predominantly in the activation of the alternative NF-B pathway is stimulation by 
BAFF, which is produced within the GC environment by FDCs82. Despite the severe reduction in 
peripheral B cells observed in mice deficient for BAFF or the BAFF-R, the remaining B cells 
were capable of forming small GCs70,389,390. However, while GC initiation and formation 
appeared normal, these GCs were found to involute progressively over time from day 7 post-
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immunization onwards. In the case of mice deficient for BAFF or treated with a BAFF 
antagonist, this defect is unlikely to be intrinsic to B cells and rather appears to be a result of 
perturbed FDC development389,390. However, in the case of BAFF-R deficient mice, the impaired 
GC maintenance may be a result of restricted GC B cell proliferation70,389. These studies are 
limited by the severe B cell defect observed at the T2 stage of B cell development and therefore 
in essence investigate only the function of the few B cells that have survived in the absence of 
BAFF. How these surviving B cells differ functionally from WT B cells prior to GC entry remains 
unknown. Potentially, the mutant cells may be unable to sustain a GC reaction. In addition, as 
these studies were entirely based on histological evaluation of GCs, there is no information on 
the quality or function of the GCs that formed in the mutant mice70,389,390. Determining the 
function of BAFF signaling during the GC reaction would require conditional deletion of the 
BAFF-R in GC B cells. Nevertheless, these studies raise the possibility that BAFF signaling in 
GC B cells may be functionally relevant, and could lead to activation of the alternative and 
potentially also the canonical NF-B pathway.  
Immunofluorescence analysis of human tonsil tissue for the expression of the separate 
NF-B subunits of the canonical and alternative pathways revealed preferential expression of 
the alternative NF-B subunit p100/p52 (NF-B2) in PCs and their precursors within the LZ of 
GCs. As p100/p52 was associated with cytoplasmic localization, this suggests that upon 
appropriate activation by cell surface receptors, PCs and their precursors may be predisposed 
to signal through the alternative NF-B pathway. Furthermore, Western blot analysis of ABC-
DLBCL and MM cell lines for NF-B subunits revealed preferential activation of the alternative 
NF-B pathway in the MM lines together with a striking downregulation of the canonical NF-B 
subunit c-REL. The virtual absence of c-REL expression is interesting as the MM lines tested 
were reported to show active canonical and alternative NF-B signaling. In regards to canonical 
NF-B activation, this designation was made based on sensitivity to an IKKβ inhibitor and via 
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the nuclear presence of RELA and p50 in these cell lines; c-REL localization was not 
analyzed318,319. The functional implications of the absence of the c-REL subunit in MM lines are 
unclear but suggest that this subunit may be dispensable in PC-derived cell lines. The role of c-
REL during the GC reaction was recently investigated by the Klein lab338 and will be discussed 
in Chapter 4.  
A preferential role for the alternative NF-B pathway in PC biology is supported by 
additional reports in the literature. Gene expression profiling of human B cell subpopulations 
revealed that PCs transcriptionally downregulate the expression of the canonical NF-B 
subunits (c-REL and p105/p50) and upregulate that of the alternative NF-B subunits (RELB 
and p100/p52)391 in comparison to B cells. In addition, gel shift studies found that nuclear RELB-
p52 heterodimers are preferentially found in mouse plasmacytoma cell lines (mouse PC tumor 
cell lines) in comparison to mouse B cell lines392. In plasmacytoma cell lines, RELB-p52 
heterodimers were found in addition to canonical NF-B heterodimers; in contrast, mouse B cell 
lines were characterized by the presence of only canonical NF-B heterodimers392. Finally, an 
important role for the alternative NF-B pathway in PCs is supported by the selection of 
mutations that lead to activation of both the canonical and alternative pathways in MM, whereas 
ABC-DLBCL is predominantly associated with mutations that activate the canonical NF-B 
pathway335. These findings collectively suggest that the alternative NF-B pathway may be 
preferentially activated in late B cell development and may promote a certain aspect of PC 
biology. 
The emerging differential expression of canonical vs. alternative NF-B subunits is 
suggestive of distinct functions at distinct developmental stages. This raises the possibility that 
the separate NF-B subunits activate differential target gene expression. In order to identify 
target genes that are differentially regulated by canonical vs. alternative NF-B dimers, we 
attempted to establish a ChIP assay to determine the target genes bound by RELA and c-REL 
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in ABC-DLBCL lines with preferential canonical NF-B activation, and the target genes bound 
by RELB in MM lines with activation of the canonical and alternative NF-B pathways. We were 
unable to detect binding of NF-B subunits to specific target genes that were identified in a 
published report203 at a fold enrichment of more than 2-4-fold over negative controls, despite 
using the same set of antibodies, primer pairs and cellular system. Of note, the report performed 
ChIP enrichments using an agarose gel-based PCR strategy rather than quantitative (qPCR). 
The fold enrichments for binding to target genes over a negative control were therefore difficult 
to estimate and thus it remains unclear how their results compared to ours. Although it is 
possible that we obtained comparable binding to these target genes, this enrichment was 
considered insufficient for ChIP-sequencing as fold enrichments of >10-fold were required. In an 
attempt to improve fold enrichments, we assayed several cell lines with constitutively active 
rather than induced NF-B signaling for the binding of all three transcriptionally active NF-B 
subunits to a range of known and predicted target genes. No consistent fold enrichments could 
be reliably detected. The problems were two-fold: enrichments for predicted target genes or 
target genes described in the literature were generally low, and binding to supposedly negative 
targets such as β-ACTIN, GAPDH and regions outside the defined B site in the IRF4 locus was 
readily detectable on agarose gels. In regards to the additional gene targets utilized in our 
assays that were not published by Saito et al. it is possible that these genes were unsuitable 
targets for our particular cellular systems or that we designed primers flanking inappropriate 
regions of the respective loci. Our primer design was guided by computational identification of 
the “B” binding consensus site 5’-GGGRNYYYCC-3’. In most cases, candidate target genes 
possess several of these predicted sites, and it was unclear which were the most functionally 
relevant. Therefore, while several target genes seemed to represent bone fide NF-B target 
genes as their expression was induced by CD40 in a Burkitt lymphoma cell line129, the actual B 
sites within the loci to which we designed flanking primers were essentially determined 
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randomly. Western blot analysis of chromatin immunoprecipitated by each of the NF-B 
antibodies did however demonstrate specific pull down of the expected target proteins, 
suggesting that the antibodies and ChIP procedure worked satisfactorily.  
Attempts to achieve robust fold enrichments were hampered by the limited number of 
previous studies in B cell systems from which reliable target genes and binding sites could be 
obtained for validation of the ChIPs. The results of a single report in the literature that defined 
target sites in a CD40-stimulated Burkitt lymphoma line203 were used as our standard for 
validation. Relatively few genome wide NF-B ChIP studies can be found in the literature. In 
addition, most of these publications specifically analyzed the RELA subunit and employed non-
B cell systems under inflammatory stimuli that activate only the canonical NF-B pathway387,393-
399. Only two recent studies focused on B cell systems396,400. One group performed ChIP-seq for 
all five NF-B subunits in an EBV-transformed lymphoblastoid B cell line with constitutively 
active canonical and alternative NF-B signaling400; this study revealed several interesting 
observations. Nearly a third of the identified NF-B sites did not contain the B binding site; 
instead, several alternative motifs were enriched. In addition, binding sites bound by each of the 
five NF-B subunits were not significantly different; in other words, NF-B subunit-specific 
binding sites were not identified. Furthermore, it was found that the majority of target genes 
were co-occupied by subunits of the canonical and alternative NF-B pathways, suggesting no 
distinction in the target genes controlled by these pathways. It is unclear how these results that 
were derived from a cell line with constitutive activation of both the canonical and alternative 
pathways (and thus have nuclear localization of all five subunits) can be extrapolated to other 
cellular contents. The question remains as to how functional specificity of the canonical vs. 
alternative NF-B pathway occurs in different contexts. Specific dimer composition paired with 
defined B sites appears to be the simplest explanation, although, as outlined above, evidence 
for this mechanism is lacking. Additional factors such as the binding of co-factors, 
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posttranslational modifications and chromatin configurations may have important roles in 
directing the transcription of NF-B target genes401. As an alternative strategy for NF-B target 
gene identification, we pursued knockdown of NF-B subunits in cell lines with constitutive 
NFB activation. We identified suitable hairpins that could effectively target RELA, c-REL and 
RELB in a cell line without constitutive NF-B activation. Due to the possibility that knockdown 
of these subunits may be toxic to cell lines that have selected constitutive NF-B activation, the 
employment of inducible targeting vectors appears necessary. NF-B subunit-specific target 
genes could be identified by inducibly knocking down each subunit prior to gene expression 
profiling. This strategy is limited in that it will not allow direct target genes to be conclusively 
identified, but is likely to provide a range of useful target gene candidates that could be 
validated in ChIP experiments. Similarly, BAFF-responsive target genes identified in Chapter 2 
could be utilized as candidates for ChIP experiments in in vitro BAFF-stimulated mouse B cells. 
Another aim of these knockdown studies is to assess the response of cell lines with constitutive 
NF-B activation to single NF-B subunit knockdown. Identifying cell lines that are particularly 
susceptible to the removal of specific NF-B subunits is of interest biologically but may also 
have therapeutic implications, which will be further explored in the concluding discussion 
(Chapter 5). As part of this thesis, the use of the conditional alleles generated in Chapter 2 was 
adopted to identify either direct or indirect targets of the alternative NF-B pathway in murine 
GC B cells; this strategy will be discussed in Chapter 4.  
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Figure 3.1. Activation of the canonical and alternative NF-B pathways in the human 
Burkitt lymphoma line, P3HR1, upon CD40 stimulation. (A) Western blot analysis of 
phosphorylated IBα in CD40L feeder cells, unstimulated P3HR1 cells and P3HR1 cells 
following co-culture with CD40L-expressing feeders cells for 6 hours (h) and 24h. (B) Western 
blot analysis of p100/p52 and BCL6 protein expression in P3HR1 cells following co-culture with 
CD40L-expressing feeder cells for 1h, 6h and 24h. (C) Immunofluorescence analysis of  the 
cellular localization of canonical and alternative NF-B subunits (red) in unstimulated P3HR1 
cells and following 24h of co-culture on CD40L-expressing feeder cells. Slides were co-stained 





Figure 3.2. Expression and activation of canonical and alternative NF-B subunits in 
normal and transformed human GC B cells and PCs. (A) Human tonsillar GC B cells ex vivo 
(0 hours (h)) and following 24h of co-culture on CD40L-expressing feeders, Western blot 
analysis of p100/p52 and BCL6 (left) and  immunofluorescence analysis for p105/p50 and 
p100/52 (right, red), slides were co-stained with DAPI (blue). (B) Immunofluorescence analysis 
of tonsil sections for p105/p50 and p100/p52 (red), BLIMP1 (green) and DAPI (blue) in the 
subepithelium and GC light zone. Data generated by Amanda Carette. (C) Western blot analysis 
of activated B cell-type diffuse large B cell lymphoma (ABC-DLBCL) and multiple myeloma 





Figure 3.3. ChIP analyses in human GC-derived lymphoma cell lines and normal GC B 
cells. (A) Analysis of binding of BCL6 or IgG control to the BCL6 locus following chromatin 
immunoprecipitation (ChIP) of P3HR1 chromatin, by agarose gel (top) and qPCR (bottom). (B) 
Analysis of binding of RELA or control IgG to IBa, BFL1 and β-ACTIN following ChIP of 
chromatin from P3HR1 cells stimulated for 24 hours (h) with CD40, by agarose (top) and qPCR 
(bottom). (C) Analysis of binding of RELA, c-REL, RELB or IgG control to BFL1, IBa, IRF4 and 
β-ACTIN following ChIP of human tonsil GC B cells that were stimulated with CD40 for 24h via 
agarose gel electrophoresis. (D) Western blot analysis of RELA protein in chromatin from 
P3HR1 cells following CD40-stimulation for 24h and in LY10 and SUDHL2 chromatin (E) 
Analysis of binding of RELA to PDX1, IBa, IRF4 and BFL1 following ChIP of SUDHL2 and 





Figure 3.4. ChIP analyses in human GC-derived lymphoma cell lines. (A) Western blot 
analysis of RELA protein bound by anti-RELA antibodies (clone c-20, Santa Cruz; clone 
ab7970, Abcam) following ChIP of P3HR1 cells following CD40-stimulation for 24 hours (h). 
Equal amounts of chromatin were used in each immunoprecipitation (IP), percentages denote 
the fraction of each IP or unbound protein loaded on the Western blot gel. (B) Analysis of 
binding of c-20 or ab7979 anti-RELA antibodies or control IgG to CD44, CCR7, CXCR5, BCL2 
and BFL1 by agarose gel following ChIP of SUDHL2 chromatin. (C) qPCR analysis of binding of 





Figure 3.5. Western blot analyses of ChIPs of human GC-derived lymphoma lines. (A) 
Western blot analysis of c-REL, RELB and RELA protein bound by anti-c-REL antibody 
following ChIP of P3HR1 (left) and P3HR1 following CD40-stimulation for 24 hours (h) (middle 
and right). (B) Western blot analysis of RELB, c-REL, and RELA protein bound by anti-RELB 
antibody and control IgG following ChIP of the multiple myeloma (MM) cell line U266. Equal 
amounts of chromatin were used in each immunoprecipitation (IP) and equal fractions of each 





Figure 3.6. Knockdown of NF-B subunits in P3HR1 cells. (A) Western blot analysis of c-
REL (top left), RELA (top right) and RELB (bottom) protein expression in P3HR1 cells following 
infection with 5 c-REL, RELA or RELB-specific shRNAs and a shRNA specific for Renilla which 
served as a negative control. (B) Western blot analysis of c-REL protein expression in LY10 in 
uninfected cells, and following infection with c-REL-specific shRNAs and a Renilla-specific 
shRNA. (C) Western blot analysis of  RELB protein expression in U266, in uninfected cells and 









CHAPTER 4:  
Maintenance of the GC reaction requires signaling through the alternative NF-B pathway 
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Section 4.1: INTRODUCTION 
Activating mutations in GC-derived lymphomas that result in constitutive activation of NF-B are 
suggestive of a functional role for this signaling cascade during normal GC development335. This 
putative function is likely to be associated with LZ B cells, as human studies have revealed that 
NF-B activation within the GC is only detectable in a subset of LZ B cells129. To specifically 
dissect the roles of the canonical subunits c-REL and RELA during the GC reaction, conditional 
alleles were generated338. Using a Cre recombinase that allows deletion in GC B cells from day 
2 of the GC reaction onwards, it was found that conditional ablation of c-REL induces the 
progressive collapse of established GCs past day 7 of the GC reaction338. This collapse could 
not be rescued by a BCL2 transgene and was therefore not caused by the defective delivery of 
pro-survival signals in the absence of c-REL. Instead, c-REL appears to be required for the 
establishment of a metabolic program that enables cell growth prior to cell division338. DZ and 
LZ B cell fractions were equally lost upon GC B cell-specific deletion of c-REL, suggesting that 
c-REL is essential for the maintenance of the GC reaction. In contrast, RELA appears to be 
dispensable for GC development and instead has a role in PC development, as PCs were 
greatly reduced in mice following ablation of RELA in GC B cells338. This PC defect may be due 
at least in part to RELA-mediated regulation of BLIMP1 expression338.   
Interestingly, many parallels are evident when comparing the activity of c-MYC and NF-
B in the GC reaction. Both NF-B and c-MYC gene signatures were found to be enriched in LZ 
B cells119,124, and NF-B gene signatures were also specifically enriched in c-MYC+ GC B 
cells162,163. Evidence strongly suggests that c-MYC+ GC B cells are undergoing T cell-mediated 
selection as they displayed an activated phenotype, were actively cycling and expressed high 
affinity BCRs162,163. As described in Section 1.3, positive selection of a high-affinity B cell within 
the LZ programs reentry to and division within the DZ, and T cell help was found to induce c-
MYC expression in LZ B cells prior to cyclic reentry into the DZ162,163. Similar to c-REL, ablation 
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of c-MYC also resulted in the dissolution of established GCs162,163,338. As c-MYC was found to be 
induced prior to cyclic reentry, GC collapse upon removal of c-MYC suggests that cyclic reentry 
sustains the population of cells proliferating within the DZ and thereby maintains the GC 
reaction over time. Therefore, and by analogy, it is possible that impaired GC maintenance in 
the absence of c-REL may be due to a role for c-REL in licensing antigen-selected LZ B cells to 
grow and divide upon reentry into the DZ. This is consistent with the impairment of the GC 
reaction observed in the absence of c-REL manifesting only after day 7 of the GC reaction, the 
time-point at which it is believed that the GC has reached maturity and is polarized into a DZ 
and a LZ that can support cyclic reentry88,107.  
To date, the role of the alternative NF-B pathway during the GC reaction has been 
studied using mice with constitutional knockout of either relb or nfkb2. These mice fail to form 
GCs following immunization, or do so in a highly impaired fashion360-362. However, experiments 
with bone marrow chimeras demonstrated that this GC defect was due to the absence of RELB 
or NF-B2 in non-hematopoietic, stromal accessory cells360,362. Mice with germline inactivation 
of upstream regulators of the alternative NF-B pathway, NIK or IKKα, also fail to form 
GCs303,349,350. In contrast to RELB or NF-B2 however, inactivation of NIK or IKKα in 
hematopoietic cells was found to inhibit GC development303,349,350. These findings are again 
suggestive of additional roles for NIK and IKKα independent of activation of the alternative 
pathway that may be important for GC development290,324-327,358, or may be indicative of 
redundancy between RELB and NF-B2.  
GCs in mice that received RELB- or NF-B2-deficient bone marrow were analyzed at 
day 9 or 10 following immunization, which implies that these subunits are not required for GC 
development at least up to 10 days post-immunization360,362. However, the occurrence of 
mutations identified in GC-derived lymphomas that result in constitutive activation of both the 
canonical and alternative NF-B pathways335, the activation of the alternative pathway observed 
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in human GC B cells and the preferential expression of alternative subunits observed in PCs 
(Fig. 3.2) all provided us with an impetus to investigate the role of the alternative NF-B 
pathway within the GC using conditional alleles. We reasoned that the initial studies followed 
GC development only up to day 10 post-immunization, thus preventing the detection of a later 
GC maintenance defect. Finally, it is possible that the RELB and NF-B2 subunits have 
redundant functions, and an effect on GC development may be uncovered only upon combined 
ablation, an experiment which has not previously been conducted using constitutional knockout 
mice. For these reasons, we utilized the relb and nfkb2 conditional alleles generated in Chapter 
2 to determine the consequences of the GC B cell-specific ablation of RELB and NF-B2 either 
alone or in combination. These studies revealed that GC maintenance is dependent on the 
combined activity of RELB and NF-B2. In contrast, single ablation of either subunit had no 
effect. In addition, while GC B cell-specific deletion of nfkb2 did not appear to impair PC 
development, reduced antigen-specific serum IgG1 and IgG1 ASCs was observed.  
Section 4.2: MATERIALS AND METHODS 
Mice 
The conditional relb and nfkb2 alleles are described in Chapter 2 and were backcrossed to 
C57BL/6 mice (n≥ 7). Cγ1-Cre mice have been described402. Mice were housed and treated in 
compliance with the US Department of Health and Human Services Guide for the Care and Use 
of Laboratory Animals and according to the guidelines of the Institute of Comparative Medicine 
at Columbia University (New York). The animal protocol was approved by the Institutional 
Animal Care and Use Committee (IACUC) of Columbia University. 
 Immunization 
Mice were immunized via intraperitoneal injection with 109 sheep red blood cells (SRBCs, 
Cocalico Biologicals) in PBS, or NP-KLH (100 µg per mouse; Biosearch Technologies) in 
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complete Freund’s adjuvant (Sigma-Aldrich). Peripheral blood and spleens were removed at the 
indicated time points for analysis. 
Flow cytometry  
Spleen cell suspensions or cultured B cells were stained on ice in PBS/0.5% BSA with the 
following antibodies, PerCP-conjugated anti-B220 (Biolegend, clone RA3-6B2), Alexa Fluor 
700-conjugated anti-CD38 (eBioscience, clone 90), PE-conjugated anti-CD138 (BD 
Pharmingen, clone 281-2), APC-conjugated anti-CD86 (eBioscience, clone GL1), PE-
conjugated anti-CD95 (BD Pharmingen, clone Jo2), PerCP-eFluor710-conjugated anti-CXCR4 
(eBioscience, clone 2B11), biotin-conjugated anti-PNA (Vector Laboratories) followed by 
streptavidin-APC (BD Pharmingen), APC-conjugated anti-CD36 (Biolegend, clone HM36) and 
PE-CF594-conjugated anti-CD19 (BD Horizon, clone 1D3). The cells were washed and 
analyzed on a FACSCalibur or LSRII (BD). To assess DNA content, cells were fixed using the 
BD Cytofix/Cytoperm Fixation Permeabilization Kit and stained with 3 M DAPI (Molecular 
Probes, Invitrogen) prior to analysis on a LSRII (BD). Data were analyzed using FlowJo 
software.  
ELISA and ELISPOT  
For ELISA, 96-well immune plates (Thermo Fisher Scientific) were coated with NP9-BSA 
(Biosearch Technologies). Mouse serum samples were incubated for 2 h at room temperature. 
Standard curves were generated using mouse IgG1 (Southern Biotech). Bound antibodies were 
detected using AP-conjugated anti–mouse IgG1 antibody (Southern Biotech). Plates were 
developed with p-nitrophenylphosphate (Southern Biotech) dissolved in substrate buffer. For 
ELISPOT analysis, the spleens and bone marrow of NP-KLH–immunized mice were removed at 
the indicated time points, and single cell suspensions were subjected to hypotonic lysis. The 
samples were plated overnight on 96-well filtration plates (Millipore) coated with NP25-BSA 
(Biosearch Technologies). The cells were plated in 1:2 serial dilutions, starting at 8 × 105 cells 
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for bone marrow-derived samples, and at 105 cells for spleen-derived fractions. NP-specific 
IgG1 ASCs were detected by AP-conjugated anti–mouse IgG1 antibody (Southern Biotech). 
Plates were developed with nitro blue tetrazolium chloride-5-bromo-4-chloro-3- indolyl 
phosphate (NBT/BCIP; Roche). 
Immunohistochemistry 
Sections of 2-3 m in thickness were cut from spleen tissue that was fixed overnight in 10% 
formalin and embedded in paraffin. Sections were stained with unlabeled anti-BCL6 rabbit 
antibody (Santa Cruz, clone N-3). Antibodies were incubated overnight at 4°C, stained with anti-
rabbit HRP-labeled polymer (Dako) and developed in aminoethylcarbazole (AEC; Sigma). 
These slides were then counterstained for IgM by overnight incubation at 4°C with alkaline 
peroxidase (AP)-conjugated anti-IgM antibody (Southern Biotech). IgM stainings were 
developed in nitro blue tetrazolium chloride–5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; 
Roche, New York, NY). The images were acquired by means of a Digital Sight camera (Nikon) 
mounted on a Nikon Eclipse E600 microscope (Nikon).  
B cell isolation and culture 
Single cell suspensions of mouse spleen were subjected to hypotonic lysis and B cells were 
purified by depletion of magnetically labeled non-B cells using the MACS B cell isolation kit 
(Miltenyi Biotec). Purified B cells from the indicated genotypes were cultured in the presence of: 
20 g/mL LPS (Sigma-Aldrich) or 10ng/mL IL5 (R&D systems), 10 ng/mL IL4 (R&D systems) 
and 12.5 ng/mL CD40L (R&D systems). Cell density in LPS cultures was 1.0 x 106 cells/mL 
using RPMI with 10% FBS and in CD40 + IL5 + IL4 cultures cell density was 0.5 x 106 cells/mL 




eGFP+ GC B cells (CD95hiPNAhi) were sorted from purified B cells isolated from 
relbfl/flnfkb2fl/flCγ1-Cre SRBC-immunized mice (day 7) and GC B cells were sorted from purified 
B cells isolated from Cγ1-Cre control mice. Cell sorting was conducted on a FACSAria (BD) and 
cells were sorted into 50% FBS in PBS. Total RNA of ~60,000-400,000 cells per sample was 
isolated using the Nucleospin RNA XS isolation kit (Macherey-Nagel) according to the 
manufacturer’s protocol, and RNA integrity >8 was determined using a  BioAnalyzer 2100 
(Agilent Technologies). ~2-70ng of RNA per sample was submitted to the New York Genome 
Center and RNA was amplified via the NuGEN Ovation RNA-Seq System V2 prior to RNA 
sequencing. 35-40 million 2x50 bp paired-end reads were sequenced per sample on the 
HiSeq2500 instrument (Illumina). DESeq analysis was used to identify differentially expressed 
genes and determine fold expression changes between genotypes.  
Gene set enrichment analysis (GSEA) 
The GSEA tool403 available from the website of the Broad Institute was used to identify gene 
signatures enriched in RELB/NF-B2-proficient vs. RELB/NF-B2-deficient GC B cells. We 
screened the collection of signatures under the category GO_MF and the curated category 
Reactome to identify signatures with significant enrichment (FDR < 25%, p ≤ 0.05). 
Immunoblot analysis  
Purified B cells were subjected to NP40-based lysis, separated by SDS-PAGE and blotted on 
nitrocellulose membranes (GE Healthcare). Samples were incubated with the following primary 
antibodies overnight at 4°C. Rabbit anti-p100/p52 (Cell Signaling Technologies, CST), goat anti-
IRF4 (Santa Cruz, clone M-17), rat anti-BLIMP1 (Santa Cruz, clone 6D3) and mouse anti-β-
actin (Sigma, clone AC-15). Horseradish peroxidase-conjugated secondary antibodies (anti-
rabbit IgG, GE Healthcare, anti-mouse IgG, Thermo Scientific, anti-goat IgG, Santa Cruz and 
anti-rat IgG, GE Healthcare) and ECL Western Blotting Substrate or SuperSignal West Dura 
Extended Duration Substrate (Thermo Scientific) were used for detection. 
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Section 4.3: RESULTS 
Combined GC B cell-specific deletion of relb and nfkb2 impairs the GC reaction. 
To determine the in vivo role of the alternative NF-B subunits RELB and NF-B2 during GC B 
cell development, we utilized conditional relb and nfkb2 alleles generated in Chapter 2. These 
alleles were crossed to Cγ1-Cre mice either alone or in combination to allow deletion in GC B 
cells402. In Cγ1-Cre mice, the expression of Cre recombinase is linked to the transcription of the 
Ig γ1 constant region segment (Cγ1)402. The expression of Cγ1-Cre is therefore induced upon 
TD immunization, and the Cγ1-Cre promoter is expressed in activated B cells as early as 2-4 
days after immunization. As GCs are the main source of class switched antibodies in response 
to TD, Cγ1-Cre is efficiently induced in GC B cells402. Expression is induced in the majority of 
GC B cells and is not restricted to just those cells that undergo CSR to IgG1402. relbfl/flCγ1-Cre, 
nfkb2fl/flCγ1-Cre or relbfl/flnfkb2fl/flCγ1-Cre mice and the corresponding heterozygous and Cγ1-
Cre control mice were immunized with sheep red blood cells (SRBCs), a TD antigen that 
induces a robust GC response. 14 days following immunization, the fractions of splenic 
CD95hiPNAhi GC B cells in relbfl/flCγ1-Cre and nfkb2fl/flCγ1-Cre were comparable to controls (Fig. 
4.1A,B). A trend towards a reduced fraction of GC B cells was observed in nfkb2fl/flCγ1-Cre 
compared to nfkb2fl/+Cγ1-Cre and Cγ1-Cre control mice; however, this difference did not reach 
significance (Fig. 4.1B). In contrast, the fraction of splenic GC B cells in relbfl/flnfkb2fl/flCγ1-Cre 
was strongly reduced in comparison to relbfl/+nfkb2fl/+Cγ1-Cre and Cγ1-Cre control mice 14 days 
post-immunization (Fig. 4.1C). Consistent with the flow cytometric data, reduced BCL6+ GCs 
were observed within B cell follicles in relbfl/flnfkb2fl/flCγ1-Cre in comparison to controls at day 14 
via immunohistochemical analysis (Fig. 4.2A). These findings therefore demonstrate that single 
ablation of either RELB or NF-B2 in GC B cells has no significant impact on the GC reaction, in 
agreement with previous studies that utilized adoptive transfer of bone marrow with 
constitutional ablation of RELB or NF-B2360,362. Instead, combined ablation of RELB and NF-
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B2 in GC B cells strongly impaired the GC reaction, demonstrating that both alternative 
pathway subunits are required for GC maintenance.  
To define the temporal kinetics of the GC impairment observed in relbfl/flnfkb2fl/flCγ1-Cre 
mice, we analyzed CD95hiPNAhi splenic GC B cells at various time-points following immunization 
with SRBCs. 7 days post-immunization, the fraction of CD95hiPNAhi splenic GC B cells was not 
significantly different between relbfl/flnfkb2fl/flCγ1-Cre mice and relbfl/+nfkb2fl/+Cγ1-Cre and Cγ1-
Cre controls (Fig. 4.2B). However, reduced fractions of GC B cells were observed from 10-12 
days following immunization in relbfl/flnfkb2fl/flCγ1-Cre mice compared to relbfl/+nfkb2fl/+Cγ1-Cre 
mice (Fig. 4.2C). It appears therefore that GC B cell development occured normally in 
relbfl/flnfkb2fl/flCγ1-Cre mice up to day 7 of the GC reaction, after which GC B cells were 
progressively lost. This phenotype is similar to the collapse of formed GCs observed following 
GC B cell-specific ablation of c-REL338 or c-MYC162,163 and is suggestive of a defect in GC 
maintenance in the combined absence of RELB and NF-B2. As observed following GC B cell-
specific ablation of c-REL338, a defect in the maintenance of formed GCs would be predicted to 
result in the equal loss of CXCR4hiCD86lo DZ and CXCR4loCD86hi LZ splenic GC B cell fractions 
over time. While the differences in the DZ and LZ B cell fractions between relbfl/flnfkb2fl/flCγ1-Cre 
mice and Cγ1-Cre control mice did reach significance (Fig. 4.3A), these differences were minor 
and thus do not indicate a preferential loss of either DZ or LZ B cells in relbfl/flnfkb2fl/flCγ1-Cre 
mice. In addition, the proliferative capacity of GC B cells in relbfl/flnfkb2fl/flCγ1-Cre mice did not 
vary significantly from controls at day 8-12 post-immunization (Fig. 4.3B), consistent with the 
almost equal fractions of proliferative DZ B cells observed between relbfl/flnfkb2fl/flCγ1-Cre and 
control mice (Fig. 4.3A). These data suggest that RELB and NF-B2 are jointly required for the 
maintenance of both DZ and LZ GC subpopulations, while GC formation appears unaffected.  
Identification of genes controlled by the alternative NF-B subunits, RELB and NF-B2, in 
GC B cells at day 7 of the GC reaction. 
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In order to identify biological programs controlled by RELB and NF-B2 that are required for GC 
maintenance, we subjected GC B cells isolated at day 7 post-immunization to RNA-seq 
analysis. As normal fractions of GC B cells were present in relbfl/flnfkb2fl/flCγ1-Cre mice at day 7 
(Fig. 4.2B), this time-point presented an opportunity to harvest GC B cells in relbfl/flnfkb2fl/flCγ1-
Cre mice prior to their loss at later time-points (Fig. 4.1C, 4.2C). We reasoned that gene 
expression changes that ultimately result in the loss of GC B cells would already be evident at 
day 7 in relbfl/flnfkb2fl/flCγ1-Cre mice. A similar strategy was successfully utilized previously to 
identify the genetic program controlled by c-REL in GC B cells338. At 7 days post-immunization 
with SRBCs, splenic CD95hiPNAhi GC B cells were sorted from 3 Cγ1-Cre control mice and 
splenic eGFP+CD95hiPNAhi GC B cells were sorted from 2 relbfl/flnfkb2fl/flCγ1-Cre mice. The use 
of eGFP positivity allowed GC B cells with ablation of RELB and NF-B2 to be specifically 
isolated, thus excluding GC B cells that escaped Cre-mediated recombination. RNA was 
extracted from these samples and subjected to RNA amplification, which was required as GC B 
cells comprise a very small proportion of total spleen, prior to RNA-seq analysis. Reduced 
transcript counts of relb and nfkb2 were identified in GC B cells from relbfl/flnfkb2fl/flCγ1-Cre mice 
compared to Cγ1-Cre controls (Fig. 4.4A). In addition, unsupervised clustering analysis revealed 
that the Cγ1-Cre samples and relbfl/flnfkb2fl/flCγ1-Cre samples clustered into two separate 
groups as expected (Fig. 4.4B), thereby validating the robustness of the RNA-seq data set.  
Differentially expressed sequence analysis (DESeq) of RELB/NF-B2-proficient vs. 
RELB/NF-B2-deficient GC B cells identified 59 transcripts with greater than 2.5-fold reduced 
expression and 84 transcripts with greater than 2.5-fold increased expression at a significance 
threshold of p<0.01. Genes were assigned to putative functional categories (Fig. 4.4C); for the 
identity of the corresponding genes, fold-change and p values, see Appendix B. Of note, the 
genetic program controlled by RELB and NF-B2 was largely mutually exclusive with the 
transcriptional program controlled by c-REL in GC B cells at day 7338, suggesting the different 
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NF-B transcription factors have distinct functions within the same GC context. Reduced 
expression of genes involved in apoptosis or proliferation was not detected in RELB/NF-B2-
deficient GC B cells compared to controls. In addition, the expression of genes encoding major 
regulators of GC and post-GC development, including BCL6, AID, c-MYC, IRF4 and BLIMP1, 
remained intact. A large proportion of transcripts with reduced expression in the combined 
absence of RELB and NF-B2 encoded genes with functions in the immune response and 
metabolism (Fig. 4.4C, left panel). In contrast, the vast majority of transcripts with increased 
expression in the combined absence of RELB and NF-B2 were non-protein coding in nature 
(Fig. 4.4C, right panel), comprising a range of RNA elements including lincRNAs, antisense 
transcripts and pseudogenes (see Appendix B). While miRNAs have been linked to functional 
roles within the GC404, the biological significance of the upregulated RNA elements identified in 
RELB/NF-B2-deficient GC B cells is unclear.  
The genes with metabolic functions that displayed reduced expression in RELB/NF-B2-
deficient GC B cells compared to controls were primarily found to have functions in lipid and 
amino acid metabolism (Fig. 4.5A, left and right). Reduced expression of genes involved in ion 
and carbohydrate metabolism was also observed in RELB/NF-B2-deficient vs. proficient GC B 
cells (Fig. 4.5A); for the identity of the corresponding genes, fold-change and p values, see 
Appendix B. In regards to lipid metabolism, RELB/NF-B2-deficient GC B cells demonstrated 
reduced expression of genes involved in lipid transport, synthesis and breakdown compared to 
controls (Fig. 4.5A, left). These included the gene encoding CD36, a molecule with 
heterogeneous functions in different cell types405. On the cell surface of endothelial cells, CD36 
serves a receptor for thrombospondin and negatively regulates angiogenesis405. On phagocytes, 
functions associated with CD36 include the recognition of lipid molecules on apoptotic cells and 
pathogens, thereby facilitating uptake405. In phagocytes, CD36 can also function as a fatty acid 
translocase that mediates the transport of long-chain fatty acids into cells405, and this function 
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was used to designate a possible role in lipid metabolism to this gene (Fig. 4.5A, left). In B cells, 
CD36 is understudied. It has been identified as an NF-B target in a murine pre-B cell line406. 
CD36 expression is rapidly induced on follicular B cells following in vitro stimulation with LPS 
and CD40407; however, CD36-deficient B cells respond normally to a range of mitogenic stimuli 
in vitro408. As CD36 is a cell surface protein, we assayed for the expression of CD36 on eGFP+ 
GC B cells from relbfl/flnfkb2fl/flCγ1-Cre mice via flow cytometry and identified reduced protein 
expression in comparison to GC B cells in Cγ1-Cre mice and eGFP+ GC B cells in 
relbfl/+nfkb2fl/+Cγ1-Cre mice at day 8-12 post-immunization (Fig. 4.5B). The reduced expression 
at the protein level provides us with additional validation of our RNA-seq data set and may 
indicate that RELB and NF-B2-deficient GC B cells have a defect in fatty acid metabolism. This 
notion is further supported by the reduced expression of the genes encoding ceramide synthase 
6 (CERS6), an enzyme involved in sphingolipid synthesis409, oxysterol binding protein-like 3 
(OSBPL3), an intracellular lipid receptor410, and solute carrier family 27 (SLC27A4), another 
long-chain fatty acid transporter with acyl-CoA synthetase activity411,412. Reduced expression of 
genes that have functions in amino acid modifications was also identified in RELB/NF-B2-
deficient GC B cells (Fig. 4.5A, right). These included the genes encoding glutathione S-
transferase theta 1 and 3 (GSTT1 and GSTT3), detoxifying enzymes that catalyze the 
conjugation of glutathione to electrophilic compounds413, UDP-GalNAC:Polypeptide N- 
Acetylgalactosaminyltransferase-Like Protein 3 (WBSCR17), an enzyme that may catalyze the 
transfer of N-acetyl-D-galactosamine to a serine or threonine residue414, and peptipdyl arginine 
deiminase, type IV (PADI4), an enzyme that catalyzes the conversion of arginine residues into 
citrulline415. Collectively, these gene expression changes suggest that RELB/NF-B2-deficient 
GC B cells may have defective lipid and amino acid metabolism. Also, c-REL was found to 
control a metabolic program in GC B cells; in contrast, however, this program was mainly 
comprised of genes involved in glycolytic processes338.  
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In comparison to controls, reduced expression of a number of immune response genes 
was detected in RELB/NF-B2-deficient GC B cells, which comprised immune trafficking, 
antiviral, inflammation, Ig and B cell-related genes (Fig. 4.5C). Within this immune response 
category, genes with functions in immune response trafficking are presented in Fig. 4.5C; for the 
identity of the remaining genes within the immune response category and associated fold-
changes and p values, see Appendix B. The immune trafficking genes included cxcl10, 
encoding CXCL10, an IFNγ-inducible, inflammatory chemokine that binds to the chemokine 
receptor CXCR3 and is primarily associated with secretion by non-B cell types including 
fibroblasts, monocytes and T cells416, although expression of CXCL10 in B cells has been 
reported417,418. CXCL10 serves as a chemotactic factor for a range of cell types, including T 
cells, DCs and natural killer cells and non-immune cell types416. Additional immune trafficking 
genes with reduced expression in RELB/NF-B2-deficient were rgs13 and rgs3 (encoding 
regulators of G protein signaling 13 and 3). Chemokines induce signaling through chemokine 
receptors that are coupled to G proteins. RGS13 and RGS3 modulate G protein-coupled 
signaling by chemokine receptors and are associated with inhibiting the responsiveness of 
chemokine receptors to chemokine ligation419. Several reports implicate RGS13 and RGS3 in B 
cell and GC B cell trafficking. Rgs13 expression is rapidly induced in activated B cells and is 
highly expressed in GC B cells420,421. RGS13 and RGS3 have been shown to inhibit signaling 
through the GC chemokine receptors CXCR5 and CXCR4 following expression in a cell line 
system420, and reduced expression of RGS13 resulted in elevated responsiveness to the GC 
chemokines CXCL12 and CXCL13 in a Burkitt lymphoma cell line422. In addition, RGS3 
expression in a B cell line also inhibited chemotaxis towards a range of lymphoid chemokines423. 
Finally, gene set enrichment analysis (GSEA)403 revealed enrichment of chemokine/chemokine 
receptor gene signatures in RELB/NF-B2-proficient GC B cells in comparison to RELB/NF-
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B2-deficient GC B cells (Fig. 4.5D). These data collectively suggest that in the absence of 
RELB and NF-B2, GC B cells may respond improperly to trafficking signals within the GC.  
PC frequencies following GC B cell-specific deletion of alternative NF-B subunits. 
We next sought to determine the in vivo role of these RELB and NF-B2 subunits during post-
GC PC development. relbfl/flCγ1-Cre, nfkb2fl/flCγ1-Cre or relbfl/flnfkb2fl/flCγ1-Cre mice and the 
corresponding heterozygous and Cγ1-Cre control mice were immunized with SRBCs and 
analyzed for splenic CD138hi PCs 14 days later (Fig. 4.6A-C). A reduced fraction of splenic PCs 
was observed in relbfl/flCγ1-Cre mice in comparison to relbfl/+Cγ1-Cre mice and Cγ1-Cre controls 
(Fig. 4.6A). In contrast, the fraction of PCs in nfkb2fl/flCγ1-Cre was comparable to controls (Fig. 
4.6B). As relbfl/flnfkb2fl/flCγ1-Cre mice have a greatly reduced fraction of GC B cells at day 14 
(Fig. 4.1C), reduced GC output would be predicted. As expected, the fraction of PCs in these 
mice was strongly reduced in comparison to controls (Fig. 4.6C). These data demonstrate that 
in contrast to the effects observed on GC development, GC B cell-specific ablation of RELB 
alone results in a reduction in PCs. This reduction in PCs is also reflected by reduced NP-
specific serum IgG1 in relbfl/flCγ1-Cre mice in comparison to relbfl/+nfkb2fl/+Cγ1-Cre and Cγ1-Cre 
control mice 14 days following immunization with the TD antigen NP-KLH (Fig. 4.8A).  
As nfkb2fl/flCγ1-Cre displayed no PC impairment at day 14 post-immunization, we 
analyzed CD138hi PCs in the spleen and bone marrow 28 days following immunization with NP-
KLH, and once again PCs frequencies were comparable to controls (Fig. 4.7). However, 
nfkb2fl/flCγ1-Cre mice were found to have greatly reduced NP-specific serum IgG1 in 
comparison to nfkb2fl/+Cγ1-Cre and Cγ1-Cre control mice at 14 and 28 days post-immunization 
with NP-KLH (Fig. 4.8B). This reduction in serum IgG1 was somewhat counterintuitive 
considering that reduced PC frequencies were not detectable in nfkb2fl/flCγ1-Cre mice (Fig. 
4.6B, 4.7). To further investigate this phenotype, we conducted ELISPOT analysis for NP-
specific IgG1 ASCs. The results revealed a strong reduction in these ASCs in the spleen and 
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bone marrow of nfkb2fl/flCγ1-Cre mice compared to control mice 14 and 28 days post-
immunization with NP-KLH (Fig. 4.8C). Therefore, despite apparently normal GC and PC 
development (Fig. 4.1B, 4.6B, 4.7), GC B cell-specific ablation of NF-B2 resulted in reduced 
antigen-specific serum IgG1 and antigen-specific IgG1 ASCs.  
As PCs comprise a very small proportion of splenic and bone marrow mononuclear cells, 
we reasoned that plasmablasts generated in vitro would prove more amenable for use in 
functional assays to further investigate the reduced antigen-specific serum IgG1 and IgG1 ASCs 
observed in nfkb2fl/flCγ1-Cre mice. To this end, we isolated NF-B2-deficient B cells from 
nfkb2fl/flCD19-Cre mice and B cells from nfkb2fl/+CD19-Cre and CD19-Cre control mice in order 
to perform published assays that promote plasmablastic differentiation. These assays involved 3 
days of stimulation with LPS or 4 days of stimulation with CD40L, IL5 and IL4191,424. While it 
appeared that cultures of NF-B2-deficient B cells had an increased propensity to undergo 
plasmablastic differentiation in comparison to control cultures in each assay (which was not an 
intuitive result), the difference did not reach significance (Fig. 4.9A). ELISPOT analysis revealed 
no significant differences in the generation of IgM ASCs in cultures of B cells from nfkb2fl/flCD19-
Cre, nfkb2fl/+CD19-Cre or control CD19-Cre mice. Therefore, the in vitro plasmablastic 
differentiation assays did not mimic the reduced ASCs observed in nfkb2fl/flCγ1-Cre mice in vivo 
(Fig. 4.9B). These assays, however, had additional limitations. First, no processing of p100 to 
p52 could be detected following LPS stimulation (Fig. 4.9C), consistent with the fact that LPS is 
known to activate the NF-B cascade via the canonical pathway. It appears therefore that the 
LPS plasmablastic differentiation assay is not suitable for the study of the alternative subunit 
NF-B2 in plasmablasts. Second, the CD40 + IL4 + IL5 assay, while demonstrating limited p100 
– p52 processing, was associated with poor induction of BLIMP1, a major regulator of PC 
development (Fig. 4.9C). Therefore, this assay also appears to have only limited value for the 
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study of PC biology. Overall, the currently available in vitro assays are not suitable for the study 
of NF-B2 in antibody generation/secretion. 
Section 4.4: DISCUSSION 
The role of alternative NF-B subunits in GC development has been obscured in mice with 
constitutional ablation of RELB or NF-B2 by phenotypes produced by non-hematopoietic cell 
types359-362. Previous work using bone marrow chimeras indicated that neither RELB or NF-B2 
alone is required in hematopoietic cells to support the GC reaction360,362. In agreement, we 
found that GC B cell development proceeds normally in mice with GC B cell-specific ablation of 
either RELB or NF-B2 alone. In contrast, combined ablation of RELB or NF-B2 resulted in the 
progressive loss of GC B cells over time, a phenotype similar to that observed following ablation 
of c-REL in GC B cells338. It appears, therefore, that RELB and NF-B2 are jointly required for 
the maintenance of the GC reaction.  
These findings revealed redundancy between the subunits of the alternative NF-B 
pathway and suggest that the loss of either RELB of NF-B2 alone does not disrupt the 
functional role of the alternative NF-B pathway within the GC. The redundancy in the absence 
of either RELB of NF-B2 may be explained by dimerization of the respective, remaining 
transcription factor with subunits of the canonical NF-B pathway. Indeed, while the classical 
dimer pair of the alternative pathway is RELB-p52, numerous homo- and heterodimer 
combinations have been described277,425. It is therefore possible that hybrid alternative/canonical 
NF-B dimers, such as RELA-p52 or RELB-p50, are able to functionally compensate for the 
absence of the classical RELB-p52 dimer of the alternative pathway. The possibility that global 
dimer compositions are altered in the absence of either RELB or NF-B2 is an interesting point 
that could be investigated with gel shift assays. Alternatively, this question could be addressed 
genetically by intercrossing conditional alleles of canonical and alternative NF-B subunits. It is 
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clear however, that redundancy does not exist generally between the canonical and alternative 
NF-B pathways, since the GC maintenance defect observed in the combined absence of RELB 
and NF-B2 is not compensated for by canonical NF-B subunits. This lack of pathway 
redundancy is further evidenced by the distinct gene expression programs controlled by cREL338 
and RELB/NF-B2 at day 7 of the GC reaction.  
GCs reach maturity at ~day 7 of the GC reaction, the time-point at which DZ/LZ 
polarization is thought to be complete and when selection of high-affinity GC B mutants, 
followed by cyclic reentry, is initiated88,107. It is clear that persistent signals are required for the 
maintenance of mature GCs, as the involution of established GCs has been observed upon 
inhibition of CD40381 and BAFF70,389 signaling as well as upon ablation of c-MYC162,163, c-REL338 
and, as described here, RELB and NF-B2. In addition, a recent study showed that GC B cells 
within spontaneous GCs in mesenteric lymph nodes and Peyer’s patches decreased over time 
following inducible ablation of NIK372. As outlined in the introduction to this chapter (Section 4.1), 
it is likely that c-REL is activated in LZ B cells undergoing selection and promotes cyclic reentry 
by enabling cell growth and division upon cyclic reentry into the DZ338. Rounds of selection and 
cyclic reentry then sustain the GC reaction over time. Similar to c-REL-deficient GC B cells, 
RELB/NF-B2-deficient GC B cells were also lost past day 7 of the GC reaction, suggesting that 
activation of the alternative NF-B pathway occurs within LZ B cells and plays a role during 
selection. Furthermore, DZ and LZ B cell subsets were lost equally over time. Such equal loss is 
suggestive of a role for RELB and NF-B2 in promoting cyclic reentry following selection either 
by ensuring the survival or growth of LZ B cells, or by enabling cycling reentry into and 
propagation within the DZ. A functional role in selection and cyclic reentry was further supported 
in the case of c-REL by the finding that c-REL-deficient GC B cells undergo reduced affinity 
maturation in comparison to controls338. A similar analysis of RELB/NF-B2-deficient GC B cells 
to determine if the selection of high-affinity BCRs is impaired within these cells would further 
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clarify whether alternative NF-B subunits are also critically involved in maintaining cycles of 
mutation and selection.  
The mechanism by which RELB and NF-B2 promote the maintenance of the GC 
reaction remains unclear. It is possible that the alternative NF-B subunits are required to 
maintain the survival of GC B cells in response to BAFF signals within the GC. This would be 
consistent with the potential role of BAFF signaling in GC maintenance70,389 and the function of 
the alternative NF-B pathway downstream of BAFF in naïve B cells (Chapter 2). Reduced 
expression of anti-apoptotic genes was not detected in RELB/NF-B2-deficient GC B cells at 
day 7; however, this does not formally exclude the possibility that RELB/p52 heterodimers 
control the expression of anti-apoptotic genes at later time-points. To exclude a role for the 
alternative NF-B subunits in the survival of B cells within the GC, the ability of a BCL2 
transgene to rescue RELB/NF-B2-deficient GC B cells could be assessed. With regard to the 
role of c-REL in GC B cells, the loss of c-REL-deficient GC B cells was not correlated with 
increased apoptosis, but rather with the failure of these cells to express a glycolytic metabolism 
program which likely promotes cell growth and subsequent proliferation338. This c-REL-regulated 
program is important for the generation of energy and building blocks for anabolic processes, 
and c-REL-deficient B cells stimulated in vitro displayed reduced oxygen consumption rate, ATP 
production and glycolytic capacity in comparison to controls338. Reduced expression of genes 
with metabolic functions was also observed in RELB/NF-B2-deficient GC B cells; however, 
these genes were primarily found to encode factors that direct fatty acid and amino acid 
metabolism. It is therefore possible that the two branches of the NF-B signaling cascade direct 
different types of cellular metabolism that may be jointly required to ensure proper GC B cell 
growth.  
In naïve B cells, NF-B2 was found to control the expression of a number of genes that 
direct trafficking within B cell follicles (Chapter 2). Similarly, reduced expression of genes 
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involved in the regulation of trafficking within the GC was detected in RELB/NF-B2-deficient 
GC B cells in comparison to controls. Dysregulated trafficking would be predicted to disrupt 
cyclic reentry and thereby prevent DZ reentry and proliferation, events that maintain the GC 
reaction. A trafficking defect would therefore be predicted to impair GC maintenance, consistent 
with the phenotype observed upon GC B cell-specific combined ablation of RELB and NF-B2. 
However, a putative defect in trafficking within the GC is not reflected by significantly altered 
fractions of DZ and LZ B cells in relbfl/flnfkb2fl/flCγ1-Cre compared to Cγ1-Cre control mice. In 
addition, studies focused on the role of rgs13, a gene involved in the regulation of trafficking that 
is expressed at reduced levels in RELB/NF-B2-deficient GC B cells, present conflicting findings 
in regards to the function of RGS13 in GC development. Analysis of RGS13-deficient mice 
revealed enlarged GCs and elevated numbers of GC B cells, suggesting that RGS13 has a role 
in limiting the GC reaction421. In contrast, in a mouse model of autoimmunity, deletion of rgs13 
was associated with smaller GCs, impaired SHM and affinity maturation426. Whether RGS13 has 
a role in limiting or maintaining the GC reaction is therefore unclear.  Proper DZ/LZ trafficking 
within the GC also ensures the proper segregation of mutation and selection processes to 
enable effective affinity maturation108. Aberrant trafficking may therefore disturb affinity 
maturation, which is a testable hypothesis that will be addressed by investigating the capacity of 
mice with GC B cell-specific ablation of RELB and NF-B2 to generate high-affinity GC B cells. 
Deletion of relb in GC B cells resulted in a significant reduction in PCs, suggesting that 
RELB has a role in PC development. This defect was however not as severe as that observed 
following GC B cell-specific ablation of the canonical NF-B subunit RELA, which resulted in 
greatly reduced PCs338. In contrast, deletion of nfkb2 in GC B cells led to the disappearance of 
antigen-specific serum IgG1 and antigen-specific IgG1 ASCs, despite the occurrence of 
apparently normal fractions of PCs in the spleen and bone marrow. It should be noted, however, 
that similar to the weak expression of eGFP following recombination of the floxed nfkb2 allele 
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with CD19-Cre, eGFP is also weakly expressed in GC B cells and PCs from nfkb2fl/flCγ1-Cre 
mice. Due to this technical limitation, we were unable to conclusively detect a preferential loss of 
eGFP+ PCs in nfkb2fl/flCγ1-Cre mice compared to nfkb2fl/+Cγ1-Cre mice, and therefore a 
possible counterselection of nfkb2-deleted cells cannot be excluded. What is clear, however, is 
that on a whole population level (assessing eGFP+ and eGFP- PCs), there does not appear to 
be any reduction in the fraction of PCs within the spleen or bone marrow following GC B cell-
specific ablation of NF-B2. This is suggestive of a functional rather than a developmental role 
for NF-B2 in PC biology, and as such contrasts with the role of RELA in the generation of 
PCs338.  
The greatly reduced levels of antigen-specific IgG1 in nfkb2fl/flCγ1-Cre mice could have 
several explanations. One possibility is that GC B cells expressing high affinity, antigen-specific 
BCRs are not generated in the absence of NF-B2, thus selectively preventing the development 
of PCs secreting high affinity antibody. This putative defect could be investigated by assessing 
affinity maturation at the IgV sequence level within nfkb2fl/flCγ1-Cre mice. Alternatively, CSR to 
IgG1 may be impaired in nfkb2fl/flCγ1-Cre mice. This possibility could be addressed by 
assessing the levels of other antibody isotypes within these mice. However, as B cells from 
mice with constitutional deletion of nfkb2 were found to be able to switch normally to all Ig 
isotypes in response to in vitro stimulation361, selective inhibition of CSR to IgG1 appears 
unlikely. A final possibility is that in the absence of NF-B2, PCs have an impaired ability to 
secrete antibody. A secretion phenotype would be expected to impact high and low affinity 
antibodies and antibodies of different isotypes equally. To address this possibility, additional 
experiments assaying the levels of other types of antibodies in nfkb2fl/flCγ1-Cre mice would be 
informative. LPS-mediated plasmablastic differentiation was used to demonstrate reduced 
expression of BLIMP1 in RELA-deficient B cells in comparison to controls, which may explain 
the PC differentiation defect observed in vivo338. In order to determine whether NF-B2-deficient 
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plasmablasts express reduced levels of factors involved in the secretion of antibody, such as 
XBP1210,216-219, a plasmablastic differentiation system would be of use. However, as LPS 
stimulation does not activate the alternative NF-B pathway, more suitable assays will need to 
be devised. In the absence of such assays, experiments on native PCs may be required. This 
strategy is however hampered by the limited numbers of PCs in murine spleen and bone 
marrow. Nevertheless, determining whether CD138hi PCs express intracellular IgG1 in 
nfkb2fl/flCγ1-Cre mice by immunohistochemical analysis of splenic and bone marrow sections 
would be a feasible experiment. 
On a final note, the phenotypes observed in mice with constitutive activation of the 
alternative NF-B pathway in GC B cells, via overexpression of NIK, do not entirely agree with 
those observed in the absence of the downstream alternative NF-B subunits. Overexpression 
of NIK had minimal impact on GC B cells315, an observation that contrasts with a possible 
elevation that would be predicted based on the loss of GCs in mice with GC B cell-specific 
ablation of RELB and NF-B2. Overexpression of NIK did however promote PC hyperplasia315, 
in agreement with the reduced fractions of PCs observed in the combined absence of RELB and 
NF-B2. However, the reduced PCs observed in relbfl/flnfkb2fl/flCγ1-Cre mice is likely to be a 
direct consequence of the reduced GC B cells observed in these mice. Inconsistent phenotypes 
are also evident upon constitutive activation of the canonical pathway in GC B cells via the use 
of a constitutively active IKKβ. Rather than an elevation of GC B cells that would be predicted 
based on the loss of GCs in the absence of c-REL338, a slight loss of GCs is observed following 
constitutive canonical NF-B activation313. In addition, constitutive canonical activation in GC B 
cells had no impact on PC development313, a phenotype inconsistent with the loss of PCs 
observed upon ablation of RELA in PCs338. These discrepancies may be explained by non-
physiological effects produced by forced over-activation of either pathway. In turn, genetic 
ablation of NF-B subunits may lead to alterations in dimer composition that produce non-
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physiological phenotypes. Despite these potential experimental limitations, it appears that other 
routes of signaling may be in operation in addition to the linear canonical and alternative NF-B 
signaling axes which have largely been defined in cell lines systems. In the case of NIK, 
activation of the canonical pathway is strongly implied as PC hyperplasia in the absence of a 
GC B cell phenotype observed following NIK overexpression would be consistent with activation 
of RELA. Interrogation of the canonical and alternative NF-B signaling routes via genetic 
manipulation of individual components may therefore provide a more nuanced picture of the NF-
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Figure 4.1. Combined GC B cell-specific deletion of relb and nfkb2 impairs the GC 
reaction. (A-C, top) relbfl/flCγ1-Cre, nfkb2fl/flCγ1-Cre or relbfl/flnfkb2fl/flCγ1-Cre mice and the 
corresponding heterozygous and Cγ1-Cre control mice were analyzed via flow cytometry 14 
days following immunization with sheep red blood cells (SRBCs) for CD95 and PNA expression 
on splenic B cells. Numbers above each gate denote the fractions of CD95hiPNAhi splenic 
germinal center (GC) B cells in mice of the indicated genotypes. (A-C, bottom) Summary of the 
frequencies of GC B cells.  Each symbol represents a mouse. Data are shown as mean ± 






Figure 4.2. Normal fractions of GC B cells are present in relbfl/flnfkb2fl/flCγ1-Cre mice up to 
day 7 of the GC reaction. (A) Spleen sections from relbfl/flnfkb2fl/flCγ1-Cre mice and the 
corresponding heterozygous and Cγ1-Cre control mice were analyzed for the expression of 
BCL6 and IgM via immunohistochemistry. 40x magnification. Data generated by Nicole Heise. 
(B) Mice of the indicated genotypes were analyzed via flow cytometry 7 days following 
immunization with sheep red blood cells (SRBCs) for CD95 and PNA expression by splenic B 
cells. Numbers above each gate denote the fractions of CD95hiPNAhi splenic germinal center 
(GC) B cells in mice of the indicated genotypes (top). Summary of the frequencies of GC B cells 
(bottom). (C) Summary of the frequencies of CD95hiPNAhi splenic GC B cells in mice of the 
indicated genotypes as determined by flow cytometric analysis of CD95 and PNA expression by 





Figure 4.3. Normal DZ/LZ fractions and proliferation capacity of GC B cells in 
relbfl/flnfkb2fl/flCγ1-Cre mice. (A) relbfl/flnfkb2fl/flCγ1-Cre mice and the corresponding 
heterozygous and Cγ1-Cre control mice were analyzed via flow cytometry 10-12 days following 
immunization with sheep red blood cells (SRBCs) for the expression of CXCR4, CD86, CD95 
and CD38 in splenic B cells.  Numbers beside each gate indicate the percentage of 
CD38loCD95hiCXCR4hiCD86lo dark zone (DZ) B cells and CD38loCD95hiCXCR4loCD86hi light 
zone (LZ) B cells in mice of the indicated genotypes (top). Summary of frequencies of DZ and 
LZ B cells (bottom). Each symbol represents a mouse. Data are shown as mean ± standard 
deviation. Statistical significance was determined by Student’s t test (*, P<0.05). (B) Mice of the 
indicated genotyes were analyzed via flow cytometry 10 days following immunization with 
SRBCs for CD95 and PNA expression on splenic B cells and DNA content was assessed via 
DAPI. Numbers beside each gate indicate the percentage of CD95hiPNAhi splenic germinal 
center (GC) B cells in G1 or G2/M and are representative of the fraction of GC B cells in G1 and 





Figure 4.4. Identification of genes controlled by the alternative NF-B subunits, RELB and 
NF-B2, in GC B cells at day 7 of the GC reaction. (A) eGFP+ germinal center (GC) B cells 
from relbfl/flnfkb2fl/flCγ1-Cre mice and GC B cells from Cγ1-Cre control mice 7 days following 
immunization with sheep red blood cells (SRBCs) were purified via flow cytometric sorting and 
RNA was subjected to RNA-sequencing (RNA-seq). The mRNA expression of RELB and NF-
B2 is presented as total transcript counts for each gene. Each symbol represents a mouse. 
Data are shown as mean ± standard deviation. Statistical significance was determined by 
Student’s t test (*, P<0.05). (B) Unsupervised clustering analysis of transcript counts obtained 
from RNA-seq of RNA isolated via flow cytometry from eGFP+ GC B cells from 
relbfl/flnfkb2fl/flCγ1-Cre mice (red) and GC B cells from Cγ1-Cre control mice (blue). (C) 
Differentially expressed sequence analysis (DESeq) of RNA from eGFP+ GC B cells from 
relbfl/flnfkb2fl/flCγ1-Cre mice and GC B cells from Cγ1-Cre control mice identified 59 transcripts 
with greater than 2.5-fold reduced expression (left) and 84 transcripts with greater than 2.5-fold 
increased expression (right) in the combined absence of RELB and NF-B2 at a significant 
threshold of p<0.01. Genes were assigned putative functional categories. For the identity of the 
corresponding genes, fold-change and p values, see Appendix Table B. eGFP+ identifies 





Figure 4.5. Reduced expression of genes with metabolic and immune trafficking 
functions in RELB/NF-B2-deficient GC B cells at day 7 of the GC reaction. Differentially 
expressed sequence analysis (DESeq) of RNA from eGFP+ GC B cells from relbfl/flnfkb2fl/flCγ1-
Cre mice and germinal center (GC) B cells from Cγ1-Cre control mice identified genes with 
functions in metabolism (A) and the immune response (C) with greater than 2.5-fold reduced 
expression in the combined absence of RELB and NF-B2 at a significant threshold of p<0.01. 
Genes were assigned to putative functional categories. Genes within the lipid and amino acid 
categories (A) and trafficking categories (C) are presented, fold-change and padj values are 
indicated. For the identity of the remaining metabolic and immune response genes, fold-change 
and padj values, see Appendix B. (B) relbfl/flnfkb2fl/flCγ1-Cre mice and the corresponding 
heterozygous and Cγ1-Cre control mice were analyzed via flow cytometry 8-12 days following 
immunization with sheep red blood cells (SRBCs) for the expression of CD95, CD38, CD36 and 
eGFP in splenic B cells. The expression of CD36 in eGFP+ CD95hiPNAhi splenic germinal center 
(GC) B cells from relbfl/flnfkb2fl/flCγ1-Cre (red) and relbfl/+nfkb2fl/+Cγ1-Cre (blue) mice and 
CD95hiPNAhi splenic GC B cells (grey) from Cγ1-Cre control mice is presented (left). Summary 
of the corresponding median fluorescence intensities (MFI) (right). Each symbol represents a 
mouse. Data are shown as mean ± standard deviation. Statistical significance was determined 
by Student’s t test (*, P<0.05). eGFP+ identifies relb/nfkb2-deleted GC B cells from 
relbfl/flnfkb2fl/flCγ-Cre and relbfl/+nfkb2fl/+Cγ1-Cre mice. (D) Chemokine/chemokine receptor gene 
signatures enriched in RELB/NF-B2-proficient GC B cells in comparison to RELB/NF-B2-
deficient GC B cells identified by gene set enrichment analysis (GSEA) using the gene set 
collections Reactome (top) and GO_MF (bottom). Normalized enrichment scores (NES), p 





Figure 4.6. Normal PC frequencies following GC B cell-specific deletion of alternative NF-
B subunits. (A-C, top) relbfl/flCγ1-Cre, nfkb2fl/flCγ1-Cre or relbfl/flnfkb2fl/flCγ1-Cre mice and the 
corresponding heterozygous and Cγ1-Cre control mice were analyzed via flow cytometry 14 
days following immunization with sheep red blood cells (SRBCs) for CD138 and eGFP 
expression of splenocytes. Numbers beside each gate denote the fractions of CD138hi splenic 
plasma cells (PCs) in mice of the indicated genotypes. (A-C, bottom) Summary of the 
frequencies of PCs.  Each symbol represents a mouse. Data are shown as mean ± standard 
deviation. Statistical significance was determined by Student’s t test (*, P<0.05; **, P<0.01). 





Figure 4.7. Normal PC frequencies in nfkb2fl/flCγ1-Cre mice. nfkb2fl/flCγ1-Cre and the 
corresponding heterozygous and Cγ1-Cre control mice were analyzed via flow cytometry 14 and 
28 days following immunization with NP-KLH for CD138 and eGFP expression of splenocytes 
(top left) and bone marrow mononuclear cells (top right). Numbers beside each gate denote the 
fractions of CD138hi plasma cells in mice of the indicated genotypes. Summary of the 
frequencies of PCs (bottom).  Each symbol represents a mouse. Data are shown as mean ± 






Figure 4.8. GC B cell-specific deletion of nfkb2 results in reduced antigen-specific serum 
IgG1 and antigen-specific IgG1 ASCs. (A) relbfl/flCγ1-Cre and the corresponding 
heterozygous and Cγ1-Cre control mice were analyzed for NP-9-specific IgG1 levels via ELISA 
14 days following immunization with NP-KLH. (B) nfkb2fl/flCγ1-Cre and the corresponding 
heterozygous and Cγ1-Cre control mice were analyzed for NP-9-specific IgG1 levels via ELISA 
14 (left) and 28 (right) days following immunization with NP-KLH. (C) nfkb2fl/flCγ1-Cre and the 
corresponding heterozygous and Cγ1-Cre control mice were analyzed for NP-25-specific IgG1 
antibody secreting cells (ASCs) in splenocytes and bone marrow mononuclear cells via 
ELISPOT analysis 28 days following immunization with NP-KLH (top). Numbers within each 
image indicate the number of ASCs observed for the indicated genotypes. Summary of the 
frequencies of NP-25-specific IgG1 ASCs (bottom). Data are shown as mean ± standard 








Figure 4.9. In vitro plasmablastic differentiation of NF-B2-deficient B cells. (A) NF-B2-
deficient B cells were isolated from nfkb2fl/flCD19-Cre mice together with wild-type (WT) B cells 
from CD19-Cre control mice and induced to undergo plasmablastic differentiation via 3 days of 
LPS stimulation or 4 days of CD40L + IL4 + IL5 stimulation. These cultures were analyzed via 
flow cytometry for the expression of CD138 and B220. Numbers beside each gate denote the 
fractions of CD138hi plasmablasts generated in the indicated cultures (left). Summary of the 
frequencies of generated plasmablasts in the indicated cultures (right). Each symbol represents 
a mouse. (B) d3 LPS and d4 CD40L + IL4 + IL5 plasmablast cultures of B cells from the 
indicated genotypes were analyzed for IgM antibody-secreting cells (ASCs) via ELISPOT. (C) 
Western blot analysis of p100/p52, IRF4 and BLIMP1 protein expression in ex vivo (day 0) B 









CHAPTER 5: Conclusions 
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Two branches of the NF-B cascade have evolved over time, the canonical and alternative NF-
B pathways, and it is likely that these pathways have both overlapping and distinct functions 
within various cellular systems. Distinguishing these functions by studying upstream regulators 
of the separate NF-B signaling pathways is limited by the possibility of pathway cross-talk. 
Therefore, analyzing the roles of the downstream transcription factor subunits appears to be a 
more effective strategy towards identifying the specific functions of the canonical and alternative 
NF-B pathways. The biological roles of the alterative NF-B subunits within the B cell lineage 
have been obscured in constitutional knockout mice by the diverse functions of these subunits 
in non-B cell types280. To overcome these limitations, conditional alleles were generated to 
investigate the roles of the alternative NF-B subunits, RELB and NF-B2, in B cell 
development. These alleles allowed the identification of complex functional requirements for 
RELB and/or NF-B2 in naïve B cells, GC B cells and PCs. The genetic tools generated in this 
study will also facilitate the investigation of the cell-intrinsic roles of RELB and/or NF-B2 in 
other cell types of the immune system. 
A large body of work has demonstrated that BAFF signaling is critical for the 
maintenance of mature B cells. However, the contribution of the alternative NF-B subunits that 
are activated downstream of BAFF remained unclear, especially in regards to their specific 
target genes. We have identified critical, B cell-intrinsic roles for RELB and NF-B2 in the 
maintenance of mature B cells. In response to BAFF, these subunits were found to control the 
expression of anti-apoptotic genes, genes that direct positioning within B cell follicles and genes 
involved in promoting B–T cell interactions. Correct positioning within the B cell niche is likely to 
ensure continued exposure to BAFF and other essential signals required for the survival and 
growth of B cells, and optimal B–T cell engagements promote effective antigen-mediated 
activation. Interestingly, it is now clear that tonic BCR signaling is unlikely to signal through the 
canonical NF-B pathway347, and BAFF-mediated activation of this pathway may explain the 
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contribution of this signaling route to B cell maintenance. Identifying the gene targets controlled 
by canonical NF-B subunits in response to BAFF will therefore provide important insights into 
the distinct roles of the canonical and alternative NF-B pathways in the maintenance of mature 
B cells. In addition, this will clarify to what extent these pathways reinforce the expression of 
shared, critical gene targets.  
Our findings may have implications for diseases of mature B cells. For example, BIRC3 
(cIAP-2), an upstream regulator of the alternative pathway, is frequently mutated in chronic 
lymphocytic leukemia (CLL)427, a malignancy of mature, resting B cells, and in splenic MZ 
lymphoma428. In addition, BAFF has been implicated in promoting autoimmunity, including 
systemic lupus erythematosus (SLE)429,430, and a monoclonal antibody specific to human BAFF 
was approved as the first targeted therapy for the treatment of SLE431,432.  Elevated levels of 
BAFF have also been associated with various B cell malignances including B-NHLs, MM and 
CLL430. Under physiological conditions, competition for BAFF stimulation serves as a limiting 
factor that restricts B cell expansion; elevated levels of BAFF therefore allow unrestricted 
expansion. Furthermore, BAFF inhibition was found to induce apoptosis in B-NHL and CLL B 
cells, and BAFF stimulation resulted in the expression of several anti-apoptotic NF-B target 
genes433,434. Therefore, one possible consequence of mutations in B cell malignancies that lead 
to constitutive activation of the NF-B cascade335 is the acquisition of independence from BAFF 
signals which may contribute to further unrestricted survival and propagation. Experimentally 
this possibility is supported by the finding that BAFF-R deficiency can be rescued by constitutive 
canonical pathway activation353 or following the inactivation of negative regulators of the 
alternative NF-B pathway, TRAF2, TRAF3 or cIAP1/2356. Our results suggest that constitutive 
activation of RELB and NF-B2, via mutation or prolonged exposure to BAFF, may promote cell 
survival, distort trafficking within the lymphoid tissue, and potentially hyperactivate B cells, all of 
which may contribute to disease pathogenesis.  
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In contrast to the maintenance of mature B cells, the molecular events that coordinate 
the dynamic environment of the GC, particularly during the selection of high affinity LZ B cells, 
are not well understood. Highly reinforced systems of mutual repression exist between the 
factors governing mature B cell and GC B cell development and those that drive PC 
development. The means by which this balance is tipped during the selection of GC B cell 
clones within the LZ to induce terminal differentiation is unclear. In addition, progression through 
the GC reaction is not linear, as selected GC B cells can be instructed to recirculate back to the 
DZ, undergo CSR or differentiate into memory B cells or PCs. These heterogeneous outcomes 
suggest that selected LZ B cells are subjected to a complex array of signals resulting in different 
developmental outcomes. In the case of PC development, a signal leading to the inhibition of 
PAX5 expression or function is critical191, whereas c-MYC induction is important for cyclic 
reentry162,163. The affinity of the BCR435,436 and the spectrum of T cell-derived signals a GC B cell 
is exposed to, either in the form of physical interactions (such as CD40-CD40L119,129) or 
cytokines (such as IL-4 and IL-21126,136,437,438), have roles in determining cell fates. Asymmetric 
distribution of key regulators during cell division may also play a critical role439, and epigenetic 
regulation may enable rapid and reversible activation or repression of key regulators such as 
BLIMP1 and IRF4, thus allowing dynamic modulation of cellular phenotypes within the 
GC269,270,440.   
Our work has demonstrated that activation of distinct NF-B pathways and even NF-B 
subunits provides an additional layer of molecular control during the critical selection phase 
within the GC (Fig. 5.1). In the case of the canonical subunits, c-REL is required for GC 
maintenance, likely via the facilitation of cyclic reentry, whereas RELA promotes PC 
development338. The work presented here has demonstrated that in addition to c-REL, the 
alternative NF-B subunits RELB and NF-B2 are also jointly required for GC maintenance. 
This requirement is also likely to be associated with cyclic reentry of LZ B cells into the DZ and 
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may be centered on the establishment of a biological program that is complementary to that 
directed by c-REL. In addition to this joint function in GC maintenance, individual roles for RELB 
and NF-B2 were identified in PCs. RELB appears to be involved in PC development whereas 
NF-B2 may control a functional aspect of PC biology related to the generation or secretion of 
high affinity IgG1. The role of RELB and NF-B2 in PCs may be related to the preferential 
expression of these subunits in human PCs and PC precursors. While it is difficult to precisely 
link receptor-mediated activation to downstream signaling events, LZ B cells are probably 
exposed to a spectrum of signals that collectively determine which NF-B subunits are activated 
in particular cells and which cellular fates are promoted. Possible signaling routes of NF-B 
activation in LZ B cells include stimulation by BAFF, CD40L, antigen and also exposure to 
particular cytokines.  
The frequency of activating NF-B mutations in ABC-DLBCL and MM335 is likely to be a 
reflection of the physiological role of the NF-B signaling cascade in LZ B cells and PCs, 
respectively. During lymphomagenesis it is possible that these endogenous roles are hijacked 
by tumor-precursor cells and contribute to pathogenesis. Understanding the normal role of NF-
B signaling within the GC may therefore provide insights that shed new light on the 
pathogenesis of these diseases. Mutations that activate the canonical or alternative NF-B 
pathway may lead to the hyperactivation of c-REL-containing dimers or the RELB-p52 
heterodimer, respectively. Our findings suggest that constitutive activation of these dimers may 
then enforce a metabolic program that induces inappropriate cell growth and/or locks GC B cells 
into a state of continuous recirculation that is independent of affinity-mediated selection and 
prevents GC exit. In contrast, constitutive activation of RELA- or RELB-containing dimers may 
lead to an overexpansion of plasmablasts and/or PCs. In regards to the role of NF-B2 in a 
functional aspect of normal PC biology, over-activation of p52-containing dimers may contribute 
to enhancing the aggressiveness of a MM precursor cell. As both normal and malignant PCs are 
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dependent on the bone marrow stroma for survival signals that activate the NF-B signaling 
cascade, activating NF-B mutations are also likely to enable growth independent of the bone 
marrow niche333.  
There is a demand for novel, targeted therapies for the treatment of B-NHL and MM as 
current treatment regimens have broad effects and are associated with significant toxicity. As 
constitutive NF-B activation is observed in ABC-DLBCL and MM, these malignancies are 
candidates for treatment with NF-B pathway inhibitors. To this end, proteasomal inhibitors, 
such as bortezomib, have been successfully utilized in the clinic for the treatment of MM441. 
These proteasomal inhibitors work in part by inhibiting NF-B signaling in MM cells and 
expression of a strong NF-B gene signature, or low levels of TRAF3 is associated with a better 
response to treatment320,442,443. However, proteasomal inhibitors are also associated with 
significant toxicity, and targeted NF-B inhibition may therefore prove to be a more effective 
strategy. This strategy may also be of use for the treatment of autoimmune diseases, as 
sequestration of BAFF leads to general B cell depletion429. Overall, it appears that inhibition of 
the canonical NF-B pathway may be particularly effective for the treatment of ABC-DLBCL, 
whereas dual inhibition of the canonical and alternative pathways may be required for effective 
MM therapy. In regards to the canonical NF-B pathway, several IKKβ inhibitors have been 
developed and toxicity has been demonstrated in MM318,323,444. Recently, pharmacological 
inhibition of NIK has been shown to have efficacy towards mantle cell lymphoma that is 
refractory to canonical pathway inhibition following treatment with BCR inhibitors445. These 
resistant mantle cell lymphomas were found to have mutations that activated the alternative NF-
B pathway, suggesting the activity of this pathway was sufficient to preserve growth upon 
inhibition of the canonical pathway445. Inhibition of the NF-B cascade at the level of 
downstream transcription factor subunits as opposed to global NF-B pathway inhibition would 
be predicted to reduce toxicity. The validity of inhibiting NF-B subunits for the treatment of B 
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cell malignancies is supported by our work that has demonstrated that specific functions can be 
ascribed to single subunits or heterodimers. To provide a further rationale for this approach, the 
effects of NF-B subunit knockout in mouse models of lymphoma could be assessed. In regards 
to the feasibility of inhibiting individual NF-B subunits, a promising advance has been the 
development of a small molecule c-REL inhibitor446. Finally, gene targets found to be controlled 
by c-REL338 or RELB and NF-B2, could potentially be utilized as biomarkers to identify patients 
in which selective inhibition of the canonical or alternative NF-B pathway or individual subunits 
may be beneficial. These biomarkers could also be used to gauge responsiveness to NF-B 
pathway inhibitors.  
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Figure 5.1. Requirement of NF-B subunits in GC B cell and PC development. Distinct NF-
B pathways and NF-B subunits have functional roles during the selection of high-affinity light 
zone (LZ) B cells within the germinal center (GC). In the case of the canonical NF-B subunits, 
c-REL is required for GC maintenance, likely via the facilitation of cyclic reentry, whereas RELA 
promotes plasma cell (PC) development338. The work presented in this thesis has demonstrated 
that in addition to c-REL, the alternative NF-B subunits RELB and NF-B2 are also jointly 
required for GC maintenance. This requirement is also likely to be associated with cyclic reentry 
of LZ B cells into the dark zone (DZ) and may be centered on the establishment of a biological 
program that is complementary to that directed by c-REL. In addition to this joint function in GC 
maintenance, individual roles for RELB and NF-B2 were identified in PCs. RELB appears to be 
involved in PC development whereas NF-B2 may control a functional aspect of PC biology 
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Differentially expressed sequence analysis (DESeq) of  
NF-B2-proficient vs. NF-B2-deficient BAFF-stimulated B cells  
Reduced expression in nfkb2-deleted B cells 
padj<0.05 
FUNCTIONAL CATEGORY GENE 
FOLD 
CHANGE padj value 
ANTI-APOTOTIC bcl2 1.325543529 0.02945239
B CELL MARKERS fcer2a (cd23) 1.325732056 0.017623548
CYTOKINE il16 1.174198435 0.015844786
il12a 1.364670688 0.025448272







DNA REPAIR bre 1.254578558 0.005088337
neil1 1.231318507 0.011716652
lig1 1.266981951 0.041050674
































































PROLIFERATION mcm5 1.374548993 6.03E-06
212 
 
 pola1 1.436176686 0.011209285
cables1 1.44033209 0.027286066
mcm2 1.239161005 0.03791968












































TRAFFICKING sell 1.471424122 1.49E-15
gpr183 (ebi2) 1.491272082 1.27E-12
cxcr5 1.185785738 0.009919532
ccr7 1.609781954 3.95E-10





TRANSPORT abcc1 1.361944309 6.92E-07
slc20a1 1.265175303 0.000132885
slc2a3 1.256328465 0.013127776















- nfkb2 2.534237408 3.72E-88
Increased expression in nfkb2-deleted B cells   
padj<0.05 
FUNCTIONAL CATEGORY GENE 
FOLD 
CHANGE padj value 
APOPTOSIS bmf 1.65972061 7.24E-18
bbc3 (puma) 1.602398362 0.002756872
B-CELL-specific fcrl5 (irta2) 1.55685032 7.61E-07
CYTOKINES il10 3.968080839 0.000229336
il12b 3.256747297 0.027089435













DNA REPAIR  polm 1.446524167 0.004511346
INTRACELLULAR TRAFFICKING cplx2 2.310715937 1.63E-11
 stxbp1 1.854395487 1.99E-09
ehd2 1.520200238 1.29E-05
itsn1 1.380361577 0.001792806
IMMUNE CELL-specific cd93 1.718718609 5.09E-08
rag1 2.611717576 0.009856109
cd44 1.304220533 0.000845661
IMMUNE RESPONSE  - ANTIGEN 




IMMUNE RESPONSE - INNATE tlr12 1.85666738 0.016883121
































































PROLIFERATION cdkn1a 1.917659738 0.015844786




PROT STAB  hspa1a (hsp70-1) 5.695433618 0.003575741
hspa1b (hsp70-
1b) 5.653293421 0.003785318
hsph1 (hsp105) 1.394889811 0.006204436
RNA akap17b 1.657912082 0.003192827
zfp385a 1.696129503 0.046728948



















































































Differentially expressed sequence analysis (DESeq) of  
RELB/NF-B2-proficient vs. RELB/NF-B2-deficient   
GC B cells at day 7 of the GC reaction  
Reduced expression in relb/nfkb2-deleted GC B cells 
>2.5 fold, p<0.01 
FUNCTIONAL CATEGORY TRANSCRIPT 
FOLD 
CHANGE p value 
CYTOSKELETON cep290 3.701368327 0.001250872
 fmn1 6.77867816 0.002083243
 nebl 3.408183756 0.002700872
 pls3 3.639672747 0.009879553
 cdc42ep4 9.822813676 0.0005552
IMMUNE RESPONSE  oasl2 3.56672381 0.00213694
 ifit1 3.538140389 0.009510845
 ephb2 10.74595395 0.000774539
 ighg2c 8.537256103 0.004010517
 tlr3 3.442985706 0.001035165
 cxcl10 4.015628084 0.00643676
 rgs3 2.885035238 0.009433817
 rgs13 3.184725593 1.44E-06
METABOLISM  gstt1 8.83364123 1.77E-05
 gstt3 3.001044657 0.000196394
 padi4 3.956754531 0.009296115
 wbscr17 20.48998638 0.00060861
 chst1 6.041301989 0.004207427
 mocos 5.674386583 0.005944022
 as3mt 2.643569946 1.58E-06
 osbpl3 2.551941535 0.003505027
 cers6 2.567999041 0.001065751
 slc27a4 2.652195026 0.004516612
 cd36 3.252357531 3.74E-10
NON-PROTEIN CODING  gm14963 27.12136716 0.000116433
 gm12063 7.718110564 0.003664288
OTHER olfr1444 8.242565212 0.002878901
 nrep 11.9868501 0.003761633
 trp73 5.053304329 0.009116683
 adam15 5.588725201 0.009544978
 hps6 2.547747033 0.005642318
 stx11 3.230499654 0.007398995
 enpp4 8.546181084 7.78E-06
220 
 
POSTTRANSLATIONAL  neurl1a 19.24256824 2.73E-06
RNA  gemin7 2.699870842 0.000506399
SIGNALLING rhobtb1 4.174352932 0.004952224
 ptpn14 2.866098295 0.005009919
 ptpn13 7.525755869 0.001412894
 evc 4.966383366 0.000100413
 wls 4.286310822 0.000270604
 daam1 3.173809654 0.001281587
TRANSCRIPTION hoxa7 28.03543672 0.000109421
 tox2 10.1999987 0.000144835
 hmga1-rs1 7.134385975 0.005625708
 zfp365 2.695290407 0.006027941
 hic1 6.826539202 0.002277476
UNKNOWN gm10800 59.2378127 1.36E-08
 gm21738 17.17454777 6.78E-07
 gm10801 24.19518446 3.49E-05
 a930033h14rik 13.3365832 0.000117682
 gm10717 18.58433817 0.000145953
 sh3bgrl 2.647161401 0.000293758
 ccdc120 5.445959362 0.00172023
 fam135a 6.437804933 0.005610792
 gm9825 2.794255416 0.006924743
 paqr7 6.794428153 0.007168583
 4930506m07rik 3.870257186 0.007304508
- relb 3.872632342 0.001113217
- nfkb2 2.93907889 0.001172224
Increased expression in relb/nfkb2-deleted GC B cells 
>2.5 fold, p<0.01  
FUNCTIONAL CATEGORY TRANSCRIPT 
FOLD 
CHANGE p value 
CYTOSKELETON dnm1 28.84816562 1.71E-06
 tppp 6.031130636 0.000340554
 col27a1 3.005588623 0.004863368
IMMUNE RESPONSE iigp1 8.369047288 0.009720592
METABOLISM  slc15a2 5.230059989 6.09E-08
 cp 4.031121943 0.002349171
 ltf 15.26600973 0.000597746
221 
 
 mgll 2.645647937 0.001999474
NON-PROTEIN CODING gm26789 5.0514664 8.62E-16
 gm26625 4.09937526 9.00E-10
 gm26749 4.178514721 3.36E-07
 gm11932 3.581939544 5.75E-07
 gm17477 7.342866239 8.25E-07
 gm4279 4.806875857 9.35E-07
 gm16153 2.503956747 2.49E-05
 gm11721 6.337946518 3.94E-05
 gm26882 2.868542527 0.000121993
 gm12543 3.211250557 0.000139233
 gm26518 2.857975964 0.00020212
 gm16316 3.850261574 0.000445266
 gm12064 2.967931907 0.00046968
 gm23346 3.2731059 0.000853068









 gm15824 4.182238288 0.001805796









 gm20717 3.690336855 0.003063738
 4933426d04rik 5.357351955 0.003378546
 gm25820 6.338011442 0.003555737
 gm20682 3.684991448 0.003602044
 rp23-224i23.1 7.417608209 0.003806439
222 
 
 1700099i09rik 3.275967106 0.004075714
 gm16305 3.307957241 0.004241203
 gm11805 2.983369408 0.005019858
 gm22304 4.347490289 0.006110111
 gm25848 2.569071108 0.006148293
 gm13510 3.983865544 0.006522137
 rpl31-ps6 4.09498902 0.007240531
 gm14335 2.63348781 0.007470624
 4933426k07rik 2.524163198 0.007472611
 gm13571 3.331657237 0.007629546
 gm13570 3.54909018 0.007968129
 gm14853 4.61051573 0.007981705
 mir5120 2.856865965 0.008087406
 gm26836 2.592935332 0.008418244
 gm11655 4.266930256 0.008922059
 4930565n06rik 2.591519262 0.009337
 gm15367 6.818256329 0.009380237
OTHER angpt2 2.900169285 0.001541543
 lrrc18 2.729916644 0.004545494
 efcab12 5.841862587 0.008085481
 h2afy3 3.412721398 0.002619242
 snap25 72.08175121 1.51E-07
 sec61a2 2.938930987 0.001541862
 kdelr3 5.756452542 0.004405829
POSTTRANSLATIONAL (Ub)  trim2 2.819847322 0.001544851
SIGNALLING camk2n1 8.271429708 0.003738905
 pla2g4c 2.933583458 0.008957931
TRANSCRIPTION adnp 3.308903224 0.002100786
TRANSPORT scn8a 2.985559464 0.001391662
 atp1a3 8.434327762 0.001444815
 slc22a23 4.575176512 0.00433535
UNKNOWN 4933408b17rik 5.410317807 0.000242984
UNKNOWN gm6104 3.31093544 0.000559432
UNKNOWN 2610203c22rik 6.299653481 0.000815857
UNKNOWN xkr6 5.22397547 0.002744925
UNKNOWN fam196b 2.514140993 0.004613704
UNKNOWN gm17227 5.075807117 0.005449014
UNKNOWN gm9754 7.642938157 0.006785963
 
 
